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Abstract 
Stilbenoids possess a wide range of biological properties such as, anticancer, 
antiplatelet aggregation, antiestrogenic, antibacterial, antifungal and antiatherogenic, etc. 
Owing to these therapeutic values, a great deal of attention attracted in the synthesis of 
derivatives of stilbenes. During the course of the study, G6 a novel stilbenoid was 
discovered, through high throughput screening, to be a potent inhibitor of mutated JAK2-
V617F. The mutated JAK2 variant has been implicated in various myeloproliferative 
disorders (MPDs) including polycythemia vera (PV), essential thrombocythemia (ET) 
and primary myelofibrosis (PMF) has been targeted by therapeutics. Chapter 2 describes 
the synthesis of analogs of the stilbenoid G6 and N-substituted stilbenes bisoxazines by 
utilizing Mcmurry reaction and Mannich condensation methods. The main emphasis of 
this work is to develop novel stilbenoids as inhibitors of JAK2-V617F mutated Jak2 
enzyme in Human erythroleukemia cells (HEL) since this mutation is discovered in the 
majority of patients with myeloproliferative disorders (MPDs). Using Mcmurry reaction, 
five novel trans-hydroxystilbenes have been synthesized from carbonyl compounds.  
Subsequently using Mannich coupling with five secondary amines and five primary 
amines, 25 novel stilbenoids and 9 novel N-substituted stilbene bisoxazines have been 
synthesized. In HEL cell assay, 8 stilbenoid analogues have been identified as potent 
inhibitors of Jak2 enzyme. 
 
xix 
 
Chapter 3 describes the modification of ketamine structurally for the synthesis of 
novel analogues to study for their agonist activity at GABAA receptors and antagonist 
activity at NMDA receptors. Ligand gated ion channels like GABAA and NMDA 
receptors are membrane-embedded proteins at synaptic cleft which controls 
intercommunication among neurons and plays an important role in motor control activity, 
learning. GABAA  receptors are responsible for inhibitory action potentials while NMDA 
receptors are responsible for excitory action potentials. Ketamine, known as dissociative 
anesthetic, produces profound analgesia at low doses to a unique cardiovascular 
stimulation and a cataleptic state at higher doses with dose dependent side effects like 
vivid dreams, disruptions of cognitive functions. The main emphasis of this work is the 
synthesis of novel analogues of ketamine by transforming carbonyl group in ketamine to 
imine functionality with small to bulkier groups and to identify an analogue of ketamine 
which is highly potent in its activity at the both GABAA and NMDA receptors and 
improved clinical actions. Studies of analogues activity against GABAA subtypes 62, 
122 receptors and NMDA subtypes NR1/2A, NR1/2B, NR1/2D receptors have been 
described. 
Chapter 4 describes the formal synthesis of (±)-Rolipram and the 
chemoenzymatic synthesis of -aryl--lactone, a Rolipram analogue. The key steps, Pd 
catalyzed arylation of diethylmalonate and the efficient use of selective acylation of 1, 3-
diol entails the formal synthesis of  (±)-Rolipram. The regioselective deacylation of -
aryl-1, 4-diacetate by lipase Pseudomonas Sepacia entails the formation of -aryl--
lactone. The efficient use of various methods including halogen exchange, Heck arylation 
xx 
 
of diethylmaleate and lactonization for the synthesis of -aryl--lactone have been 
discussed. The present work provides an efficient and general route to -lactones. 
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Chapter 1 
A short review of small molecule inhibitors of Janus Kinase 2, Phosphodiesterase 
IV, and GABAA and NMDA receptors 
1.1 Significance of small molecule inhibitors. 
A number of small molecule inhibitors
1
 have been discovered and are currently 
used in therapy of many diseases including cancer
2
 and inflammation.
3
 The successful 
treatment of chronic myeloid leukemia by imitinib
4
 (1, Fig. 1-1) among other different 
types of cancers and treatment of non small lung cancer (NSCLC) by gefitinib (2)
5
 and 
erlotinib (3)
6
 serves as examples that small molecule inhibitors can be effective drugs. 
Currently, Most of the drug discovery efforts are focused on developing small molecule 
inhibitors with exquisite selectivity, specificity, affinity for binding with proteins and to 
identify off-target interactions. Small molecule inhibitors have a greater advantage for the 
elucidation of the mechanism of cellular processes and so are very useful tools. Since 
they are more stable than peptide inhibitors and are often easily cell permeable, use of 
them as inhibitors of protein-protein interactions
7
 is particularly helpful.  
 
Fig. 1-1. Structures of kinase inhibitors 
2 
 
Imitinib 1 (Fig. 1-1) is a potent inhibitor of three tyrosine kinases: ABL 
(Ableson), platelet-derived growth factor receptor (PDGFR) and KIT. The main feature 
that prompted the use of imitinib in clinical trials
8
 is its inhibitory action against ABL 
tyrosine kinase. Constitutively activated Janus Kinase 2 (Jak2) has been implicated in 
myeloproliferative neoplasms
10
 (MPNs), i.e. polycythemia
 
vera (PV), essential 
thrombocythemia (ET) and primary myelofibrosis (PMF). A large number of patients 
with myeloproliferative neoplasms (MPNs) have mutated JAK2-V617F,
11
 which 
prompted the development of Jak2 inhibitors
12
 for the treatment of MPNs. Several groups 
are working on Jak2 inhibitors with favourable pharmacokinetics and toxicity profiles 
which are good for clinical evaluation. 
 
Fig. 1-2. Structures of Phosphodiesterase-4 inhibitors. 
Phosphodiesterase-4 (PDE4), an enzyme belonging to the family of eleven 
phosphodiesterase isoenzymes identified so far, has absolute specificity for cyclic 
adenosine-3’,5’-monophosphate (cAMP) and is considered potential therapeutic targets13 
for the treatment of chronic inflammatory disorders,
14
 such as chronic obstructive 
pulmonary disease (COPD).
15
 PDE4 is abundant and is the major regulator of cAMP 
metabolism
16
 in almost every proinﬂammatory and immune cell. PDE4 inhibitors, of 
varied structural classes, suppress a myriad of in vitro responses, such as proliferation 
and the generation and/or release of histamine.  
3 
 
For example small molecule Cilomilast
17
 (4) (Fig. 1-2), a selective 
phosphodiesterase-4 inhibitor, has demonstrated encouraging therapeutic efficacy in 
clinical trials of COPD. Now, several other selective PDE4 inhibitors are in clinical trials 
such as tetomilast
18
 (5), roflumilast
19
 (6) (Fig. 1-2).  
Antagonists of NMDA receptors
20
 are currently under constant development to 
treat neurogenerative disorders such as Parkinson’s, Alzheimer’s, Huntington’s diseases, 
cerebral ischemia, epilepsy, neuropathic pain, brain stroke and multiple sclerosis
21
. The 
rational for design of inhibitors is strongest for the acute treatment of ischemia
22
. A 
majority of NMDA antagonists developed so far have adverse effects such as 
hallucinations, increase in blood pressure, catatonia and anesthesia. Fortunately, all of the 
side effects so far identified are dose-limiting. A number of potent small molecule 
NMDA antagonists have been developed. For example, Ifenprodil
23
 (7) proved to be 
neuroprotective in animal models of stroke without the severe side effects of earlier 
drugs. 
 
Fig. 1-3. Structures of Antagonists of NMDA receptors. 
 
 
 
4 
 
Various animal models also revealed that Ifenprodil (7) is beneficial and 
significantly superior in neuroprotection of Anoxia (Hypoxia), Seizures, Ischemia and 
brain injury. Traxoprodil
24
 (8) (Fig. 1-3) is another small molecule NMDA  antagonist 
which also has neuroprotective, analgesic and anti-Parkinson’s effects in animal studies 
although human studies proved less beneficial for the treatment of brain injury after 
stroke. The clinical trial, however, revealed another important therapeutic benefit of 
Traxoprodil (8), as a rapid acting antidepressant.  NMDA subtype selectivity has been the 
driving force for development of  small molecule antagonist; similar to that of  
benzodiazepines (such as Valium 9) which enhance activation of GABAA receptors.  
Several small molecules have also been developed which are agonists for GABAA 
receptors with subtype selectivity such as sedatives, hypnotics, anxiolytics, anxiogenic, 
insomnia and memory enhancers. For example, Zolpidem
25
 (10, Ambien), Zaleplon
26
 
(11), Eszopiclon
27
 (12,(Lunesta) and Indiplone
28
 (13) (Fig. 1-4) have shown to be 
therapeutically beneficial in insomnia treatment. These findings reveals that small 
molecule inhibitors have significant importance in design and development of drug 
targets of protein-protein interactions. 
 
Fig. 1-4. Structures of Agonists of GABAA receptors. 
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1.2. Small molecules as Jak2 inhibitors. 
Small-molecule kinase inhibitors most commonly target the highly conserved 
adenosine triphosphate (ATP)-binding domain in enzyme. Since the discovery of the 
mutation JAK2-V617F
29
 in Jak2 and its implication in myeloproliferative neoplasms
30
 
(MPNs), many number of Jak2 inhibitors have been developed and some are under 
clinical trials. Majority of them are small molecules. 
 
Pyrrolopyrimidine 
INCB018424 (14 in Fig. 1-5) has shown potent inhibition activity against Jak2 
with IC50 of 2.8 nM. However, the selectivity has been an issue and it has also shown 
potent to moderate activity against Jak1, Tyk2 kinase proteins.  
 
Fig. 1-5. Structures of Jak2 inhibitors in clinical studies. 
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INCB018424
31
 (14) treatment of murine model of JAK2-V617F driven 
malignancy resulted in significant attenuation
 
of spleen growth and significantly 
increased mice survival compared with mice treated with vehicle alone. These inhibitors 
belongs to pyrrolopyrimidine class compounds. 
Another clinical candidate CP-690,550
33
 (16 in Fig. 1-5) for rheumatoid arithritis, 
also been shown to have potent inhibition activity against Jak2 enzyme with IC50 of 20 
nM. It has also shown higher degree of selectivity for Jak2 over Jak1/3 enzymes. This 
inhibitor has been identified as a lead candidate at Pfizer for rheumatoid arthritis 
treatment from a screening of over 400,000 small molecules library.  Interestingly this 
compound, like INCB018424  (14 in Fig. 1-5) also belongs to the pyrrolopyrimidines 
class of molecules.  Based on this pyrrolopyrimidine ring system, several structure-
activity studies have revealed other potent Jak family inhibitors. 
Aminopyrimidines 
Extensive in vitro and in vivo studies have revealed an interesting 
aminopyrimidine class compound TG101348
34
 (17 in Fig. 1-5) as a potent Jak2 inhibitor 
with IC50 of 3 nM. This inhibitor also turned out to be highly selective for Jak2 when 
profiled against over 230 kinases. 
The potency and promising clinical efficacy reported for TG101348 (17) has led 
to structure-activity relationship investigations and new compounds have been developed. 
For example CYT-387
35
 18 (Fig. 1-6) has been recently found to be another potent Jak2 
inhibitor which belongs to the aminopyrimidine class of compounds. Series of other 
aminopyrimidines (19-25) developed in structure-active relationship studies
35
 with CYT-
387 (19) have shown high potency than 19 (Fig. 1-6). 
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Fig. 1-6. Aminopyrimidine compounds as potent Jak2 inhibitors. 
Synthesis of these aminopyrimidines (19-25) involves two steps, starting from 
various phenyl boronicacids. Regioselective cross-coupling of phenylboronic acids with 
pyrimidine dichloride and condensation with anilines or palladium catalyzed Buchwald 
reaction yields various aminopyrimidines (19-25) as shown in Scheme 1-1. 
 
Scheme 1-1. Synthesis of various pyrimidine analogues  by Burns et. al. 
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Benzoxazoles 
Benzoxazole compounds also have shown attractive Jak2 inhibitory profiles in 
cellular assays. For example novel benzoxazole 26-31 (Fig. 1-7) synthesized by 
Gerspacher et. al.
36
 showed high inhibitory potency against Jak2 with IC50 values in 3.0 
to 8.0 nM range. Synthesis of the benzoxazoles 26-31 was reported to be relatively 
straightforward and convergent (Scheme 1-2).  
 
Scheme 1-2. Synthesis of various benzoxazole analogues by Gespacher et. al. 
 
 
Fig. 1-7. Benzoxazole compounds as Jak2 inhibitors. 
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Miscellaneous 
Apart from aminopyrimidines and benzoxazoles, small molecules belonging to 
various other scaffolds such as Tricyclic pyridones, pyrrolotriazines, purines, 
aminopyrazolopyrimidines, monocyclic pyridines and pyrimidines (Fig. 1-8) have also 
shown promising therapeutic efficiency in anti Jak2 activity. For example, INCB16562
32
 
15 (Fig. 1-5) is a potent inhibitor of Jak2 enzyme with IC50 of 0.25 nM. In a combination 
studies, the growth of myeloma xenografts in mice was suppressed and antitumor activity 
was enhanced by oral administration of INCB16562 (15) which belongs to the pyridine 
class of compounds. 
 
Fig. 1-8. Recently reported potent Jak2 inhibitors. 
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1.3 Phosphodiesterase 4 inhibitors as anti-inflammatory drugs. 
Phosphodiesterase-4
14
 (PDE4) enzyme is ubiquitous among inflammatory and 
immune cells.  Inhibition of PDE4 effectively increases the intracellular cyclic adenosine-
3’,5’-monophosphate (cAMP) level, which in turn provides critical negative regulation of 
various cellular functions in these immune cells. Regulation of cAMP level by PDE4 
enzyme is also critical in airway smooth muscle, and pulmonary nerves. PDE4 inhibition 
suppresses the recruitment and activation of several inflammatory cells such as 
neutrophils, CD8 T cells, macrophages, and eosinophils, that are thought to be important 
in the pathobiological processes that take place in the airway diseases such as chronic 
obstructive pulmonary disease (COPD) and asthma. PDE4 inhibitors also show 
suppressive activity on various in-vitro responses, including production of cytokines, cell 
proliferation and chemotaxis, release of inflammatory mediators, and NADPH oxidase 
activity. Owing to this therapeutic benefits, development of PDE4 inhibitors as anti-
inflammatory drugs has attracted extensive research efforts.  
Small molecules like Cilomilast
17a
 4 and Roflumilast
19
 6  (Fig. 1-2) have 
promising efficacy in PDE4 inhibition and are in phase-III clinical trials for the treatment 
of COPD. Despite significant progress in this area, designing new pharmacophores for 
the development of PDE4inhibitors such that they cover most of pulmonary diseases and 
increasing therapeutic index is a major effort in medicinal chemistry
17b
.  Various small 
molecules such as oxazoles, triazolodiazines, quinazolines and pyridinemethanlos have 
been developed as a selective and potent inhibitors of PDE4 enzyme. For example, kuang 
et. al.
37
 identified several oxazole compounds (32-37) for this purpose (Fig. 1-9).  
11 
 
 
Fig. 1-9. Oxazoles as Phosphodiesterase-4 inhibitors. 
The oxazole-4-carboxyamide analogs 32-37 were synthesized as shown in 
scheme 1-3 and found to have potent inhibition activity against PDE4 enzyme with IC50 
values in 0.5 to 2.2 nM range.  
 
Scheme 1-3. Synthesis of Oxazole compounds as potent Phosphodiesterase-4 inhibitors. 
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Triazolodiazines have also shown potent inhibition of PDE4 enzyme. For 
example, skoumbourdis et. al.
38
 synthesized several triazoloindoles (38-40) (Fig. 1-10) 
with high potency and selectivity for PDE4 enzyme. The triazoloindazoles 40-42 were 
highly selective even for PDE4 enzyme isoforms with IC50 values in the 1.5 to 3.0 nM 
range. Synthesis of these novel triazolodiazines was accomplished in two steps. 
Cyclization of pyridazine benzamide to intermediate triazolopyridazine and cross 
coupling of this intermediate with various phenyl boricacids via Suzuki reaction yields 
triazolodiazines efficiently (Scheme 1-4). 
 
Fig. 1-10. Triazolodiazines as inhibitors of phosphodiesterase 4 inhibitors. 
 
Scheme 1-4. Synthesis of Triazolodiazines in two steps by skoumbourdis et. al. 
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1.4 Small molecules as agonists of GABAA receptors 
  
GABAA receptors have been therapeutic target
39
 of many drugs. Majority of them 
are small molecules which interact with GABAA receptors as allosteric modulators. For 
example, benzodiazepines, barbiturates and neurosteroids interact at these receptors. 
GABAA receptors are functionally characterized as ligand gated Cl
-
 ion channels with a 
GABA (-amino butyric acid) recognition site. Normally, GABA binds to GABAA 
receptor fecilitating the Cl
-
 ion flux into the cells leading to inhibitory neurotransmission. 
These receptors also have binding sites for external modulators called allosteric 
modulators.  
 
Fig. 1-11. Diagramme representing GABAA receptor with binding sites  for allosteric 
modulators (Reprinted from Richards. G, Schoch. P, Haefely. W; Seminars in 
Neurosciences. 1991, 3, 191. with permission from Elsevier). 
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Allosteric modulators typically modulates Cl
-
 ion flux along with GABA at these 
receptors resulting many beneficial effects for the treatment of anxiety, insomnia, 
agitation, seizures, muscle spasms, alcohol withdrawal and premedication for medical, 
dental procedures. Thus barbiturates, benzodiazepines, neurosteroids and their analogues 
have been developed as small molecule agonists and inverse agonists for therapeutic 
benefits. Benzodiazepines
40
 such as diazepam 41, midazolam 42, lorazepam 43, 
oxazepam 44 and quazepam 45 (Fig. 1-12) are extensively used as sedatives, hypnotics 
and anticonvulsants which enhance the effect of GABA potentiation at GABAA receptors 
and thus characterized as agonists or positive modulators. Flumazenil 46 and Imidazenil 
47 (Fig. 1-12) are other benzodiazepines which acts as antagonists mainly and reverse the 
effects of benzodiazepines by competitive inhibition at their binding site on GABAA 
receptors and thus used as antidote for benzodiazepine overdose. Benzodiazepines are 
heterocycles derived by fusion of benzene and 1, 4-diazepines.  
 
Fig. 1-12. Benzodiazepine class of compounds as agonist and antagonists of GABAA 
Receptors. 
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The synthesis of benzodiazepines, a short three steps process, is the major 
attraction for the development of benzodiazepines as allosteric modulators of GABAA 
receptors apart from their unique anticonvulsant effects. For example, the synthesis of 
first benzodiazepine derivative, chlordiazepine
41
 50 was achieved as depicted in Scheme 
1-5 via Sternbach rearrangement. 
 
Scheme 1-5. Chlordiazepoxide 48 synthesis by Sternbach rearrangement. 
Neurosteroids are another group of small molecules which acts on GABAA 
receptors as allosteric modulators
42
 apart from NMDA and Sigma receptors. Because of 
this pharmacological property, they have been used as sedatives for the purpose of 
general anesthesia for surgical procedures 
43
. Neurosteroids such as minaxolone 49, 
alphaxolone 50 and alphadolone 51 (Fig. 1-13) are mainly composed of four cycloalkane 
rings and have wide range of pharmacological properties from sedatives to treatment of 
epilepsy.  
 
Fig. 1-13. Neurosteroids as agonists of GABAA receptors for anesthesia. 
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Phenobarbitol 52 and Pentobarbitol 53 (Fig. 1-14) are also small molecules which 
at submicromolar concentration act on GABAA receptors as agonists producing 
anesthesia.  Etomidate 54 and propofol 55 (Fig. 1-14) are also well known small 
molecules which primarily acts as agonists at GABAA receptors and thus used 
extensively as intravenous anesthetic agents.  
 
Fig. 1-14. Barbiturates and other small molecules as agonists for GABAA receptors. 
Many number of small molecules are being constantly developed for the allosteric 
modulation of GABAA receptors since beneficial effects of targeting GABAA receptors 
therapeutically encompasses over a wide range from hypnotics to neuropathic pain 
management.  
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1.5 NMDA antagonists  
NMDA receptors as therapeutic target by antagonists plays critical role in pain 
management and anesthesia. Vast number of small molecule antagonists exerts this 
pharmacological purpose. This is feasible because protein-protein interactions have been 
better understood mechanistically over the last several years. Due to the enhanced 
mechanistic understanding, significant progress in the development of small, drug like 
molecules that are capable of blocking NMDA receptor has been made. Functionally, 
NMDA receptors also have several binding sites that can bind to other antagonists. 
 
Fig. 1-15. Schematic representation of potential sites for drug action within the NMDAR 
protein complex. (Reprinted from Kalia, L. V.; Kalia, S. K.; Salter, M. W. The Lancet 
Neur. 2008, 7, 742. with permission from Elsevier) 
. 
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 So modulation of NMDA receptors can be achieved through actions at different 
recognition sites such as the primary transmitter site (competitive), the phencyclidine site 
located inside the cation channel(uncompetitive), the polyamine modulatory site and the 
strychnine-insensitive, co agonistic glycine site (glycine) (Fig. 1-15).  
Following few small molecules exemplify the purpose of negative modulation of 
NMDA receptors. Memantine 56 (Fig. 1-16) is fused cycloalkane ring system which 
function at NMDA receptors as uncompetitive antagonist. Memantine has been widely 
accepted as a very well tolerated medicine towards the treatment of Parkinson’s disease 
and Alzheimer’s dementia. Memantine functions as antagonist at NMDA receptor with 
low affinity. This unique feature results in its fast  binding and dissociating from the 
receptor and thus less psychotomimetic effects. Memantine, an aminoadamantane, has 
been used in more than 200000 patients for the treatment of dementia. 
 
Fig. 1-16. Small cycloalkane rings with phenyl substituents as NMDA antagonists. 
Ketamine 57 is an another NMDA receptor blocker which has been used in 
clinical practice for many years. Being used as dissociative anesthetic, ketamine has also 
been in clinical trials for neuropathic pain treatment. Phencyclidine 58 is another 
dissociative anesthetic which was used as surgical anesthetic but discontinued due to 
adverse side effects. Dizocilpine (MK-801) 59 is also another antagonist which is in 
clinical trials as an antidepressant.  
19 
 
Various other small molecule drugs have been in clinical practice and many more 
are undergoing  clinical trials as antagonists of NMDA receptors. The significance of 
using small molecules as drugs comes with many advantages from wide range of libraries 
being screened for the lead compound to ready access to preparation. 
In summary, the development of various small molecules as drugs has advantage 
over large molecules such as peptides.  Small molecules can cross cell membranes easily 
than large molecules, provided enough lipophilicity. Large molecules such as peptides 
can be degraded easily if orally administered and cannot cross cell membranes easily. 
Since fewer interactions like hydrogen bonds are enough to inhibit or activate enzymes 
and receptors activity of the molecules can be modulated by small changes in its 
structures. This advantage combined with the ease of preparation of the library of small 
molecules for screening makes small molecules as attractive drugs.  
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Chaper-2 
Synthesis of Novel Stilbenoids as Inhibitors of Jak2 enzyme: Application of 
Mcmurry Reaction and Mannich Condensation  
2.1 Janus Kinase and its role in cell signaling 
Janus kinases (Jaks) are cytoplasmic protein kinases bound to the cytoplasmic 
tails of cytokine receptors.  Upon binding of the ligand in the extracellular portion of the 
cell, JAK undergo conformational changes causing autophopshorylation of tyrosine 
residues on the C-terminal end of the cytokine receptors and further activation of Signal 
Transducers and Activators of Transcription (STAT) proteins (Fig. 2-1), which function 
as a gene transcription factors.
1
 The mammalian JAK kinase family comprises four 
members: JAK1, JAK2, JAK3 and TYK2.
2
 JAKs are expressed ubiquitously, except 
JAK3 which is primarily expressed in hematopoietic cells.
3
 JAKs comprises seven 
regions (JH1-JH7) with significant sequence homology which are referred to as the Jak 
homology domains (Fig. 2-1).
4
 JH1 domain, also known as tyrosine kinase domain, binds 
ATP and harbors phosphor-transferase activity of the protein. JH2 domain, which lacks 
tyrosine kinase activity and also known as pseudo kinase domain, negatively regulates 
the kinase activity of JH1 domain.
4b,5
 JH4-JH7 domains, collectively referred to FERM 
domain, directly mediate the interaction of the Janus kinases with other cellular proteins 
such as cytokine receptors.
6
  
Genetic knockout studies of Jaks to gain insight into the function of each Jaks 
have shown importance of Jak2 implied in the death of Jak2 deficient mice 
25 
 
embryonically due to impaired erythropoiesis and profound anemia.
7
 Apart from playing 
a critical role in embryonic development,
7
 the Jaks have been implicated in several 
cancers.
8
 The discovery of a somatic mutation in Jak2 resulting in valine to phenylalanine 
substitution at position 617 (Jak2-V617F)
9
 in majority of patients with myeloproliferative 
disorders (MPDs) including polycythemia vera (PV), essential thrombocythemia (ET) 
and primary myelofibrosis (PMF) has been targeted by therapeutics.
10
   
Its enhanced activity is usually associated with abnormal cell proliferation in a 
series of hematologic malignancies including lymphoid and myeloid leukemias, 
Hodgkin’s lymphoma and various B-cell non-Hodgkin’s lymphomas.11  Several 
molecular inhibitors of constitutively activated Jak2 have been under study in high 
throughput screening and significant structural improvement in these inhibitors could be 
the clinical benefit in treating this MPDs at molecular pathogenesis. 
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Fig. 2-1. The JAK–STAT pathway.12 a). A schematic representation of the Janus kinase 
(JAK)– (STAT) pathway. b). The domain structure of JAKs. c).  The domain structure of 
STATs. (Reprinted by permission from Macmillan Publishers Ltd.: Nat. Rev. 
Immunol.2003, 3, 900−911, copyright 2003). 
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2.2 Jak2 inhibition by small molecular inhibitors 
Given the critical role that Jak2 plays in the pathophysiology, identification of 
specific Jak2 inhibitors has become an important step towards the development of an 
effective targeted therapy for myeloproliferative disorders. Reports on JAK2 inhibition 
have revealed structural platforms (Fig. 2-3) like AG490,
8a
  LFM-A13,
13
 INCB20,
14
 
WP1066,
15
 SD-1008,
16
 aminoindazoles,
17
 phenylaminopyrimidines,
18
 and lestaurtinib 
(CEP701).
19
  However, only a small number of JAK2 inhibitors have been reported and 
face issues with target specificity. For example, AG490, lacks sufficient target specificity 
and may not be limited to JAK2 inhibition.
20
 Specific JAK2 inhibition is highly desirable 
since off-target effects may cause serious immuno-modulative or proliferative side 
effects.  
 
 
Fig. 2-2. Structures of some Jak2 inhibitors. 
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2.3 Significance of stilbenes in biological applications 
The activity of stilbenes has been widely studied for their biological role against 
pathogens and for pharmacological properties.
21
 The biological activity encompasses a 
wide range that includes anticancer therapy. Resveratrol (Fig. 1-4), present in grapes and 
other medicinal plants
22
, is a well known stilbene as chemopreventive agent against 
major stages of carcinogenesis
23. It’s other biological properties24 include antifungal, 
antibacterial, anticancer,
25
 antiviral,
26
 estrogenic,
27
 platelet antiaggregating
28
(Fig. 2-4) 
and heart protecting activities.
29
 Resveratrol was found to be highly beneficial to the 
cardiovascular system and has shown potent anti tumorigenic effect.
30
 Piceatannol, a 
naturally occurring phenolic stilbenoid (Fig. 2-6), is the only stilbene that is a known 
protein tyrosine kinase inhibitor.  It inhibits LMP2A, a viral tyrosine kinase implicated in 
diseases associated with the Epstein- Barr virus.
31
  
 
Fig. 2-3. Resveratrol and its analogues as inhibitors of platelet aggregation induced by 
collagen.  
 Antimicrobial compounds
32
 in grape wines belong to family of stilbenes. For 
example, 3,5-dimethoxy-4′-hydroxy stilbene (Dimethoxy Resveratrol in Fig. 2-5),  
present in grapevine leaves has relatively high activity as antifungal compound.
32a
 
 It has been shown that the total phenolic compounds extracted from red wine 
inhibit the oxidation of human low-density lipoproteins (LDL) which otherwise may 
promote atherogenesis.
33
 Analogues of resveratrol,
34
 like piceatannol,
35
 are also known to 
29 
 
possess antimicrobial activities. The presence of phenolic hydroxyl/methoxyl groups in 
this stilbenes, which have high affinity for proteins, is thought to cause scavenging of the 
the reactive oxygen species (ROS) and partly explains their associated biological roles.
36
 
Previous studies also showed that hydroxystilbenes are capable of DNA binding and 
cleavage can also occurs in combination with metals.
37
 Owing to these therapeutic values, 
the synthesis of derivatives of resveratrol has attracted a great deal of attention recently 
since they cannot be obtained in large quantities by extractive procedures. Thus several 
stilbene derivatives have been synthesized and found to be showing good antibacterial 
activity against Staphylococcus aureus, Streptococcus faecalis, Bacillus subtilis and 
Bacillus anthracis.
32d,38
 For example, Dimethoxy Resveratrol derivatives were shown to 
be active against several gram-positive and negative bacteria. Piperidino stilbenes was 
also found to be active against Stephylococccus Aureas with MIC of 5 mG (Fig. 1-5).  
 
Fig. 2-4. Structures and Antimicrobial activities of Piperidino stilbenes and Resveratrol  
analogues against Gram-positive and Gram-negative bacteria. 
Since Resveratrol has been studied extensively for its antiproliferative activity,
39
 
there have been many number of other stilbene analogues studied. Combretastatin A4 is a 
naturally found stilbene (Fig. 2-6) in the bush willow tree Comretum caffrum and shown 
to be a potent inhibitor of tubilin assembly (IC50=1.2 M)
40
 and strongly cytotoxic 
against selected human cancer cell lines. It’s evaluation against DU-145 prostate cancer 
30 
 
cell lines showed activity with GI50 = 2 nM. Phosphate prodrug of Combretastatin 
A4(CA4P),
41
 with water soluble property, is currently being evaluated as a vascular 
disrupting agent, which targets and damages tumor vasculature, in human clinical trials. 
 
Fig. 2-5. Stilbenes as inhibitors of tubulin assembly and with activity in prostate cancer 
cell lines.  
Diethylstilbestrol was found to be antiandrogen in  MOP cell line evaluation
42
 
with EC50=1 M though it does not have a significant effect on tubulin polymerization.
43
 
Piceatannol has been reported  to possess substantial antileukemic
44
 activity and also 
shown to be a potent inducer of apoptotic cell death in BJAB (Burkitt-like lymphoma 
cells) cell line with an ED50=25 M.
45
 It is also found to be  a potent inhibitor of protein 
tyrosine kinases (p56
lck 
and Syk) with an inhibitory constant (Ki) of 15 µM.
31a,46
 Further it 
was shown to suppress TNF (tumor necrosis factor-) induced activation of NF-B 
(nuclear transcription factor) at 50 M concentration.47 
Tamoxifen,
48
 belongs to stilbene class of compounds, was discovered to be a 
selective estrogen receptor modulator. It is widely used currently for the treatment of all 
stages of hormone-responsive breast cancer
49
 and currently approved by the FDA for the 
chemoprevention of this disease.
50
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Fig. 2-6. Tamoxifen and its analogues as antiestrogen compounds for the treatment of 
advanced breast cancer. 
Z-Hydroxytamoxifen,
51
 an active metabolite of Tamoxifen,
52
 was found to be an 
active antiestrogenic stilbene.
53
 It also possess a high in-vitro potency for the estrogenic 
receptor
54
 and is a weaker agent than the tamoxifen in-vivo due to rapid clearance
55
 from 
cell line. Z-Toremifen was also found to be effective for the treatment of estrogen 
receptor positive advanced breast cancer
56
 and has been marketed for the treatment of 
advanced breast cancer.
57
 E-Droloxifen is another stilbene found to be a new 
antiestrogen
58
 and is under clinical trials for the treatment of breast cancer in 
postmenopausal women. Potential uses of E-Droloxifen
59
 could be in endometriosis, 
Alzheimer’s disease, Uterine fibroid disease among others. The pronounced biological 
activities of tamoxifen analogues have encouraged the synthesis of many novel structural 
congeners.
60
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2.4 Synthetic approaches towards stilbenes 
Stilbenes have been synthesized via various methods.
61
 These methods include 
reactions catalyzed  by Pd, Ru, Ti, Zn, Rh, Ni, Mo and ylide formation in wittig reaction. 
Following sections will describe a few methods that are widely used. 
Guiso et. al. 
62
 have synthesized E-Resveratrol (Scheme 2-1) via a Heck reaction 
between 3,5-diacetoxy styrene and 4-acetoxy phenyl iodide catalyzed by Pd(OAc)2 and 
PPh3 in 70% yield. Since aryl iodide is more reactive than ArBr and ArCl in Heck 
reaction, it was chosen in this reaction. This reaction also yielded small amounts of  
partially deacylated by products. The resulted triacetoxy stilbene was hydrolyzed to E-
Resveratrol with NaOMe. 
 
Scheme 2-1. Synthesis of E-Resveratrol by Guiso et. al.via heck reaction. (a). Pd(OAc)2, 
PPh3, Et3N, CH3CN, 85
0
C. (b). NaOMe, MeOH, THF. 
Sengupta et. al. 
63
 used aryldiazonium salts in double heck reaction (Scheme 2-2) 
with vinyltriethoxysliane to synthesize symmetrical trans-stilbenes with 40-70% yields 
for various substituents. 
 
Scheme 2-2. Synthesis of Stilbenes by sengupta et. al.via heck reaction. (a). Pd(OAc)2, 
MeOH,  60
0
C, 1hr. 
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Suzuki-Miyaura reaction has also been used for the synthesis of stilbenes since 
the method is highly selective, tolerant of functional groups on either coupling partners 
and reagents is fairly insensitive towards water. Andrus et. al. 
64
 (Scheme 2-3)  used 
imodozolium chloride catalyst in combination with Pd(OAc)2 to couple aryldiazonium 
salts and aryl vinylboronic acids in suzuki reaction for the synthesis of trans-stilbenes. 
  
Scheme 2-3. Synthesis of Stilbenes by Andrus et. al.via suzuki reaction. (a). Pd(OAc)2, 
THF, 0
0
C to room temperature, imidazolium chloride, 3hrs, 68-87% yields. 
Stille coupling
65
 with modified reagents is also an useful method for the synthesis 
of stilbenes. For example, Nishibayashi et. al. 
66
 (Scheme 2-4) used organotellurides 
instead of organostannes in Stille type coupling for the synthesis of  trans-stilbenes. 
Various organotellurides reacted with alkenes in the presence of palladium salts  and 
oxidant like AgOAc for the efficient synthesis of stilbenes.  
 
Scheme 2-4. Synthesis of Stilbenes by Nishibayashi et. al.via Stille coupling. (a). 
Pd(Cl)2, AgOAc, Et3N, MeOH, 25
0
C, 20 hrs. 
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Cross metathesis reaction presents another possible method for the synthesis of 
both symmetrical and unsymmetrical stilbenes.
67
 Since schrock et. al. 
68
demonstrated that 
trans-stilbenes can be synthesized by using Mo-based catalyst, this method has garnered 
attention recently. Chang et. al. 
69
 synthesized symmetrical stilbenes from the 
corresponding para-substituted styrene by using Ru-based Grubbs 2
nd
 generation catalyst. 
Velder et. al. 
70
 synthesized a broad spectrum of unsymmetrically substituted stilbenes 
(Scheme 2-5) using Grubbs 2
nd
 gen. catalyst. 
 
Scheme 2-5. Synthesis of Stilbenes by Velder et. al. 
70
 via cross-metathesis. (a). Grubb’s 
2
nd
 generation cat.(2 mol%), CH2Cl2, 40
0
C, 1.5 hrs. 
Wittig or Horner-Wadsworth-Emmons reactions have attracted greater attention 
for the synthesis of stilbenes from two aromatic building blocks although it affords both 
(E)- and (Z)-alkenes. This reaction of benzyl ylides with substituted benzyl aldehydes 
proved to be unsatisfactory since it afforded poor control over the configuration of the 
newly formed C=C double bond yielding mixtures. This is mainly attributed to semi 
stability or instability of the ylides. Pettit et. al. 
71
 synthesized cis-stilbenes (Scheme 2-6) 
using wittig reaction with a Z to E ratio of 1.4:1. Both isomers were isolated by column 
chromatography. Photochemical isomerization of trans isomer proceeded to yield cis-
stilbenes with 62% overall yield. 
35 
 
 
Scheme 2-6. Synthesis of (Z)-Stilbenes by Pettit et. al.
71
 via wittig reaction. (a). n-BuLi, 
THF, 0
0
C then aldehyde in THF, Argon. Z to E ratio of products 1.4:1. (b). Benzil, 
Benzene, 254 nm lamp, Argon. (c). Zn/AcOH. (d).  
Horner−Emmons−Wadsworth olefination is another reaction which provides 
greater selectivity for the synthesis of trans-stilbenes and avoids the formation of 
byproduct triphenylphosphine oxide, a byproduct of  wittig reaction. For example, 
Heynekamp et. al. 
72
 synthesized substituted (E)-stilbenes (Scheme 2-7) by reacting 
benzylphosphonic acid diethylester with various substituted benzaldehydes using sodium 
methoxide as a base.  
 
 
Scheme 2-7. Synthesis of (Z)-Stilbenes by Heynekamp
72
 et. al.via Horner-Emmons-
Wadsworth reaction. (a). NaOMe, 18-crown-6, DMF. 
There are also several methods for the synthesis of stilbenes that are catalyzed by 
transition metals. Among them, Mcmurry reaction
60b,73
 is versatile in the formation of 
stilbenes via coupling of carbonyl compounds, such as diarylketones and aldehydes. It 
provides ready access to symmetrical stilbenes by avoiding byproducts as is the case in 
other methods. It is also efficient in terms of functional group tolerance, solid-liquid 
biphasic work up and does not require expensive metal catalysts, or ligand.  Mcmurry 
reaction,
74
 a reductive coupling of carbonyl groups, is catalyzed by low valent titanium. 
36 
 
The formation of the stilbene is the result of a induced reductive dimerization to 
form carbon-carbon bond which is followed by the deoxygenation of the pinacolate 
intermediate. The Mcmurry reaction has been exploited in organic synthesis and usually 
provides (E)-stilbenes. (Z)-stilbenes
75
 can be preferentially obtained if geometric 
constraints control the orientation of the two carbonyl moieties. Thus this reaction is 
versatile in terms of controlling stereochemistry of the double bond and  functional group 
tolerance. Some of the stilbenes synthesized by this method have shown potent 
nematocidal activity. 
76
 Mcmurry reaction has been used in the synthesis of highly 
functionalized stilbenes such as Tamoxifen, 
73a
 Droloxifen
59
 and related compounds. 
52
  
 
 Scheme 2-8. Observed stereoselectivity in the synthesis of (Z)-4-Hydroxytamoxifen. 
 
Scheme 2-9. Synthesis of (Z)-4-Hydroxytamoxifen by Gautheir et. al. 
52
 via Mcmurry 
reaction with modified reaction conditions. (a). TiCl4, Zn, THF, 0
0
C to reflux. (b). 
Cl(CH2)2N(CH3)2, K2CO3, acetone, H2O. (c). MeLi, THF, -78
0
C. 
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Mcmurry reaction yields mixed results for synthesis of unsymmetrical stilbenes 
especially when  the carbonyl compound used is diaryl ketone and is reacted with 
equimolar amounts of other ketone or aldehyde. However,  by using diaryl ketone in less 
than equimolar amount, the desired unsymmetrical stilbene can be obtained in good 
stereoselectivity and yield. For example, Gauthier et. al. 
52
demonstrated that using diaryl 
ketone and propiophenone in 1:3 ratio, the cross coupled product was obtained with E/Z 
ratio of 100:1 in 82% yield (Scheme 2-9). The mechanistic investigation
52,59
 of the 
reaction revealed a steric preference in the transition state in which the sterically smaller 
alkyl chain aligned with the bulkier substituted  phenol group (Scheme 2-8) thus 
minimizing the steric interaction. This steric preference was elegantly exploited  by 
Gauthier et. al. in the design of the synthetic route to (Z)-4-Hydroxytamoxifen and other 
analogues like (E)-Droloxifen.  
2.5 Synthesis of novel stilbenes via Mcmurry reaction 
Recently, we have identified a novel small-molecule inhibitor of Jak2, named G6, 
(Fig. 2-8) using structure-based virtual screening. 
77
 We showed that G6 has a specific 
inhibitory effect on Jak2 kinase activity as measured by in vitro enzyme assays. In an in 
vivo and ex vivo study, G6 greatly reduced growth of Jak2-Val617phe mutated human 
pathological cells isolated from the bone marrow of a polycythemia vera patient who was 
Jak2-V617F positive in a dose dependent manner with IC50 value of 50 nM. Our 
laboratories have also reported that the core stilbenoid ring system
78
 present in G6 is 
essential for maintaining its ability to inhibit Jak2 kinase activity.  In the course of our 
studies towards the synthesis of G6 and its analogs, our efforts were led on to the 
investigation of the Mcmurry reaction. 
38 
 
 
Fig. 2-7 Structure of G6 (compound 11). 
As illustrated in Scheme 2-10, synthesis of the various G6 analogs was 
envisioned using Mcmurry coupling of the hydroxyl benzaldehyde or ketones to 
synthesize the corresponding hydroxystilbene followed by the Mannich coupling with the 
appropriate amine.  Five stilbenes, 6-10 (see Table. 2-1, Scheme 2-11) were synthesized.  
Mcmurry coupling of the ketone and aldehyde in the presence of Zinc and titanium 
tetrachloride in dry THF led to a mixture of E- and Z- stilbenoids to a varying degree.  
 
Scheme 2-10. Synthesis of stilbenoids from ketones and aldehydes. 
Separation of these isomers involving column chromatography proved to be a 
difficult task due to the dynamic isomerization on the column. Next, we tried various 
solvents for recrystallization to isolate the  isomers selectively. However, several 
attempts to separate and isolate the Z- isomer were unsuccessful. The E-stilbenoid, being 
more stable, was the only isomer isolated in these recrystallization. When 4’-hydroxy 
propiophenone 1 was treated with the low valent titanium reagent, prepared from 
TiCl4/Zn, at reflux, diethylstilbestrol was obtained as an inseparable E/Z mixture. This 
E/Z mixture upon recrystallization from 15% ethylacetate/hexane resulted 6 (>100:1 E/Z 
ratio) with pure E isomer in 73% yield. 
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Scheme 2-11. Reagents and Conditions. i. TiCl4, Zn, Dry. THF, reflux. 
Table 2-1. Stilbenes 6-10 from various carbonyl compounds. 
Aldehyde or ketone R1 R2 R3 Stilbene 
E/Z  
ratio 
%  
Yield 
4’-Hydroxy propiophenone  (1) -C2H5 -H -OH 6 100 : 1 73 
4’-Hydroxy acetophenone    (2) -CH3 -H -OH 7 100 : 1 65 
4’-Hydroxy benzaldehyde    (3) -H -H -OH 8 100 : 1 71 
3’-Hydroxy acetophenone    (4) -CH3 -OH -H 9 85 : 15 76 
3’-Hydroxy benzaldehyde    (5) -H -OH -H 10 100 : 1 84 
 
trans- 4,4’-Diethyl stilbestrol(6): The 1H NMR of trans- diethylstilbestrol 6 was in 
complete agreement with the one in literature (Fig. 2-9b).
79a
 A NMR spectral comparison 
of the cis- and trans- mixture before and after crystallization is shown in figure 1-8.  The 
methylene (Ha’) and methyl (Hb’) protons in the trans isomer were upfield than of those  
(Ha and Hb) in the cis-stilbestrol (Fig. 1-8a). Methyl (Hb’) protons in trans- 6 were at 
0.6 ppm while those (Hb) were at 0.7 ppm in the cis-isomer. This upfield shift in the 
resonance of the methyl and methylene in the trans isomer can be  attributed to the 
diamagnetic shielding due to their proximity to the aromatic ring.  The diamagnetic 
shielding was also observed in the upfield shift in the resonance position of the aromatic 
protons in the cis- isomer  (Fig. 2-9a). 
79a
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Fig. 2-8. 
1
H NMR spectra of Diethyl stilbestrol 6 (a). trans and cis mixture . (b). isolated  
trans isomer after recrystallization. 
trans- 4,4’-Dihydroxy dimethylstilbene (7): Using reaction conditions similar to as 
previously described the 4’-Hydroxy acetophenone (2) in Mcmurry coupling also gave 
E/Z mixture which upon recrystallization from (9:1) methanol and water furnished 7 (>99 
: 1 ratio) with 65% yield. In the 
1
H-NMR spectrum, the methyl groups in the trans-
isomer of 7 also showed signal upfield than that of in the cis-isomer (Fig. 2-10); as seen 
in the case of Diethylstilbestrol 6.  Similar trend was also observed for aromatic protons 
of 7 in which were upfield in the cis-isomer that in the trans- isomer. This could also be 
attributed to diamagnetic shielding effect as explained in the case of Diethylstilbestrol 6.  
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Fig. 2-9. Comparisons of 
1H NMR spectrums of 4,4’-dihydroxy dimethylstilbene 7 as 
mixture and trans isolated. (a). Mixture of isomers trans and cis. (b). Pure trans isomer 
after recrystallization. 
Next, 4’ and 3’-Hydroxy benzaldehydes (3 and 5) also gave E/Z mixtures which 
upon recrystallization from methanol furnished pure isomers with 71% and 84% yields. 
Crude product from 3’-Hydroxy acetophenone in recrystallization from methanol resulted 
in 85:15 (E/Z ratio) which used in next step directly. Unambiguous structural 
characterization of the stilbene was carried out using the 
1
H and 
13
C NMR spectroscopic 
analysis . 
76,79
 
In all of the stilbenes synthesized, trans-isomer was obtained predominantly. This 
predominant formation of trans-product suggests that the orientation of phenyl rings 
plays an important role in the transition state as shown in Fig. 2-11. The generally 
accepted mechanism, proposed by Mcmurry
73b,80
 and several other, 
59
 is that the carbonyl 
compounds are reduced by metallic titanium to give a radical anion species leading to 
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their homolytic coupling followed by the deoxygenation of the pinocolic intermediate to 
result in the desired stilbene. It is noteworthy to mention that unless the orientation of 
carbonyl compounds are constrained by geometrical restraints
81
 like it was observed in 
the cases such as cyclophanes, 
82
 calix[4]arenes
75
 and 2,3-dicarbonyl substituted benzene 
derivatives
83
 with rigid scaffold structures, the carbonyl compounds prefer to orient 
themselves such that with phenyl groups are always syn to  the smaller alkyl groups. So 
this could explain the predominant formation of trans-isomers as this orientation could 
minimize the interaction between bulkier phenyl rings. 
 
Fig. 2-10. Observed stereoselectivity in the synthesized stilbene in Mcmurry reaction. 
2.6 Synthesis of novel stilbenoids via Mannich condensation 
Stilbenes 6-10 synthesized have been coupled with various amines in Mannich 
condensation as shown in scheme 2-12 and the list of compounds is included in Table 2-
2. As an example of the process, Diethylstilbestrol 6 was treated with 2.1 molar 
equivalent of dimethylamine and 2.2 molar equivalent of   paraformaldehyde at reflux to 
synthesize stilbenoid 11. The stilbenoid 11 showed proton signals  in 
1
H NMR spectrum 
(Fig. 2-12a) at 3.6 ppm for benzylic protons (He), 2.8 and 1.3 ppm for ethylamine 
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protons (Hc and Hd), aromatic protons at 6.8-7.0 ppm, the Ha at 2.1 ppm and the Hb 
protons at  0.7ppm.  
13
C NMR spectrum also confirmed the structure of the symmetrical 
stilbenoid 11. Importantly, the NMR data confirmed that the  reflux condition used in this 
reaction did not alter the trans-configuration of this product.  
 
Fig. 2-11. Compound 11 spectrums. (a). 
1
H NMR spectrum. (b). 
13
C NMR spectrum. 
Following the general synthetic protocol established for the synthesis of 11 above, 
Diethyl stilbestrol 6 was treated with four other amines dimethyl amine, piperidine, 
pyrrolidine and morpholine to synthesize four other stilbenoids 12-15 (Table 2-2). All of 
them obtained in excellent yield with preserved trans- configuration. 
 
Scheme 2-12. Reagents and Conditions. (a). amine, paraformaldehyde, MeOH, reflux. 
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Table 2-2. List of synthesized stilbenoids (11-35) and stereo selectivity.  
 
Compound R1 R2 E/Z ratio Compound R1 R2 E/Z ratio 
11 (G6) C2H5 
N
 
E 24 H 
N
 
E 
12 C2H5 N  E 25 H 
N
O E 
13 C2H5 
N
 
E 26 CH3 
N
 
4 : 1 
14 C2H5 
N
 
E 27 CH3 N  
3.5 : 1.5 
15 C2H5 
N
O 
E 28 CH3 
N
 
4 : 1 
16 CH3 
N
 
E 29 CH3 
N
 
4 : 1  
17 CH3 N  E 30 CH3 
N
O 
4.5 : 1.5  
18 CH3 
N
 
E 31 H 
N
 
E 
19 CH3 
N
 
E 32 H N
 
E 
20 CH3 
N
O 
E 33 H 
N
 
E 
21 H 
N
 E 
34 H N
 
E 
22 H N  E 35 
H 
N
O 
E 
23 H 
N
 
E     
 
In a similar manner, 4,4’-dihydroxy-dimethyl stilbene 9 (E/Z ratio as 85:15) was 
treated with five different amines diethyl and dimethyl amine, piperidine, pyrrolidine and 
morpholine to synthesize stilbenoids 26-30.  In this mannich condensation, stilbenoid 26 
was obtained with 4:1 E/Z ratio.  Stilbenoid 27, 28 and 30 were obtained with 7:3, 4:1 
and 3:1 E/Z ratios, respectively.   In the case of stilbenoid 29, E/Z  ratio was 4:1 (Fig. 2-
13).   
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Fig. 2-12. 1H NMR spectrums. a. Compound 9. b. Signals for stilbenoid 29. 
Stilbenes 7, 8, and 10 were also treated with 2.2 mmols of appropriate amines 
(dimethyl and diethylamine, pyrrolidine, piperidine and morpholine) and 
paraformaldehyde in methanol at 80
0
 C to synthesize the 11 analogues in good to 
excellent yield (Scheme 2-12, Table 2-2).  
The chemical structures of the stilbenoids obtained were confirmed by 
1
H- and 
13
C- NMR analysis. For example, 
1
H NMR spectra of stilbenoids 17, 22 and 34 shown 
below (Fig. 2-14) indicates excellent purity and the absence of any side products.  
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Fig. 2-13. 1H NMR spectrums. (a). Compound 17. (b). Compound 22. (c). Compound 34. 
 
2.7 Synthesis of novel N-substituted stilbenebisoxazine analogues via double 
condensation 
Stilbenes (8 and 10) were also converted to N-substituted bisoxazines by Mannich 
condensation with various primary amines. As an illustrative procedure, stilbene 8 was 
treated with 2 equivalents of p-methoxy benzyl amine and 4.2 equivalents of 
paraformaldehyde to form bisoxazine ring as shown in scheme 2-13. This reaction gave 
1,3-bisoxazone 39 as the major product. In 
1
H NMR spectrum (Fig. 2-15), the 
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corresponding signals for methylene protons (Hb, Hc and Hd) were observed at 4.15, 4.0 
and 4.9 ppm respectively. Methoxy group protons(Ha in Fig. 2-15) showed signal at 3.75 
ppm and aromatic proton between 6.75-7.35 ppm range. This product 39 was also 
obtained as the only isomer as there is no presence of E/Z mixture or side products from 
the 
1
H NMR spectrum (Fig. 2-15).  
 
 
Fig. 2-14. 
1
H NMR spectrum of Compound 39. 
 
Encouraged by this result, Stilbenes (8 and 10) were treated with 2.0 equivalents 
of various primary amines and 4.2 equivalents of paraformaldehyde in Mannich 
condensation in MeOH at reflux. Five different amines- cyclohexyl and cyclopentyl 
amines, benzyl and p-methoxy benzyl amines, Furfuryl amine- were used in this mannich 
condensation to synthesize various N-substituted stilbenebisoxazines (36-44) as shown in 
scheme 2-13 and Table 2-3 in good to excellent yields.  
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Scheme 2-13. Reagents and Conditions. (a). amine, paraformaldehyde, MeOH, reflux. 
Table 2-3. List of synthesized stilbenoid rings (36-44) and stereo selectivity.  
 
Stilbene R1 R2 Product R3 
8 OH H 36 
 
8 OH H 37 
 
8 OH H 38 
 
8 OH H 39 
OMe
 
9 H OH 40 
 
9 H OH 41 
 
9 H OH 42 
 
9 H OH 43 
OMe
 
9 H OH 44 
O  
 
The chemical structures of all the N-substituted stilbenebisoxazines were 
confirmed by 
1
H- and 
13
C- NMR analysis. 
1
H NMR spectra of N-substituted 
stilbenebisoxazines 38, 41 and 43 shown below (Fig. 2-16) indicates excellent purity and 
the absence of any side products. 
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Fig. 2-15. 
1
H NMR spectrums. (a). N-Benzyl stilbenebisoxazine 38. (b). N-Cyclopentyl 
stilbenebisoxazine 41. (c). N-(p-methoxybenzyl) stilbenebisoxazine 43. 
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2.8 Evaluation of the novel stilbenes and stilbenoids against JAK2-V617F Mutated 
JAK2 Enzyme 
Stilbenes (6 to 10) and stilbenoids (11-35) synthesized were evaluated for JAK2 
enzyme activity.  Proliferation of HEL cells is mediated by the constitutively active Jak2-
V617F signaling which promotes a G1/S phase transition, thereby leading to increased 
cellular proliferation.
10a-e
 G6 (Stilbenoid 11) has been identified as a potent inhibitor of 
Jak2 enzyme in structure based virtual screening. In an in vivo and ex vivo study, G6 
greatly reduced growth of JAK2-Val617phe mutated human pathological cells. 
Elaborated details of this work have been discussed  at the end of this chapter. We 
observed that the phenol OH in G6 forms strong hydrogen bonds with the backbone NH 
group of Leu932 and a salt bridge is formed between N of 3
0
 amine in G6 and Asp994 
(see Fig. 2-20 and Fig. 2-21). These interactions might be the important to consider 
during further modification of the G6.  To study these interactions and tolerance of 
various groups on the G6, we here describe structural modification of G6 in an effort to 
derive a structure activity relationship (Fig. 2-8). G6 and its structurally related 
derivatives were therefore first analyzed for their ability to inhibit the Jak2-V617F 
dependent proliferation of HEL cells. Viable cell numbers were determined by trypan 
blue exclusion and hemocytometer after 72 hrs. Each sample was measured in triplicate. 
Inhibition by G6 (Compound 11) was arbitrarily set at 100%  and the percent inhibition 
for all the other compounds relative to G6 was defined as 1.00 - (∆ drug / ∆ vehicle 
control). To determine the ability of each of these compounds to inhibit Jak2-V617F 
mediated HEL cell proliferation, cells were treated with G6 or its derivatives. Viable cell 
numbers for each treatment were determined. 
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Anti Jak2 activity of 4,4’-dihydroxy stilbenoids in terms of HEL (Human Erythro 
Leukemia) cell assay were shown in Table 2-4. The results of anti Jak2 activity of 3,3’-
dihydroxy stilbenoids were shown in Table 2-5 in terms of HEL cell assay. This cell line 
is homozygous for the V617F mutation which induces constitutive Jak2 phosphorylation 
and drives HEL cell proliferation. We investigated five different amines, i.e. 
dimethylamine, diethylamine, piperidine, pyrrolidine and morpholine to probe the 
importance of the interactions observed in G6 (11) between N atom of amine and Asp994 
in Jak2 catalytic activation loop
77
.   
In an HEL cell inhibition assay of 4,4’-dihydroxy stilbenoids (Table 2-4), The 
favourable configuration around alkene found to be disubstitution than tetrasubstitution. 
This can be observed in compounds 22 and 24 in comparison with compounds 12-20. In 
other words, When R1 is ethyl and methyl (12-20), the enzyme inhibitory potency against 
JAK2 is low. If alkene has only phenyl groups (22 and 24), the potency is similar to G6 
(11). Small alkyl groups like methyl and pyrrolidine (22 and 24) in amine proved to be 
better fit in enzyme binding site than larger rings like pyrrolidine and morpholine. It was 
also found that 4,4’-dihydroxy stilbene (8) itself is highly potent inhibiting Jak2 enzyme 
than G6 (11). This is also true with 3,3’-dihydroxy stilbene (10). This suggests that 
hydroxyl groups are efficient enough to make enhanced interactions with JAK2 enzyme 
binding site to improve potency. Structures of potent active compounds 8, 10, 22 and 24 
are shown in Fig. 2-18. 
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Table 2-4. Jak2 activity of G6 and its 4,4’-Dihydroxy stilbenoid analogues. 
 
Comp. R1 R2 
% HEL 
Inhibition 
(10 µM) 
at 72 hrs 
Comp. R1 R2 
% HEL 
Inhibition 
(10 µM) 
at 72 hrs 
6 C2H5 H 65 17 CH3 N  
60 
7 CH3 H 63 18 CH3 
N
 
72 
8 H H 106 19 CH3 
N
 
74 
11 (G6) C2H5 
N
 
100 20 CH3 
N
O 
nd 
12 C2H5 N  
74 21 H 
N
 
85 
13 C2H5 
N
 
80 22 H N
 
99 
14 C2H5 
N
 
89 23 H 
N
 
nd 
15 C2H5 
N
O 
48 24 H 
N
 
96 
16 CH3 
N
 
26 25 H 
N
O 
nd 
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Table 2-5. Jak2 activity of G6 and its 3,3’-Dihydroxy stilbenoid analogues . 
 
Compound R1 R2 E/Z ratio 
% HEL 
Inhibition  
(10 µM) at 72 hrs 
11 (G6) C2H5 
N
 
100 : 1 100 
9 CH3 H 85 : 15 35 
10 H H 100 : 1 106 
26 CH3 
N
 
4 : 1 61 
27 CH3 N  3.5 : 1.5 55 
28 CH3 
N
 
4 : 1 84 
29 CH3 
N
 
4 : 1  68 
30 CH3 
N
O 
4.5 : 1.5  39 
31 H 
N
 
E 74 
32 H N
 
E 36 
33 H 
N
 
E 50 
34 H N
 
E 35 
35 H 
N
O 
E 25 
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Fig. 2-16. Activity Comparison of 3,3’ and 4,4’-Dihydroxy Stilbenoids. 
Inhibitory activity comparison of 4,4’ and 3,3’-dihydroxy stilbenoids (Fig. 2-17) 
with same alkyl groups on alkene and amines reveals several trends. In 4,4’-dihydroxy 
stilbenoids, The potency increases sequentially over diethylamine, dimethyl, piperidine, 
pyrrolidine (16-19) with methyl on alkene and with disubstitution on alkenes (21-24) 
over diethylamine, piperidine, pyrrolidine. As previously said, small alkyl groups methyl 
and pyrrolidine (22 and 24) showed increased potency. 3,3’-dihydoxy stilbenoids assay 
(Table. 2-5 and Fig. 2-17) revealed that while free amine bases are not able to increase 
the potency but few salts (Table 3) showed very potent activity than G6.   
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Fig. 2-17. Stilbenoids which shows potent activity against JAK2 enzyme. 
 
Fig. 2-18. Structures of salts of stilbenoids. 
The assay of few salts (Fig. 2-19) was done to follow the inhibition activity 
(Table 2-6) dependence on solubility. Even in salts, large alkyl ring on N did not 
improve the inhibitory activity as evident in 33a than G6 (Compound 11). But dimethyl 
and diethyl amine, showed good inhibitory activity and greatly increased the potency 
than G6. This may be due to fact that salts have the advantage of having charges on N 
already making them more soluble in carrier polar media and making better interactions 
in the binding pocket.  
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Table 2-6. Anti Jak2 activity of salts of 3,3’-Dihydroxy stilbenoid analogues . 
Comp. -R1 
% HEL 
Inhibitio
n(10 µM) 
at 72 hrs 
Comp. -R1 
% HEL 
Inhibitio
n(10 
µM) at 
72 hrs 
26a -Methyl 112 26 -Methyl 61 
31a -H 112 31 -H 74 
27a -Methyl 114 27 -Methyl 55 
33a -H 
62 
33 -H 
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In this Anti Jak2 activity, Salts of stilbenoids 26a, 31a and 27a have shown two 
times increased potency than their corresponding free amines 26, 31, 27 (see Fig. 2-19 
and Table 2-6). This strongly indicates that there is enhanced interaction of small alkyl 
groups and free hydroxyl groups on stilbenoids with Jak2 enzyme and so better solubility.   
2.9 Conclusions 
             In summary we have developed the methodology for efficient synthesis of 
stilbenoids based on Mcmurry and Mannich condensation protocol. The assay studies of 
these compounds has provided that substitution around alkene in the stilbenoid molecule 
has a critical role in deciding inhibitory activity and revealed several potent inhibitors of 
Jak2 enzyme. Also by varying the alkyl groups in amine substituent we were able to 
identify the potent inhibitors (compounds 8, 10, 22 and 24).  These assay studies also able 
to demonstrate that not only amine and their salts also active inhibiting Jak2 as observed 
enhanced  potency which is evident in 26a, 31a and 27a. 
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2.9 Inhibition of JAK2-V617F kinase activity by G6 (Stilbenoid 11) 
Recently, In collaboration with Dr. Peter, P. Sayeski, we identified G6 (Stilbenoid 
11) as a inhibitor of JAK2 enzyme using structure-based virtual screening.
29
 It was shown 
that G6 has a specific inhibitory effect on Jak2 kinase activity as measured by in vitro 
enzyme assays.
29
 In an in vivo and ex vivo study, G6 greatly reduced growth of JAK2-
Val617phe mutated human pathological cells isolated from the bone marrow of a 
polycythemia vera patient who was Jak2-V617F positive in a dose dependent manner 
with IC50 value of 50 nM (Fig. 1-20). We have also reported that the core stilbenoid ring 
system present in G6 is essential for maintaining its ability to inhibit Jak2 kinase activity. 
From analysis of the G6 binding mode in Jak2 active site
77
, The human erythroleukemia 
(HEL 92.1.7) cell line is homozygous for the Jak2-V617F mutation and this gain-of-
function mutation is responsible for its transformed phenotype.
10d
 
 
Fig. 2-19. Binding mode of G6(grey) at the Jak2(green) vanderwall surface.
77
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Fig. 2-20. Anti Jak2 enzyme activity of G6 (stilbenoid 11)
77
. Left. Inhibition of JAK2 
Val617Phe kinase activity by G6 (IC50 = 60 ± 4.5 nM). Right. Growth inhibition of G6 
on a  human pathological cells isolated from polycythemia vera patient . 
2.10 Antimicrobial activity of stilbenoids 
Previous studies revealed that hydroxy stilbenes and analogues of Resveratrol 
possess antimicrobial activities. The presence of phenolic hydroxyl/methoxyl groups in 
these stilbenes, which have high affinity for proteins, generally attributed to scavenge the 
reactive oxygen species(ROS) and partly explain their associated biological roles.
36
 
Studies also shown that hydroxystilbenes are capable of DNA binding and cleavage can 
also occurs in combination with metals.
37
 Thus pronounced biological role of stilbenes 
encouraged us to screen several stilbenoids synthesized in our lab. Each of the stilbenoid 
synthesized, as illustrated in Scheme 2-12 and Table 2-2, and N-substituted 
stilbenebisoxazine synthesized, as illustrated in Scheme 2-13 and Table 2-3, was assayed 
for the ability to inhibit the growth of select strain of clinically significant bacteria.   
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The invitro MIC determination for each compound were performed against a 
multi drug resistant hospital acquired methicillin resistant S. aureus (MRSA) and 
methicillin resistant S. epidermidis (MRSE).  From the results of these MIC (minimum 
inhibitory concentration) assays, most active compounds are presented in Table 2-7. To 
explore the broad spectrum activity of these compounds (Fig. 2-22), we also employed 
the modified Kirby-Bauer assay  using two gram-positive pathogens, E. Faecalis  and B. 
Anthracis,  Gram-negative pathogen, E. Coli, and the eukaryote Saccharomyces 
cerevisiae (yeast) (see Table 2-7). 
 
Fig. 2-21. Structures of active stilbenoids and N-Substituted stilbenebisoxazines. 
From the analysis of data, Most observable feature is that not only stilbenes with 
free hydroxyl groups are able to show potent antibacterial activity but also stilbenes with 
bisoxazine rings on phenyl groups were able to show moderate antimicrobial activity. 
This fact is quite interesting than previously predicted observation that  free hydroxyl 
moiety in stilbenes is vital to show enhanced activity. Alkene with methyl group and 
dimethyl groups on tertiary amine in stilbenoid (Compound 27) was able to show 
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enhanced activity in MRSA (MIC 21.25 g/mL) and MRSE (MIC 15 g/mL) studies 
than other stilbenoids with larger rings like piperidine, pyrrolidine, cyclohexyl and 
cyclopentyl groups.  This compound also showed potent activity against both Gram-
positive bacteria and Gram-negative bacteria than other compounds. Another exciting 
feature in this data is that all of the N-substituted stilbenebisoxazine analogues(36, 40-41) 
were equally potent in MRSE assays although stilbenebisoxazine (40) with cyclohexyl 
ring shown greater potency (MIC 25 g/mL) than other stilbenebisoxazine with rigid 
cyclopentyl group(Compound 41) in MRSA studies. In conclusion from these data,  these 
novel scaffolds certainly serve as a starting points for the development of new drugs that 
are certainly needed to combat MRSA and anthrax infections and may promote additional 
SAR studies of stilbenoid compounds for therapeutic use. 
Table 2-7.  Antimicrobial assay of stilbenoids. Minimum inhibitory concentration values 
(g/mL) against MRSA and MRSE bacteria and Zone of inhibition values (millimeters) 
against various bugs. 
c
 
Compound 
No. 
MIC (G/mL) Zone of Inhibition (mm) 
MRSA
a
 MRSE
b
 
B. 
Anthracis 
E. 
Faecalis 
E.Coli Yeast 
12 62.5 33.33333 ND
d
 ND
d
 ND
d
 ND
d
 
26 25 25 23.33 27.33 0.00 24.00 
27 21.25 15 30.67 36.67 33.33 27.33 
28 33.75 25 16.00 27.33 0.00 23.33 
29 25 25 24.00 32.00 27.33 31.33 
40 25 25 14.67 27.33 30.67 24.00 
41 50 25 23.33 26.00 25.33 0.00 
36 50 25 0.00 26.67 0.00 0.00 
 
a Methicillin-resistant Staphylococcus aureus. b Methicillin-resistant Staphylococcus epidermidis. 
c Positive control is DMSO (dimethyl sulfoxide). d ND = not determined. 
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2.11 Experimental Procedures 
All solvents were dried and distilled prior to use and organic solvent extracts 
dried over Na2SO4. 
1
H NMR and 
13
C NMR spectra were recorded on a Bruker 250 MHz 
spectrometer in CDCl3 and DMSO-d6 with TMS as the standard. Chemical shifts are 
reported in parts per million, multiplicities are indicated by s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet) and bs (broad singlet). Thin-layer chromatography 
(TLC) was performed on glass plates coated with 0.25 mm thickness of silica gel.  
2.12.1 General Procedure for the synthesis of Stilbenes:  
In a flame dried 2 neck round bottom flask fitted with magnetic stirrer bar and 
reflux condensor, dry THF (180 mL or 1.5 Molar) and Zinc (8 equivalents) was taken 
under N2 atmosphere. Then reaction mixture was cooled to 0
O
c in an ice bath. To this 
mixture TiCl4 (4 equivalents) was added dropwise while maintaining the reaction 
temperature at 0
O
C. After addition was complete, reaction mixture was refluxed for 2 
hours. Then this brown color reaction mixture was cooled again to 0
O
c. Aldehyde or 
Ketone(1 equivalent) was taken in 20 mL of dry THF was added to this ice cooled 
reaction mixture slowly portion wise. Then this reaction mixture was allowed to reflux 
until TLC (2:3 mixture of ethylacete/hexane) shows that all the aldehyde or ketone is 
consumed in the reaction. After reaction is complete, reaction mixture was concentrated 
and ethylacetate was added. To this mixture saturated K2CO3 solution was added and 
allowed to stir for another 7 hours. Reaction mixture was filtered and residue was washed 
with ethylacetate. Filtrate was extracted with ethylacetate. Organic layer was washed 
with saturated NaCl solution, water, dried over anhydrous Na2SO4 and concentrated. This 
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crude mixture was chromatographed on silica column eluting with 1:9 mixture of 
ethylacetate:hexane mixture to receive E and Z stilbenes as a mixture.  
Representative procedure for E-4,4'-[1,2-diethyl-1,2-ethenediyl]bis Phenol (6):
79a
 
To a solution of Zinc (20.9 g, 0.319 mol) in dry THF (150 mL)  was added TiCl4 
(22.73 g, 0.119 mol) dropwise at 0
0
C under N2 atmosphere. After addition was complete, 
reaction mixture was refluxed for 2 hours. Then this brown color reaction mixture was 
cooled again to 0
O
c.  A solution of 4’-hydroxy propiophenone (6 g, 0.039 mol) in  dry 
THF (50 mL) was added to this ice cooled reaction mixture slowly portion wise. Then 
this reaction mixture was allowed to reflux for 6 hrs. Then the reaction mixture was 
concentrated and ethylacetate was added. To this mixture sat. K2CO3 solution was added 
and allowed to stir for another 7 hours. Reaction mixture was filtered and residue was 
washed with ethylacetate. Filtrate was extracted with ethylacetate. Organic layer was 
washed with saturated NaCl solution, water, dried over anhydrous Na2SO4 and 
concentrated. This crude mixture was chromatographed on silica column eluting with 1:9 
mixture of ethylacetate:hexane mixture to receive cis/trans mixture. This cis/trans 
mixture received in column has been recrystallized from 15% ethylacetate/hexane 
mixture to receive pure E isomer with >99% purity, which is also confirmed from 
literature values, with 73% yield. 
1
H NMR (d6-DMSO, MHz): δ 9.1 (bs, 2H), 6.7-6.6 (d, 
4H, j=8.5 Hz), 6.5-6.4 (d, 4H, j=8.5 Hz), 1.8 (q, 4H, j=7.5 Hz), 0.5 (t, 6H, j=7.5 Hz). ; 
13
C 
NMR (62.5 MHz, d6-DMSO): δ 155.7, 137.9, 132.5, 129.3, 114.8, 28.0, 13.3. 
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E/Z-4,4'-[1,2-dimethyl-1,2-ethenediyl]bis Phenol (7):  
Cis/trans mixture received in column has been recrystallized from (9:1) methanol: 
water to receive E/Z mixture as 99 : 1  ratio with 65% yield. 
1
H NMR (d6-DMSO): 7.0 
(dd, 4H, J = 2, 1.75 Hz), 6.7 (dd, 4H, J = 2, 1.75 Hz), 1.8 (s, 6H); 
13
C NMR (62.5 MHz, 
d6-DMSO): 155.6, 134.4, 131.3, 129.1, 128.1, 114.8, 22.4. 
E- 4,4'-(1,2-ethenediyl)bis Phenol  (8):
76
  
Crude product has been recrystallized from methanol to receive pure isomer with 
71 % yield. 
1
H NMR (250 MHz, MeOD): 7.3 (d, 4H, J = 8 Hz ), 6.9 (s, 2H ), 6.7 (d, 4H, 
J = 8 Hz ); 
13
C NMR (62.5 MHz, d6-DMSO): 156.7, 128.6, 127.2, 125.2, 115.4. 
E/Z-3,3'-[1,2-dimethyl-1,2-ethenediyl]bis Phenol (9):  
Crude product has been recrystallized from methanol to receive E/Z mixture as 85 
: 15 ratio with 76 % yield . 
1
H NMR (250 MHz, d6-DMSO): 9.1 (bs, 2H), 7.1 (m, J = 
7.75 Hz ), 6.88 (t, 2H, J = 7.75 Hz ), 6.6 (m), 6.4 (m, 6H), 2.0 (s, 6H), 1.8 (s); 
13
C NMR 
(62.5MHz, d6-DMSO): 157.1, 156.5, 145.6, 131.9, 129.1, 128.4, 119.6, 115.5, 112.6, 
22.0, 21.4. 
E- 3,3'-[1,2-ethenediyl]bis Phenol (10):
76
  
Crude product recrystallized from methanol to receive E isomer  with 84% yield. 
1
H NMR (250 MHz, MeOD): 7.1 (t, 2H J = 8 Hz), 7.0 (s, 2H), 6.9 (ddd, 2H, J = 8.5, 2.5, 
1.5 Hz), 6.9 (dd, 2H, J = 2.75, 1.75 Hz), 6.6 (ddd, 2H, J = 8, 2, 1 Hz). 
 
 
 
 
64 
 
2.12.2 General Procedure for the synthesis of Stilbenoids:  
Stilbene(1 equivalent) was taken in one neck round bottom flask and 15 mL of 
methanol was added. Paraformaldehyde(2.1 equivalents) and appropriate amine(2.2 
equivalents) was added. Then this reaction mixture was allowed to reflux until TLC (2:3 
mixture of ethylacetate:hexane) shows that reaction is complete. Then mixture is cooled 
to room temperature and concentrated. To this mixture ethylacetate and 1M HCl solution 
is added. Aqueous phase is separated and treated with 1M NaOH solution until pH is 7. 
Then this aqueous solution is extracted with ethylacetate. Organic layer is washed with 
saturated NaCl solution, water and dried over anhydrous Na2SO4. This organic layer is 
concentrated and dried in vacuuo. This mixture containing mannich products has been 
purified by flash chromatography over silicagel  characterized by eluting with 
dichloromethane : methanol : triethylamine mixture(99:0.5:0.5) to receive pure product 
yields ranging from 80 to 95 %. 
Representative procedure:  
E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-[(diethylamino)methyl]-Phenol (Pure 
isomer) (11) : 
To a solution of 6(0.388g, 1.447 mmol) in MeOH was added 
paraformaldehyde(0.095 g, 3.183 mmol) and diethyl amine(0.232g, 3.183 mmol). The 
reaction mixture was refluxed for 8 hrs. Then reaction mixture was cooled to room 
temperature and concentrated under reduced pressure. To this mixture ethylacetate and 
1M HCl solution is added. Aqueous phase is separated and treated with 1M NaOH 
solution until pH is 7. Then this aqueous solution is extracted with ethylacetate. Organic 
layer is washed with saturated NaCl solution, water and dried over anhydrous Na2SO4. 
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This organic layer is concentrated and dried in vacuuo. Crude reaction mixture 
chromatographed over silica gel by eluting with dichloromethane : methanol : 
triehtylamine mixture( 99:0.5:0.5) to receive pure product 11 as white color solid with 92 
%  yield.
 1
H NMR (CDCl3): δ 6.9 (d, 2H, J = 1.5 Hz ), 6.8 (d, 4H, J = 8 Hz ), 3.79 (S, 
4H), 2.6-2.6 (q, 8H, J = 7.25 Hz ), 2.1-2.08 (q, 4H, J = 7.5 Hz ), 1.1-1.0 (t, 12H, J = 7.25 
Hz), 0.8-0.7 (t, 6H, J = 7.5 Hz ) ; 
13
C NMR (CDCl3): δ 156.4, 138.7, 133.3, 129.8, 128.7, 
128.5, 121.5, 115.4, 57.1, 54.0, 46.5, 46.3, 28.6, 13.5, 11.4, 11.3. 
E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-[(dimethylamino)methyl]-Phenol (Pure 
isomer) (12) : 
 1
H NMR (CDCl3): δ 6.7 (d, 2H, J = 8.25 Hz), 6.7 (d, 4H, J = 3Hz), 3.5 (s, 4H), 
2.2 (s, 12H), 2.0 (q, 4H, J = 7.25 Hz), 0.6 (t, 6H, J = 7.5 Hz); 
13
C NMR (CDCl3): δ 156.2, 
138.7, 133.4, 129.0, 128.4, 121.4, 115.4, 63.0, 44.5, 28.5, 13.4; 
E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-Phenol (Pure isomer) 
(13) : 
1
H NMR (CDCl3): δ 6.9 (d, 1H, J = 2 Hz ), 6.8 (d, 1H, J = 2 Hz ), 6.7 (d, 2H, J = 
2.5 Hz ), 6.7 (d, 2H, J = 3.5 Hz), 3.7 (s, 4H), 2.5 (bs, 8H), 2.0 (q, 4H, J = 7.5 Hz), 1.7 (m, 
8H, J = 3.25 Hz), 0.6 (t, 6H, J = 7.5 Hz); 
13
C NMR (CDCl3): δ 156.2, 138.7, 133.3, 
128.8, 128.0, 121.9, 115.2, 59.0, 53.5, 28.5, 23.6, 13.5. 
E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-[(piperidine)methyl]-Phenol (Pure isomer) 
(14) : 
1
H NMR (CDCl3): δ 6.90 (d, 1H, J = 2 Hz ), 6.8 (d, 1H, J = 2 Hz ), 6.7 (d, 2H, J = 
2 Hz), 6.7 (d, 2H, J = 2 Hz), 3.5 (s, 4H), 2.4 (bs, 8H), 2.03 (q, 4H, J = 7.5 Hz), 1.5 (m, 
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8H, J = 5 Hz ), 1.4 (bs, 4H), 0.6 (t, 6H, J = 7.5 Hz ); 
13
C NMR (CDCl3): δ 156.3, 138.7, 
133.4, 128.8, 128.6, 121.0, 115.3, 62.3, 54.1, 53.9, 28.5, 25.9, 24.0, 13.5. 
E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-[(morpholine)methyl]-Phenol (Pure isomer) 
(15) :  
1
H NMR (CDCl3): δ 6.9 (d, 1H, J = 2 Hz), 6.9 (d, 1H, J = 2 Hz ), 6.7 (m, 4H), 3.7 
(t, 8H, J = 4.5 Hz), 3.6 (s, 4H), 2.5 (bs, 8H), 2.0 (q, 4H, J = 7.5 Hz), 0.6 (t, 6H, J = 7.5 
Hz); 
13
C NMR (CDCl3): δ 155.7, 138.7, 133.7, 129.3, 128.9, 120.1, 115.5, 66.8, 62.0, 
52.9, 28.5, 13.4. 
4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(diethylamino)methyl]-Phenol (16) :  
(E/Z: 5:1) 
1
H NMR (CDCl3): δ 6.9-6.9 (m, 3H), 6.7-6.6 (m, 6H), 6.5-6.3(m, 1H), 
3.7 (s, 4H), 3.4 (s), 2.6-2.5 (q, 8H, J = 7.5 Hz ), 2.3 (q, 2H, J = 7.5 Hz), 2.0 (s), 1.7 (s, 
6H) 1.0 (t, 6H, J = 7.5 Hz), 1.0-0.9 (m) ; 
13
C NMR (CDCl3): δ 156.4, 156.1, 155.8, 154.8, 
135.6,135.2, 132.2, 131.6, 131.5, 129.9, 129.6, 121.5, 121.1, 115.0, 114.4, 57.1, 56.7, 
46.3, 46.1, 22.7, 21.4, 11.3, 11.0 . 
4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(dimethylamino)methyl]-Phenol (17) :  
(E/Z 100 : 1) 
1
H NMR (CDCl3): δ 7.1 (dd, 2H, J = 2 Hz ), 6.8 (d, 2H, J = 2 Hz ), 
6.8 (s, 1H), 6.8 (s, 1H), 3.6 (s, 4H), 2.3 (s, 12H), 1.8 (s, 6H); 
13
C NMR (CDCl3): δ 156.2, 
135.3, 132.1, 128.6, 128.1, 121.4, 115.5, 63.0, 44.5, 22.6. 
4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-Phenol (18) :  
(E/Z 100 : 1) 
1
H NMR (CDCl3): δ 6.9 (dd, 2H, J = 2 Hz ), 6.7 (d, 2H, J = 2 Hz ), 
6.7 (s, 1H), 6.7 (s, 1H), 3.7 (s, 4H), 2.5 (bs, 8H), 1.8-1.7 (bs, 8H); 
13
C NMR (CDCl3): δ 
156.2, 135.2, 132.1, 128.4, 127.7, 121.9, 115.3, 58.9, 53.5, 23.6, 22.6. 
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4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(Piperidine)methyl]-Phenol (19) :  
(E/Z 100 : 1) 
1
H NMR (CDCl3): δ 6.9 (d, 1H, J = 2 Hz ), 6.9 (d, 1H, J = 2 Hz ), 
6.8 (d, 2H, J = 2 Hz ), 6.7 (s, 1H), 6.6 (s, 1H), 3.6 (s, 4H), 2.4 (bs, 8H), 1.7 (s, 6H), 1.5 
(m, 8H, J = 5.25 Hz ), 1.4 (bs, 4H); 
13
C NMR (CDCl3): δ 156.3, 135.3, 132.1, 128.4, 
128.3, 121.1, 115.4, 62.3, 53.9, 25.9, 24.0, 22.7. 
E-4,4'-(1,2-ethenediyl)bis[2-[(diethylamino)methyl]-Phenol (21) :  
1
H NMR (CDCl3): δ 7.3 (d, 1H, J = 2 Hz ), 7.2 (d, 1H, J = 2 Hz), 7.1 (s, 2H), 6.8 
(s, 2H), 6.8 (d, 2H, J = 8.25 Hz ), 3.8 (s, 4H), 2.6 (q, 8H, J = 7 Hz ), 1.1 (t, 12H, J = 7.5 
Hz ); 
13
C NMR (CDCl3): δ 157.8, 128.9, 126.5, 126.1, 125.6, 122.2, 116.3, 57.0, 46.3, 
11.2. 
E-4,4'-(1,2-ethenediyl)bis[2-[(dimethylamino)methyl]-Phenol (22) :  
1
H NMR (CDCl3): δ 7.2 (d, 1H, J = 2 Hz ), 7.1 (d, 1H, J = 2 Hz ), 7.0 (s, 2H), 6.7 
(s, 2H), 6.7 (d, 2H, J = 8.25 Hz ), 3.5 (s, 4H), 2.2 (s, 12H); 
13
C NMR (CDCl3): δ 157.6, 
128.9, 126.7, 126.1, 125.6, 122.0, 116.3, 62.9, 44.5. 
E-4,4'-(1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-Phenol (23) : 
1
H NMR (CDCl3): δ 7.2 (d, 1H, J = 2 Hz ), 7.1 (d, 1H, J = 2 Hz ), 7.0 (s, 2H), 6.7 
(s, 2H), 6.7 (d, 2H, J = 8.25 Hz ), 3.7 (s, 4H), 2.5 (bs, 8H), 1.7 (bs, 8H); 
13
C NMR 
(CDCl3): δ 157.5, 128.9, 126.5, 125.6, 122.5, 116.1, 58.9, 53.5, 23.6. 
E-4,4'-(1,2-ethenediyl)bis[2-[(piperidine)methyl]-Phenol (24) :  
1
H NMR (CDCl3): δ 7.2 (d, 1H, J = 2 Hz ), 7.0 (s, 2H), 6.7 (s, 2H), 6.7 (d, 2H, J = 
8.25 Hz ), 3.6 (s, 4H), 2.4 (bs, 8H), 1.5 (m, 8H, J = 5 Hz ), 1.4 (bs, 4H); 
13
C NMR 
(CDCl3): δ 157.6, 128.9, 126.5, 126.2, 125.6, 121.7, 116.2, 62.2, 53.9, 25.8, 24.0. 
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E-4,4'-(1,2-ethenediyl)bis[2-[(morpholine)methyl]-Phenol (25) : 
1
H NMR (CDCl3): δ 7.2 (d, 1H, J = 2 Hz), 7.2 (d, 1H, J = 2 Hz ), 7.0 (s, 2H), 6.7 
(s, 2H), 6.7 (d, 2H, J = 8.25 Hz ), 3.6 (t, 8H, J = 4.5 Hz ), 3.6 (s, 4H), 2.5 (bs, 8H); 
13
C 
NMR (CDCl3): δ 157.0, 129.2, 126.9, 126.6, 125.7, 120.8, 116.4, 66.8, 61.9, 52.9. 
3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(diethylamino)methyl]-Phenol (26) :  
(E/Z : 4:1) 
1
H NMR (CDCl3): δ 6.6-6.5 (m, 2H), 6.4 (s, 2H), 6.2 (dd, 2H, J = 2 Hz 
), 3.5 & 3.3 (2s, 4H), 2.4 (q, 8H, J = 7.5 Hz ), 2.0 & 1.8 (2s, 6H), 1.0 (t, 12H, J = 7.5 Hz 
); 
13
C NMR (CDCl3): δ 157.3, 145.3, 132.3, 127.2, 124.2, 120.2, 119.2, 116.5, 56.7, 48.3, 
46.2, 23.2, 21.4, 11.2 . 
3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(dimethylamino)methyl]-Phenol (27) :  
(E/Z : 7:3) 
1
H NMR (CDCl3): δ 6.8 (s, 1H, ), 6.7 (s, 1H), 6.6 (s, 2H), 6.6-6.5 (2s, 
2H), 3.5 (s, 4H), 3.4 (s, 2H), 2.2 & 2.1 (2s, 12H), 2.0 & 1.7 (2s, 6H)  ; 
13
C NMR (CDCl3): 
δ 157.7, 145.3, 132.5, 127.9, 119.8, 119.7, 118.9, 116.2, 115.8, 62.7, 44.5, 44.4, 22.4, 
21.3. 
3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-Phenol (28) :  
(E/Z : 4:1 ) 
1
H NMR (CDCl3): δ 6.6 (S, 1H), 6.5 (s, 1H), 6.4 (s, 1H), 6.3 (s, 1H), 
6.2 (d, 1H, J = 2 Hz ), 6.2 (d, 1H, J = 2 Hz ), 3.8 & 3.6 (2s, 4H), 2.4 (bs, 8H), 2.0 & 1.8 
(2s, 6H), 1.7 (bs, 8H); 
13
C NMR (CDCl3): δ 157.7, 157.1, 145.3, 132.3, 127.4, 126.8, 
120.1, 119.6, 118.8, 116.4, 115.8, 58.5, 53.5, 53.4, 23.6, 22.4, 21.4. 
3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(piperidine)methyl]-Phenol (29) :  
(E/Z : 4:1 ) 
1
H NMR (CDCl3): δ 6.5 (s, 1H), 6.4 (s, 1H), 6.3 (s, 1H), 6.3 (s, 1H), 
6.2 (d, 1H, J = 2 Hz ), 6.2 (d, 1H, J = 2 Hz ), 3.6 & 3.4 (2s, 4H), 2.4 (bs, 8H), 2.0 & 1.7 
(2s, 6H), 1.5 (m, 8H, J = 5 Hz ), 1.4 (bs, 4H); 
13
C NMR (CDCl3): δ 157.7, 157.1, 145.3, 
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145.1, 132.5, 132.3, 128.0, 127.3, 120.2, 119.4, 118.9, 118.7, 116.4, 115.8, 61.9, 61.7, 
53.9, 53.8, 25.9, 24.0, 22.4, 21.4. 
3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-[(morpholine)methyl]-Phenol (30) :  
(E/Z : 4.5:1.5 ) 
1
H NMR (CDCl3): δ 6.6 (s, 1H), 6.5 (s, 1H), 6.4 (s, 1H), 6.3 (s, 
1H), 6.2 (d, 1H, J = 2 Hz ), 6.1 (d, 1H, J = 2 Hz ), 3.6 (t, 8H, J = 4.75 Hz ), 3.5 (s, 4H), 
2.4 & 2.3 (bs, 8H), 2.0 & 1.7 (2s, 6H); 
13
C NMR (CDCl3): δ 157.2, 156.6, 145.7, 145.3, 
132.3, 128.5, 127.8, 120.5, 119.3, 118.5, 117.8, 116.6, 115.9, 66.8, 61.7, 61.6, 53.2, 52.8, 
22.4, 21.4. 
E-3,3'-(1,2-ethenediyl)bis[2-[(diethylamino)methyl]-Phenol (31) :  
1
H NMR (CDCl3): δ 6.9 (m, 6H), 6.8 (d, 2H, J = 2.75 Hz), 3.7 (s, 4H), 2.5 (q, 8H, 
J = 7.25 Hz), 1.0 (t, 12H, J = 7.25 Hz) ; 
13
C NMR (CDCl3): δ 158.4, 138.0, 128.6, 128.3, 
121.6, 117.6, 113.7, 56.6, 46.3, 11.1. 
E-3,3'-(1,2-ethenediyl)bis[2-[(dimethylamino)methyl]-Phenol (32) :  
1
H NMR (CDCl3): δ 7.0-6.9 (m, 8H), 3.6 (s, 4H), 2.2 (s, 12H); 
13
C NMR (CDCl3): 
δ 158.2, 138.1, 128.5, 128.3, 121.5, 117.7, 113.5, 62.6, 44.5. 
E-3,3'-(1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-Phenol (33) :  
1
H NMR (CDCl3): δ 6.9-6.9 (m, 4H), 6.8-6.8 (m, 4H), 3.7 (s, 4H), 2.5 (bs, 8H), 
1.7 (bs, 8H); 
13
C NMR (CDCl3): δ 158.2, 138.0, 128.3, 128.0, 122.1, 117.5, 113.4, 58.6, 
53.5, 23.6. 
E-3,3'-(1,2-ethenediyl)bis[2-[(piperidine)methyl]-Phenol (34) :  
1
H NMR (CDCl3): δ 7.0-6.8 (m, 8H), 3.7 (s, 4H), 2.5 (bs, 8H), 1.3-1.2 (m, 12H); 
13
C NMR (CDCl3): δ 158.2, 157.9, 157.8, 138.3, 138.0, 129.8, 128.6, 128.3, 128.2, 128.1, 
121.2, 119.6, 117.6, 117.3, 166.3, 114.3, 113.5, 61.9, 54.4, 53.9, 25.8, 24.0. 
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E-3,3'-(1,2-ethenediyl)bis[2-[(morpholine)methyl]-Phenol (35) : 
1
H NMR (CDCl3): δ 7.2-6.9 (m, 8H), 3.7 (s, 8H), 3.6 (s, 4H), 2.6 (bs, 8H); 
13
C 
NMR (CDCl3): δ 157.6, 138.3, 129.0, 128.4, 120.2, 118.0, 113.6, 66.8, 61.6, 52.9. 
2.12.3 General procedure for the synthesis of stilbenebisoxazine 
analogues: 
Stilbene (1 equivalent) was taken in one neck round bottom flask and 15 mL of 
methanol was added. Paraformaldehyde(4.2 equivalents) and appropriate amine(2 
equivalents) was added. Then this reaction mixture was allowed to reflux until TLC (2:3 
mixture of ethylacetate:hexane) shows that reaction is complete. Then mixture is cooled 
to room temperature. Then the precipitation observed was collected by filtration and the 
residue was washed with cold. Methanol several times. This solid received, pure product 
in all cases, was dried in vacuuo and characterized by 
1
H and 
13
C NMR. 
Representative procedure : 
E-6,6'-(vinylene)bis[3-cyclohexyl-3,4-dihydro- 2H-1,3-Benzoxazine] (36) : 
To a solution of 4,4’-dihydroxystilbene 8 (0.2 g, 0.952 mmol) in MeOH (15 mL) 
was added paraformaldehyde (0.12 g, 4.0 mmol) and cyclohexylamine (0.22 mL, 1.904 
mmol). The reaction mixture was refluxed for 8 hrs. Then reaction mixture was cooled to 
room temperature. The resulting white color precipitate was collected by filtration and 
washed with cold MeOH (5 mL). This precipitate was pure enough in NMR spectra and 
obtained yield was 93% as white color precipitate. 
1
H NMR (400 MHz, CDCl3)  7.1 - 
7.2 (m, 2H), 7.0 - 7.1 (m, 2H), 6.7 - 6.8 (m, 3H), 6.6 - 6.7 (m, 2H), 4.9 - 5.0 (m, 4H), 4.0 - 
4.1 (m, 4H), 2.6 - 2.7 (m, 2H), 1.8 - 2.0 (m, 5H), 1.6 - 1.8 (m, 7H), 1.5 - 1.6 (m, 3H), 0.9 - 
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1.3 (m, 12H). 
13
C NMR (101 MHz, CHLOROFORM-d)  154.8, 130.3, 126.4, 125.7, 
124.9, 122.0, 116.9, 80.7, 59.0, 47.6, 31.8, 26.3, 25.7. 
E-6,6'-(vinylene)bis[3-cyclopentyl-3,4-dihydro- 2H-1,3-Benzoxazine] (37): 
 
1
H NMR (400 MHz, CDCl3)  7.1 - 7.3 (m, 2H), 6.9 - 7.1 (m, 2H), 6.6 - 6.9 (m, 
4H), 4.9 (br. s., 4H), 4.0 (br. s., 4H), 3.1 - 3.2 (m, 2H), 1.8 - 2.0 (m, 4H), 1.6 - 1.8 (m, 
5H), 1.3 - 1.6 (m, 10H). 
13
C NMR (101 MHz, CHLOROFORM-d)  154.2, 130.2, 126.1, 
125.6, 125.1, 120.5, 116.5, 81.7, 59.5, 49.5, 31.4, 23.8. 
E-6,6'-(vinylene)bis[3-benzyl-3,4-dihydro- 2H-1,3-Benzoxazine] (38): 
 
1
H NMR (400 MHz, CDCl3) 7.2 - 7.4 (m, 13H), 7.0  (m, 2H), 6.7 - 6.8 (m, 4H), 
4.8 - 4.9 (m, 4H), 3.8 - 4.0 (m, 8H). 
13
C NMR (101 MHz, CDCl3)  153.5, 130.5, 129.0, 
128.5, 127.5, 126.2, 125.8, 125.4, 116.7, 82.2, 55.5, 49.6. 
E-6,6'-(vinylene)bis[3-(4-methoxy benzyl)-3,4-dihydro- 2H-1,3-Benzoxazine] (39): 
1
H NMR (400 MHz, CDCl3)  7.2 - 7.3 (m, 6H), 7.0 - 7.1 (m, 2H), 6.8 - 6.9 (m, 
12H), 4.8 - 4.9 (m, 4H), 4.1 - 4.1 (m, 4H), 3.9 - 4.0 (m, 4H), 3.7 - 3.8 (m, 7H). 
13
C NMR 
(101 MHz, CDCl3)  159.0, 153.7, 130.2, 127.6, 126.2, 125.7, 125.4, 120.0, 116.1, 113.8, 
82.2, 55.3, 54.9, 49.5.  
E-7,7'-(vinylene)bis[3-cyclohexyl-3,4-dihydro- 2H-1,3-Benzoxazine] (40): 
 
1
H NMR (400 MHz, CDCl3)  6.8 - 7.0 (m, 10H), 4.9 - 5.0 (m, 4H), 4.0 (s, 4H), 
2.6 - 2.7 (m, 2H), 1.8 - 2.0 (m, 7H), 1.6 - 1.8 (m, 8H), 1.5 (dd, J = 3.71, 15.81 Hz, 4H), 
0.9 - 1.3 (m, 17H). 
13
C NMR (101 MHz, CDCl3)  155.2, 136.8, 127.9, 121.3, 118.7, 
114.0, 80.3, 58.7, 47.3, 31.6, 25.9, 25.5. 
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E-7,7'-(vinylene)bis[3-cyclopentyl-3,4-dihydro- 2H-1,3-Benzoxazine] (41): 
1
H NMR (400 MHz, CDCl3)  6.7 - 7.0 (m, 8H), 4.8 - 4.9 (m, 4H), 3.9 - 4.0 (m, 
4H), 3.0 - 3.2 (m, 2H), 1.8 - 2.0 (m, 5H), 1.3 - 1.7 (m, 16H). 
13
C NMR (101 MHz, 
CDCl3)  155.1, 137.2, 128.7, 127.8, 120.3, 119.1, 114.1, 81.8, 59.8, 49.7, 31.6, 24.0. 
E-7,7'-(vinylene)bis[3-benzyl-3,4-dihydro- 2H-1,3-Benzoxazine] (42): 
 
1
H NMR (400 MHz, CDCl3)  7.1 - 7.4 (m, 21H), 6.8 - 7.0 (m, 11H), 4.8 - 4.9 
(m, 4H), 3.8 - 4.0 (m, 9H), 3.6 - 3.7 (m, 3H). 
13
C NMR (101 MHz, CDCl3)  154.3, 
138.2, 137.2, 129.0, 128.5, 128.3, 128.2, 127.9, 127.4, 119.1, 114.0, 82.3, 73.7, 57.0, 
55.7. 
E-7,7'-(vinylene)bis[3-(4-methoxy benzyl)-3,4-dihydro- 2H-1,3-Benzoxazine] (43): 
1
H NMR (400 MHz, CDCl3)  7.2 - 7.3 (m, 6H), 6.8 - 7.0 (m, 10H), 4.8 - 4.9 (m, 
4H), 3.9 (s, 4H), 3.8 (m, 5H), 3.7 - 3.8 (m, 9H). 
13
C NMR (101 MHz, CDCl3)  159.2, 
154.6, 137.4, 130.4, 119.7, 119.3, 114.2, 114.1, 113.8, 82.3, 55.5, 55.1, 49.1. 
E-7,7'-(vinylene)bis[3-furfuryl-3,4-dihydro- 2H-1,3-Benzoxazine] (44): 
1
H NMR (400 MHz, CDCl3)  7.3 - 7.4 (m, 2H), 6.8 - 7.0 (m, 10H), 6.2 - 6.3 (m, 
2H), 4.8 - 4.9 (m, 4H), 3.9 - 4.0 (m, 4H), 3.8 - 3.9 (m, 4H). 
13
C NMR (101 MHz, CDCl3) 
 154.1, 151.5, 142.6, 137.2, 128.1, 119.2, 114.1, 110.2, 109.0, 81.9, 49.5, 48.2. 
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Chapter 3 
Synthesis of Novel Ketamine Analogues and Their Activity at GABAA and NMDA 
Receptors. 
3.1 Introduction 
Ligand gated ion channels are membrane-embedded proteins at synaptic cleft 
which controls intercommunication among neurons. Each receptor has a function of 
allowing the flow of ions like Cl
-
, Na
+
, K
+
 resulting in excitation or inhibition.  When a 
neurotransmitter like -aminobutyric acid (GABA) binds to its respective receptor-
channel (GABA receptors), chloride ions flow through the receptor 
1
 channel reducing 
the likelihood of initiating action potentials. GABAa receptors
2
 are most ubiquitously 
expressed ligand gated Cl
-
 ion channels in the mammalian central nervous system.
3
 These 
receptors are assembled from a diverse family of 19 homologous subunits
4
  ((1-6), (1-3), 
(1-3), ,  and (1-3)), which are differentially expressed throughout the brain.
5
 The 
GABAa receptor is a pentameric complex composed of closely related subunits in 2:2:1 
stoichiometry in which ,  and  subunits expressed as most abundant subunits.6 From 
previous studies with the transgenic mice and with subtype selective subunits, it has been 
established that while 1-containing receptors are responsible for mediating sedative and 
muscle relaxant properties, 3 and/or 2-containing receptors are responsible for anxiety. 
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Fig.3-1.  General representation of GABAa (Left) and NMDA (Right) receptors. 
( Reprinted by permission from Macmillan Publishers Ltd: Belelli, D.; Lambert, J. J. Nat. 
Rev. Neurosci. 2005, 6, 565, copyright 2005) 
Subtypes 62/3 in the GABAa receptor are expressed at high levels within 
mature cerebellar granule neurons.
7
 Cerebellar granule cells are the most abundant 
neurons in the CNS. They play pivotal role in the cerebellar motor control
8
 and learning 
activity. Upon binding agonist -Aminobutyric acid (GABA) to receptors, a major 
inhibitory neurotransmitter, the pore opens to allow Cl
-
 ion influx
9
 which leads to 
inhibitory neurotransmission. GABAa receptors also contains a site of action for a 
number of allosteric modulators like barbiturates, neurosteriods, ethanol, 
benzodiazepines,
5,10
 barbiturates,
11
 picrotoxin,
12
 zinc cations,
13
 loreclazole
14
 and 
anesthetics including thiopental,
15
 propofol
16
 and etomidate.
17
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In contrast N-methyl-D-aspartate (NMDA) receptors
18
 are glycine and glutamate 
gated receptors. When a neurotransmitter binds to NMDA receptors, the pore opens to 
allow influx of cations
19
 like a Ca
+
 ions which are implicated in synaptic plasticity and 
learning.
20
 The influx of Ca
+ 
ions into neuronal cell results membrane depolarization 
causing the propagation of excitory signal and also triggering intracellular signaling 
pathways.
21
 Overactivation of these receptors has been implicated in conditions such as 
ischemic stroke and traumatic brain injury,
22
 where the glutamate levels are elevated. In a 
central nervous system (CNS), subunits like NR1, NR2 and NR3 forms the 
heterotetrameric NMDA receptor complex. 
23
 Two NR1 and two NR2A or NR2B 
subunits assembles in a hetereotetrameric complex to form most common NMDA 
receptors in adult CNS. In general,  NMDA receptors contributes to differing biophysical 
and pharmacological properties.
23
  Ketamine and Phencyclidine (PCP) (Fig. 3-2), known 
as dissociative anesthetics, produce profound analgesia at low doses to a unique 
cardiovascular stimulation and a cataleptic state at higher doses.
24
 Both ketamine and 
PCP, primarily acting at NMDA receptors as uncompetitive antagonists
25
 via reducing 
excitory input, show differing CNS depression levels. PCP shows markedly higher 
affinity
26
 for this target than ketamine while the ketamine possesses a higher CNS 
depressant activity and produce a better quality of anesthesia than PCP.
27
 
Neurotransmitter systems like dopamine D2 receptors,
28
 5-HT2 receptors,
29
 mu and 
kappa opioid receptors,
30
 sigma receptors and muscarinic cholinergic receptors,
31
 voltage 
gated K
+
, Na
+
 and Ca
2+
 channels
32
 are also shown to get affected by ketamine and PCP 
besides NMDA receptors though at significantly higher concentrations.  
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Fig.3-2.  Structures of Ketamine and Phencyclidine (PCP). 
Studies have yet to find about the mechanism by which ketamine produces a 
higher CNS depression than PCP while at anesthetic doses.
33
  Dose-dependent side 
effects like vivid dreams, illusions, disruptions of cognitive function, mood changes have 
been reported with ketamine administration which are also observed in schizophrenia.
34
 
The psychotomimetic effects of the ketamine have been shown or proposed to mediated 
by its inhibitory effect on GABAergic interneurons leading to increase in the glutamate 
release.
35
 Administration of subanesthetic doses of the ketamine shown to have 
therapeutic efficacy for the treatment resistant major depression.
36
 Other symptoms 
associated with ketamine like saccade, nystagmus, hyperlocomotion and prepulse 
inhibition deficit found to be a model system
37
 to study schizophrenia and to identify 
even hit-to-lead compounds for the inhibition of a ketamine induced hyperlocomotion for 
the schizophrenic studies in animals. However, the spectrum of ketamine analogues
38
 is 
narrow so far in terms of broadening ketamine’s desired effects to improve clinical 
actions, decreasing its incidence of side effects and therapeutic efficacy on the selective 
affinity towards receptors.  
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3.2 Synthetic approaches towards ketamine analogues 
Only few reports exist toward the efforts to synthesize ketamine analogues. Yang 
et. al. synthesized amino tetralone analogues of ketamine (Scheme. 3-1) for locomotor 
activity tests in mice.
38b
 In these compounds, benzene ring was fused with cyclohexanone 
ring restricting conformational flexibility. 1-amino-1-methyl-2-tetralone was synthesized 
starting from 2-amino-2-phenyl-propionic acid via intermediate pthalimidophenyl 
acetylchloride. 2-amino-2-methyl-1-tetralone was synthesized from benzyl acetone via 
amino cyanide intermediate (see Scheme 3-1). 
 
Scheme 3-1. Synthesis of tetralone analogues of ketamine by Yang et. al.  
Though none of the tetralones produced hypnosia or profound ataxia, 2-amino-2-
methyl-1-tetralone caused an increased locomotor activity while 1-amino-1-methyl-2-
tetralone decreased but not significant when compared with ketamine. 
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Recently, Zarantonello et.al. reported novel ketamine analogues. In their strategy, 
ketamine was modified by introducing amide in cyclohexanone ring  and with various 
tertiary and secondary amines attached in the place of methylamine for evaluation as 
NMDA receptor antagonists.
39
 Ketamine analogues A and B, which have amide group in 
cyclohexanone ring (Scheme. 3-2) were synthesized from chlorophenyl amine acetic 
acid. Intermediate amino nitrile was synthesized from chlorophenyl amineacetic acid by 
alkylation. Upon reductive cyclization of this intermediate in the presence of CoCl2 and 
NaBH4, the resulting cyclic amide was further methylated with methyl iodide to isolate 
novel analogues A and B as a mixture which were separated by HPLC purification.  
 
Scheme 3-2. Synthesis of lactam with methylamine analogues of ketamine by 
Zarantonello et. al.  
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In a similar strategy, analogues of phencyclidine (C and D) were synthesized 
from bromophenyl methylacetate via piperidine nitrile intermediate (see Scheme 3-3 ). 
Nitrile group in this intermediate was then reduced and cyclized in the case of synthesis 
of six membered ring as in C and cyclized directly by reductive hydrogenation in the case 
of synthesis of 5 membered ring as in D. Methylated amides ( E and F ) were synthesized 
from the amides (C and D ) by methylation. 
The evaluation of A and B against NMDA receptor with NR2-A and NR2-B 
subunits showed that amide functionality in cyclohexanone ring was not tolerated. The 
same loss of functional activity was observed even in the case of C-F in comparison to 
ketamine.  
 
Scheme 3-3. Synthesis of lactam with piperidine analogues of ketamine by Zarantonello 
et. al.  
From this structure and activity relationship studies, any appreciable activity was 
observed only in the analogue (G) in which cyclohexyl ring was preserved and phenyl 
group has methoxy substituent (Scheme 3-4).  
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Scheme 3-4. Synthesis of ketamine analogue with phenyl group substitution. 
3.3 Synthesis of Novel ketamine analogues: 
 Ketamine analogues with modification of cyclohexyl ring to amide
39
 (Scheme 3-
2 and 3-3) or fused cyclohexane with benzene
38b
 (Scheme 3-1) resulted in a loss of 
functional activity. The functional activity was sustained only when cyclohexyl ring is 
preserved (Scheme. 3-4) in ketamine or phencyclidine. When the phenyl group was 
introduced with various substitutions, the activity was modestly retained in comparison 
with ketamine. So to synthesize novel analogues of ketamine with cyclohexyl ring intact, 
we transformed the carbonyl group in cyclohexane to few other analogues with imine 
substitutions as  depicted in Scheme 3-5 and Table 3-1. 
 
Scheme 3-5. Synthesis of ketamine analogues. See Table 3-1 for Appropriate reagents 
and conditions. 
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Table 3-1: Reagents and Conditions to synthesize ketamine analogues. 
Entry Reagents Solvent 
Condition
s 
Yield Product 
1 
 
NH2OH.HCl, 
CH3COONa.H2O, 
 
MeOH: H2O 
(7:3) 
reflux 70 % 
 
 
2 
 
NH2OMe.HCl, 
CH3COONa.H2O. 
 
MeOH: H2O 
(7:3) 
reflux 78 % 
 
 
3 
 
NH2OPh.HCl, 
CH3COONa.H2O 
 
MeOH: H2O 
(7:3) 
reflux 90 % 
 
 
4 
NH2CONHNH2.HCl, 
CH3COONa.H2O 
 
 
MeOH: H2O 
(7:3) 
 
 
reflux 
 
 
60 % 
 
5 
 
NaBH4 
 
MeOH r. temp. 80 % 
 
 
 
6 (Ph3P)3PCH3Br, n-
BuLi, 
 
 
dry. THF -780C to r. 
temp. 
No Product 
7 MeNH2. HCl,  
CH3COONa.H2O,  
MeOH or 
CH2Cl2 or 
Toluene 
reflux Product is unstable 
     
8 NH2-NH2. HCl, 
Pyridine 
 
MeOH 
 
reflux  Product is unstable 
9 
 
NH2CSNHNH2.HCl, 
CH3COONa.H2O,  
 
MeOH: H2O 
(7:3) 
reflux No Product 
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Ketamine carbonyl group was converted to the oxime by treating with 
hydroxylamine in the presence of sodium acetate at reflux to synthesize oxime 2 in 70% 
yield as a white color solid. The structure of the oxime 2 was confirmed by its NMR 
spectra (Fig. 3-3). In a 
1H NMR spectrum, methylene hydrogens (Ha and Ha’) next to 
C=N group showed resonance at 2.5 and 2.8 ppm. Carbon in C=N-OH groups showed 
resonance at 161 ppm in 
13
C NMR. The absence of any signal between 200-220 confirms 
that ketamine has been transformed to oxime 2. Absence of any isomers of hydroxyl 
group on C=N could be observed in both 
1
H and 
13
C NMR spectra (Fig. 3-3). 
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Fig.3-3. NMR Spectra of Oxime 2. TOP. 
1
H NMR. BOTTOM. 
13
C NMR. 
In a similar fashion, ketamine 1 was treated with methoxylamine to synthesize 
methoxime 3. In this reaction, methoxime 3 has obtained in 78% yield as a light yellow 
color solid. In the structural determination of methoxime 3 by NMR spectra, methylene 
hydrogens (Ha and Ha’) have showed resonance at 3.3 ppm and methoxy hydrogens 
showed resonance at 3.9 ppm (Fig. 3-4). In both 
1
H and 
13
C NMR spectra, isomers of 
methoxime 3 were also not present (Fig. 3-4).  
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Fig.3-4. NMR Spectra of Methoxime 2. TOP. 
1
H NMR. BOTTOM. 
13
C NMR. 
When the ketamine 1 was treated with benzoxylamine in the presence of sodium 
acetate, benzoxime 4 was isolated as white color solid. Although benzoxylamine group is 
bulky, the reaction proceeded smoothly yielding the product in 90% yield. Presence of 
resonance for benzyl methylene hydrogens (Hf) at 5.4 ppm in 
1
H NMR spectrum and 
C=N carbon at 158 ppm in 
13
C NMR spectrum confirmed the product.  It could be worthy 
to assume that bulkier benzoxyl group allows the formation of only one isomer which 
could be observed in 
1
H and 
13
C NMR spectra (Fig. 3-5).  
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Fig.3-5. NMR Spectra of Benzoxime 4. TOP. 
1
H NMR. BOTTOM. 
13
C NMR. 
Semicarbazone 5 was also synthesized by treating the ketamine 1 with 
semicarbazide as light yellow color solid. In a wittig reaction with (PPh3)3CH2PBr 
reagent, the ketamine carbonyl was attempted to convert into a terminal alkene by 
treating wittig reagent and n-BuLi at low temperature (-78
0
C). But the product could not 
be observed as only the reactant ketamine 1 was recovered. This reaction was repeated 
with varying equivalent ratios of reagents and temperatures. But in all cases, only 
ketamine 1 was recovered. So to test the reagent purity, wittig reagent and n-BuLi was 
treated with benzophenone. In this case, the reaction mixture with 1 hr stirring at room 
temperature, after addition of benzophenone to wittig reagent and n-BuLi, showed the 
product on TLC (1:4 EtOAc:Hexanes) which was confirmed in both 
1
H NMR and 
13
C 
NMR spectra.  
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Even in the reactions of ketamine 1 with HOCH2CH2NH2. HCl and 
NH2CSNHNH2. HCl (Thiosemicarbazide), the product was not observed. In all these 
reactions, only the reactant ketamine 1 was observed on TLC and NMR spectra. From 
these reactions, one can assume that ketamine carbonyl group is sterically crowded to be 
reached by bulky reagent. Methyl amine was also treated with the ketamine 1 to convert 
into N-methylimine. But the product was not stable even under dry conditions. So the 
ketamine was recovered as the end product.  
 
 
 
Fig.3-6. NMR Spectra of Hydroxy 6 (Diastereomer ratio 1:0.5). TOP. 
1
H NMR. 
BOTTOM. 
13
C NMR. 
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The hydroxy analogue 6 was synthesized by treating ketamine 1 with sodium 
borohydride. This reaction yielded both diastereomers. The presence of the diastereomers 
was observed on both 
1
H and 
13
C NMR spectra (Fig. 3-6). The CH-OH hydrogen (Ha 
and Ha’ in Fig. 3-6) for both diastereomers showed  resonances at 4.5 and 4.25 ppm in 
the 
1
H NMR spectrum and the respective CH-OH carbon at 64 and 63 ppm in the 
13
C 
NMR spectrum. The ratio of diastereomers has been calculated as 7:4 from 
1
H NMR 
spectrum. All of the ketamine analogues synthesized was used for the GABAA and 
NMDA receptors assay to evaluate their agonist activity at GABAA receptors and 
antagonist activity at NMDA receptors. Hydroxy 6 analogue, which received as 
diastereomeric mixture was used for receptor assay as such without separation. 
3.4 Agonist activities of ketamine analogues on 62  and 22  receptors: 
The GABAa subtypes 62  and 122  receptors are expressed at high levels 
exclusively within mature cerebellar granule neurons. In the previous study,
40
 ketamine 
has potentiated the GABA current arising from 6- and -containing GABAa receptors in 
oocytes, dissociated granule neurons and cerebellar slices isolated from rodents within 
anesthecally relevant concentration. This study also shown that PCP (Phencyclidine) and 
Mk-801 (a potent non-competitive inhibitor of NMDA receptor) was less active 
compared to ketamine in potentiating tonic chloride current arising from GABAA 
receptors containing 6- and -subtypes. These subtypes were chosen to test against new 
analogues within the oocyte expression system since their association with cerebellum 
has a pivotal role in motor control activity.  
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Table 3-2: Agonist activity of ketamine analogues on GABAa receptors. 
Conc. 
62a 122a 
Ketamine 
Oxime 
(Monosalt) 
Oxime 
(Disalt) 
Hydroxy Ketamine 
Oxime 
(Disalt) 
 
10 
 
116.2 
 
128.2 
 
165.4 
 
100 
 
- 
 
- 
20 157.1 193.746 239 100 0 122.678 
50 218.3 312.04 418 123.98 105 153.41 
100 - - - 135.41 119 214.5 
 
a = values depicted are I Average (n. amp). I Average = (IGABA + Drug / I GABA) 100. 
 
Agonist activities of ketamine analogues are shown in Table 3-2. At various 
concentrations, Oxime 2 has shown high sensitivity as shown in Figure 3-7. Oxime 2 in 
both forms has greatly potentiated the GABAA current relatively than ketamine at various 
concentrations. On 62 subtype receptors, Oxime 2 disalt has shown greater 
potentiation at 20 M concentration. Even on 122  receptors, Oxime 2 has greatly 
potentiated GABAa current at 20 M when ketamine is not able to potentiate any current. 
It has shown nearly two fold increase at 50 M concentration on 62 subtype receptor 
and similarly on 122  receptors at 100 M concentration.  
Methoxime 3 and benzoxime 4 analogues have not evoked considerable response 
from receptors.  Even Semicarbazone 5 has also been less sensitive than ketamine 
towards receptors potentiating GABAA current. Hydroxy analogue 6 has shown less 
sensitivity than ketamine towards both GABAa receptors. This could be seen even at 
higher concentration like 100 M (Table 3-2). 
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Fig 3-7. Agonist activities of ketamine 1 and oxime 2 on GABAa receptors. TOP. 
62receptors. BOTTOM. 122 receptors. 
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From this analysis, Bulkier groups like methoxime and benzoxime are less 
effective in potentiation. Among polar groups, Bulkier group like one in semicarbazone 5 
and smaller group like hydroxyl  were also insensitive towards GABAa receptors. It 
indicates that double bond and the presence of small polar groups as in oxime 2 are 
crucial to potentiate. The increased potentiation can be attributed to the reduced 
lipophilicity in oxime 2 than ketamine.  
3.5 Antagonist activities of ketamine analogues on NMDA Receptors: 
Initially, new analogues synthesized were tested at 50 M concentration against 
three different receptors (Table 3-3 and Fig. 3-8) for their antagonist activity. 
Modification of the carbonyl group in ketamine to oxime has increased inhibition at 
NMDA-A and –B receptors while the comparable activity can be observed at NMDA-D 
receptors (Table 3-3 and Fig. 3-8). Particularly it had a greater inhibition at NMDA-A 
receptors than ketamine and similar to PCP. It even had a similar inhibition at NMDA-B 
and –D receptors. This could establish the fact that oxime 2 is target specific towards 
NMDA-A receptors at 50 M concentration. Replacement of the carbonyl group in 
ketamine with other analogues like methoxime, benzoxime and semicarbazone has 
resulted decreased effect on all receptors (Table 3-3, Fig. 3-8). % Recovery of current 
measured post drug treatment to reflect anesthetically effectiveness of drug has also 
shown that oxime 2 retains similar effect on A and B receptors (Fig. 3-9) while showing 
ineffectiveness at D receptors compared to ketamine. Oxime 2 also shown comparable 
activity with PCP (Phencyclidine) at NMDA-A and –D receptors in inhibition. At 
NMDA-B and –D receptors, it shown greater affinity than PCP as obvious from  %  
recovery of current measured  at these receptors (Table 3-3 and Fig. 3-9). 
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Table 3-3: Antagonist activities of ketamine analogues on NMDA receptors.
a, b, c
 
Compound 
NMDA-A (NR1/2A) NMDA-B (NR1/2B) NMDA-D (NR1/2D) 
% 
Inhibition 
% 
Recovery 
% 
Inhibition 
% 
Recovery 
% 
Inhibition 
% 
Recovery 
Ketamine 57.627 84.745 80.512 34.564 88.09 26.19 
Oxime 89.23 86.1538 83.0188 33.9622 86.666 52.272 
Methoxime 25.257 98.453 75.597 71.6417 57.5 82.5 
Benzoxime - - 40.993 77.639 49.315 79.452 
Semicarbazon
e 
33.557 - 50.757 98.484 33.3333 - 
PCP 88.372 93.953 96.774 59.677 87.5 66.666 
 a = % Inhibition = (I Glu/Gly – I Drug /I Glu/Gly) 100. b = % Recovery = (I Post treatment – I Glu/Gly) 100. 
c = Drug concentration is 50 M at receptor. 
 
 
Fig 3-8. Activity of ketamine analogues against NMDA receptors at 50 M concentration 
inhibiting NMDA response. 
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Fig. 3-9. % Recovery of response from NMDA receptors post drug(50 mM conc.) 
treatment . 
Thus encouraged by this result, oxime 2 affinity studies have been conducted at 
various concentrations to determine IC50 values (Table 3-4 and Fig. 3-10). The % 
recovery reflects long lasting effect of drug as anesthetic to determine anesthetically 
relevant concentration. Though oxime 2 showed greater or similar inhibition at 50 M 
concentration with ketamine at all NMDA receptors, it’s affinity was attenuated over a 
range of concentrations from 0.1 to 200 M in terms of  % recovery of response (Table 
3-4 and Fig. 3-10) by observing IC50 values. 
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Table 3-4 : Affinity studies of ketamine and oxime against NMDA receptors with IC50 
values. 
NMDA Receptor 
% Recovery 
(Ketamine) 
% Recovery 
(Oxime) 
IC50 
(Ketamine) 
IC50  
(Oxime) 
NMDA-NR1/2A 28 74 2.32 5.911 
NMDA-NR1/2B 19 31 0.82 1.068 
NMDA-NR1/2C - 44 - 0.747 
NMDA-NR1/2D 24 68 0.76 1.068 
 
Fig 3-10. %  Recovery of response from NMDA receptors after post drug treatment (over 
various conc.). 
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Recovery is very less for ketamine than oxime means ketamine has long lasting 
effect and so more affinity. Oxime shown similar inhibition at NMDA-B, C, D receptors 
while it has two fold increase in terms of IC50 values than ketamine at NMDA-A 
receptors.  
3.6 Conclusions 
 Modification of carbonyl group in ketamine to oxime, methoxime, benzoxime, 
semicarbazone and hydroxyl groups has provided an insight into the effect of size of the 
groups towards GABAa receptors. Oxime has shown to reduce lipophilicity while 
methoxime, benzoxime shown increased lipophilicity. This study has also shown that 
polar groups like semicarbazone and hydroxyl were not able to increase the potency 
towards GABAa receptors. Thus oxime 2 has been better agonist at GABAa receptors 
exhibiting two times more excitory post synaptic potential than ketamine. From this study 
, though anesthetic efficacy of ketamine and PCP (Phencyclidine) as non-competitive 
inhibitors of NMDA (N-Methyl-D-Aspartate) led to classifying them as dissociate 
anesthetics, Oxime 2 has shown improved or similar potency towards various NMDA 
receptors. This could be beneficial to study further anesthetic efficacy of oxime 2 in 
epileptic seizures, other convulsant side effects which are associated with ketamine. 
Ketamine is known to be more effective anesthetic across different animal species but in 
humans it is associated with various adverse effects like inducing catalepsy at higher 
doses and hallucinations at lower doses. Since oxime has shown greater or comparable 
potency at lower doses as antagonist exciting postsynaptic potential at various NMDA 
receptors and less duration of affinity, it could be interesting to study its efficacy across 
various animals.  
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3.7 Experimental Section 
General  
1
H-NMR and 
13
C-NMR spectra were recorded on a Bruker 250 MHz and Varian 
400 MHz  spectrometer in CDCl3 and DMSO-d6 with TMS as the standard.  Chemical 
shifts are reported in ppm, multiplicities are indicated by s (singlet), d (doublet), t 
(triplet), q (quartet), p (quintet), h (sextet), m (multiplet) and bs (broad singlet) coupling 
constants reported in hertz (Hz). All 13C NMR spectra were proton decoupled. Thin-
Layer chromatography (TLC) was performed on glass plates coated with 0.25 mm 
thickness of silica-gel. All solvents were dried and distilled prior to use and organic 
solvent extracts were dried over Anhydrous. Na2SO4. Toluene and tetrahydrofuran were 
distilled from sodium and benzophenone and were stored in a dry box. Chromatographic 
purifications were performed by flash chromatography using silica gel (63-200μ) from 
Dynamic Adsorbents Inc. Pd(dba)2 and P(t-Bu)3 were purchased from Aldrich Inc. All 
reagents and bases were purchased from Aldrich, Fisher Science, VWR and used without 
further purification. Aryl bromide 5 was prepared using literature procedure. Ketamine 
was purchased from Aldrich chemical company and used as received. 
 
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone oxime (2): To as solution of 
NH2OH. HCl and CH3COONa. H2O in MeOH:H2O (7:3) stirred at room temperature for 
15 minutes, was added ketamine and the resulting solution was stirred at reflux for 16 hrs 
before cooling to room temperature. The reaction mixture was filtered and the filtrate was 
partitioned between CH2Cl2 and sat. NaHCO3 solution. The filtrate was extracted with 
CH2Cl2 (2×30 mL) and the combined organic layer was washed with brine solution. The 
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organic layer was dried over anhydrous. Na2SO4 and concentrated under reduced 
pressure. The crude reaction mixture received was purified over silica gel column 
chromatography by eluting with initially CH2Cl2 and later with (1:9) MeOH:CH2Cl2 to 
receive oxime 2
 
as pale yellow solid. 
1
H NMR (250 MHz, CDCl3)  7.4 - 7.5 (m, 1H), 7.0 
- 7.3 (m, 3H), 2.6 - 2.8 (m, 1H), 2.4 - 2.5 (q, J = 5.8 Hz, 1H), 2.1 - 2.3 (m, 1H), 2.0 - 2.1 
(m, 3H), 1.5 - 1.7 (m, 5H). 
13
C NMR (63 MHz, CDCl3)  160.1, 140.1, 133.8, 131.6, 
129.1, 128.1, 126.5, 64.0, 37.1, 29.4, 24.5, 22.2, 21.7. 
 
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone O-methyl-oxime (3): To as 
solution of NH2OMe. HCl and CH3COONa. H2O in MeOH:H2O (7:3) stirred at room 
temperature for 15 minutes, was added ketamine and the resulting solution was stirred at 
reflux for 16 hrs before cooling to room temperature. The reaction mixture was filtered 
and the filtrate was partitioned between CH2Cl2 and sat. NaHCO3 solution. The filtrate 
was extracted with CH2Cl2 (2×30 mL) and the combined organic layer was washed with 
brine solution. The organic layer was dried over anhydrous. Na2SO4 and concentrated 
under reduced pressure. The crude reaction mixture received was purified over silica gel 
column chromatography by eluting with initially CH2Cl2 and later with (1:9) 
MeOH:CH2Cl2 to receive methoxime 3
 
as pale yellow solid. 
1
H NMR (400 MHz, CDCl3) 
 7.9 - 8.0 (m, 1H), 7.2 - 7.4 (m, 3H), 3.91 - 4.0 (m, 3H), 3.3 (td, J = 4.10, 13.96 Hz, 1H), 
3.2 (td, J = 4.49, 13.73 Hz, 1H), 2.4 - 2.5 (m, 3H), 2.1 - 2.3 (m, 1H), 1.6 - 1.8 (m, 3H), 
1.4 - 1.5 (m, 1H), 1.2 - 1.4 (m, 1H). 
13
C NMR (101 MHz, CDCl3)  156.3, 135.5, 132.4, 
132.2, 131.9, 131.0, 128.3, 67.4, 62.7, 39.4, 28.8, 26.1, 24.7, 22.0. 
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2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone O-benzyl-oxime (4): To as 
solution of NH2OCH2Ph. HCl and CH3COONa. H2O in MeOH:H2O (7:3) stirred at room 
temperature for 15 minutes, was added ketamine and the resulting solution was stirred at 
reflux for 16 hrs before cooling to room temperature. The reaction mixture was filtered 
and the filtrate was partitioned between CH2Cl2 and sat. NaHCO3 solution. The filtrate 
was extracted with CH2Cl2 (2×30 mL) and the combined organic layer was washed with 
brine solution. The organic layer was dried over anhydrous. Na2SO4 and concentrated 
under reduced pressure. The crude reaction mixture received was purified over silica gel 
column chromatography by eluting with initially CH2Cl2 and later with (1:9) 
MeOH:CH2Cl2 to receive benzoxime 4
 
as pale yellow solid. 
1
H NMR (400 MHz, CDCl3) 
 7.7 (d, J = 8.06 Hz, 1H), 7.1 - 7.4 (m, 8H), 5.0 - 5.2 (q, J = 8.2 Hz, 2H), 2.9 - 3.1 (m, 
2H), 2.2 - 2.3 (m, 3H), 1.9 - 2.0 (m, 2H), 1.3 - 1.8 (m, 4H). 
13
C NMR (101 MHz, CDCl3) 
 158.3, 138.7, 135.1, 132.1, 131.1, 129.9, 128.7, 128.4, 127.8, 127.6, 66.4, 38.8, 29.1, 
26.0, 24.5, 22.1. 
 
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone O-semicarbazone (5): To as 
solution of NH2CONHNH2. HCl and CH3COONa. H2O in MeOH:H2O (7:3) stirred at 
room temperature for 15 minutes, was added ketamine and the resulting solution was 
stirred at reflux for 16 hrs before cooling to room temperature. The reaction mixture was 
filtered and the filtrate was partitioned between CH2Cl2 and sat. NaHCO3 solution. The 
filtrate was extracted with CH2Cl2 (2×30 mL) and the combined organic layer was 
washed with brine solution. The organic layer was dried over anhydrous. Na2SO4 and 
concentrated under reduced pressure. The crude reaction mixture received was purified 
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over silica gel column chromatography by eluting with initially CH2Cl2 and later with 
(1:9) MeOH:CH2Cl2 to receive semicarbazone 5
 
as pale yellow solid. 
1
H NMR (400 
MHz, DMSO-d6)  9.6 (br. s., 1H), 7.7 - 7.8 (m, 1H), 7.4 - 7.5 (m, 3H), 4.0 - 4.1 (m, 2H), 
3.0 - 3.1 (d, J = 4.9 Hz, 2H), 2.1 (s, 3H), 1.5 - 1.8 (m, 3H), 1.2 - 1.4 (m, 3H). 
13
C NMR 
(101 MHz, DMSO-d6)  158.3, 149.1, 134.8, 133.2, 133.0, 132.3, 128.7, 67.8, 36.8, 28.2, 
26.7, 25.9, 22.3. 
 
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanol (6): To a solution of ketamine in 
MeOH at 0
O
C was added NaBH4 portion wise and allowed to stir at room temperature for 
12 hrs. The reaction mixture was cooled to 0
O
C
 
and quenched with sat. NH4Cl solution 
by adding dropwise. The resulting reaction mixture was partitioned between CH2Cl2 and 
sat. NH4Cl solution and extracted with CH2Cl2 (2×30 mL), The organic layer was dried 
over anhydrous. Na2SO4 and concentrated at reduced pressure. The crude reaction 
mixture received was purified over silica gel column chromatography by eluting with 
(2:8) EtOAc:Hexanes to receive hydroxyl analogue 6
 
as amorphous white solid.  
1
H 
NMR (250 MHz, CDCl3)  7.2 - 7.4 (m, 4H), 7.0 - 7.2 (m, 4H), 4.4 - 4.5 (m, 1H), 4.2 - 
4.3 (m, 1H), 2.4 - 2.5 (m, 1H), 1.9 - 2.1 (m, 2H), 1.8 - 1.9 (m, 3H), 1.2 - 1.7 (m, 5H), 0.8 - 
1.0 (m, 1H). 
13
C NMR (63 MHz, CDCl3)  140.5, 137.9, 133.2, 132.3, 132.0, 131.9, 
131.2, 128.3, 126.7, 69.8, 64.0, 62.9, 29.9, 28.7, 28.3, 28.0, 26.5, 22.5, 20.8, 20.3, 19.3. 
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Chapter - 4 
Selective Acylation of Diols: Formal Synthesis of (±)-Rolipram and its (±)--Lactone 
Analogue 
4.1 General Introduction 
Rolipram is a potent and selective inhibitor of phosphodiesterase IV (PDE 4). It 
was initially developed and marketed as antidepressant by Schering AG.
1
 PDE4 is the 
main enzyme which regulates the concentration of secondary messenger cAMP (cyclic 
adenosine-3’,5’-monophosphate). Rolipram (Fig. 4-1) was known to exert its effect by 
increasing the levels of cAMP within mature brain cells. In its course of action, it inhibits 
PDE4 enzyme which hydrolyzes the phosphodiester bridge in cAMP which is the cause 
of inflammatory processes.
2
 PDE4 enzyme is also known to be involved in pathologies 
related to multiple sclerosis, coronary failure, asthma, pulmonary diseases and diabetes.
3
 
So, Rolipram as a pharmacological probe is an important tool to further study the 
structural requirements for selective inhibition of PDE 4.
2b,3a
  Though both enantiomers 
of Rolipram are active against PDE4, the (R)-isomer is the more active one.
4
 Numerous 
approaches 
4-5
 have been reported for the synthesis of Rolipram.  
 
Fig. 4-1. Structure of Rolipram and its analogue -Lactone. 
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4.2 Synthetic approaches towards Rolipram and -substituted lactone  
        Several methods exist to synthesize - Substituted -lactams and -lactones in both 
racemic and optically pure forms. Metal catalysts like Rh, Zn, CoCl2, NiCl2 or organo 
catalysts like epicinchonine have been widely used. Various methods including cross-
coupling between 4-aryl pyrrolidones and aryl halides, Michael addition to ,-
unsaturated esters or aryl nitroolefines and metal catalyzed 1,4-addition of arylboronic 
acids to ,β-unsaturated γ-lactams have been applied to synthesis of - substituted -
lactams and specifically Rolipram.  In following sections, a short review of a few 
important methods for the synthesis of rolipram and - substituted -lactone is included.  
Garcia et. al 
1
 reported a racemic synthesis of rolipram by employing Heck-
Matsuda arylation of 3-pyrroline with aryldiazonium tetrafluoroborates (Scheme 4-1). 
The racemic rolipram was then resolved into its enantiomers by chromatographic 
resolution. 
 
Scheme 4-1. Garcia et. al synthesis of (±)-Rolipram via Heck-Matsuda arylation of 3-
pyrroline.  
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Scheme 4-2. Demnitz et. al synthesis of (R) & (S)-Rolipram via chromatographic 
separation of two diastereomers.  
Demnitz et. al. 
5g
  (Scheme 4-2) added nitromethane to aryl ,-unsaturated 
esters via Michael addition. The resulting racemic nitrobutyric acid was resolved via 
chromatographic separation of two readily separable diastereomeric amides obtained with 
(S)-(-)-phenyl ethylamine. Reduction followed by a reflux resulted in formation of 
Rolipram. 
Paraskar et. al. 
5l
 (Scheme 4-3) used NaBH4 in combination with CoCl2 catalyst 
and chiral ligand for reductive cyclizations of a suitably substituted azido ,-unsaturated 
ester in the key step to synthesize (R)-Rolipram. The intermediate, azido ,-unsaturated 
ester, was synthesized via suzuki reaction from Guaiacol. 
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Scheme 4-3. Paraskar et. al synthesis of (R)-Rolipram via chiral bis-oxozoline ligand, 
NaBH4 and CoCl2.  
Michael addition is another alternative method used in the synthesis of rolipram. 
Hynes et. al 
5m
 (Scheme 4-4) utilized organocatalyst epicinchonine derivative for the 
Michael addition of malonate nucleophile to aryl nitro olefin enantioselectively in the key 
step.  The resulting nitro ester was further reduced and cyclized using NiCl2 and NaBH4 
followed by decarboxylation to (R)-rolipram.  
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Scheme 4-4.  Hynes et. al synthesis of (R)-Rolipram via Michael addition.  
 Mulzer et. al 
5a
 chose enolate of N-acetyloxozolidone to add to the nitroolefine in 
a Michael addition (Scheme 4-5). Resulting nitro oxozolidone was recrystallized from 
methanol to receive single diastereomer which upon catalytic hydrogenation yielded (R)-
rolipram.  
 
 
Scheme 4-5. Mulzer et. al synthesis of (R)-Rolipram via Michael addition.  
Yoon et. al 
5j
 utilized Rhodium catalyzed regioselective intramolecular C-H 
insertion of a -diazo--(phenylsulfonyl)-acetamide in the key step for the synthesis of 
rolipram (Scheme 4-6). 
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Scheme 4-6. Yoon  et. al synthesis of (±)-Rolipram via Rhodium catalyzed C-H 
insertion.  
Honda et. al. 
5d
 used the enantioselective silyl ether formation from phenyl 
cyclobutanone in a key step to synthesize -substituted -butyrolactones. This lactone is 
further used to synthesize (R)-Rolipram (Scheme 4-7). 
 
Scheme 4-7. Honda et. al 
5d
 synthesis of (R)-Rolipram via -Aryl--butyrolactone.  
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Mandai et. al.pused Pd(OAc)2 catalyzed coupling of (Z)-2-butene-1,4-diols with 
aryl iodide to synthesize tetrahydro-2-furanols (Scheme 4-8) which upon oxidation with 
PCC led to -substituted -butyrolactones.  
 
Scheme 4-8. Mandai et. al synthesis of -Aryl--butyrolactone. 
4.3 Formal synthesis of (±)-Rolipram 
Selective protection of diols
6
 is an important concept in which one hydroxyl 
group is protected while the other hydroxyl could be converted to various functional 
groups. This selective protection of hydroxyl groups has been reported in various 
symmetric and unsymmetric diols. Selective protection of alcohols can be achieved with 
groups like acetates, benzoates and carbonates, e.g., the boc group. Adsorbents like silica 
gel (SiO2),
7
 Alumina (Al2O3),
8
 Phase transfer catalysts, 
8a
 metal catalysts
6c
 and lipases
9
 
have been widely used as catalysts to achieve monoprotection in diols. Infact, lipases 
have been used in our lab previously for selective protection of diols. Lipase catalyzed 
disymmetrization of meso 1,3-diols is an efficient strategy which has been used in our lab 
to synthesize (S)-Imperanene
10
 and Carbafuranomycin
11
 analogues. In our effort to 
synthesize rolipram, we applied the monoacylation of 1,3-diols by silicagel (SiO2) 
catalyst to achieve maximum yield. The strategy for the formal synthesis of (±)-Rolipram 
is shown in Scheme (4-9). The synthesis of the azido ester (19) from the monoacetate (9) 
represents the formal synthesis of Rolipram. The synthesis of the diester (6) was 
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envisioned through cross coupling of the aryl bromide (5) to diethylmalonate via Hartwig 
protocol. The precursor aryl bromide (5) was synthesized from guaiacol. The diester (6) 
would then be reduced to the prochiral 1,3-diol (7) which would be monoacylated with 
SiO2 catalyst. The monoacetate(9) would then be converted to the azidoester (19) through 
homologation of free hydroxyl group and azide substitution. The synthesis of the 
Rolipram from azidoester (19) can then be accomplished through the reported protocol 
described by Honda et. al.
5d
 The following sections document our effort to accomplish 
the synthesis of Rolipram by selective protection of diols. 
 
Scheme 4-9. Retrosynthetic analysis for the synthesis of -Lactam or (±)-Rolipram. 
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4.3.1 Synthesis of arylbromide (5) 
Aryl bromide (5) was synthesized from guaiacol (1) in 4 steps by following the 
reported literature procedure as shown in scheme (4-10). 
5l
  
 
Scheme 4-10. Synthesis of Aryl Bromide from Guaiacol  
Phenolic group in Guaiacol 1 was acylated to fecilitate bromine substitution at 
para to the methoxy group. The acylated guaiacol (2) was then treated with NBS (N-
Bromosuccinimide) in acetonitrile at 60
0
C to receive compound 3 in 85% yield as a light 
yellow color solid. The deacylation in compound 3 was performed by treating with 
NaHCO3 in methanol at reflux to receive bromophenol 4 as a light yellow color solid in 
95% yield. The cyclopentyl group was introduced in bromophenol 4 by treating it with 
cyclopentyl bromide and K2CO3 in DMF at 100
0
C to receive aryl bromide 5 as light 
brown color liquid in 96% yield (Scheme 4-10). 
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4.3.2 Synthesis of the prochiral 1,3-diol (7) 
The 1,3-Diester (6) was synthesized by palladium catalyzed reaction of aryl 
bromide (5) with diethyl malonate. The coupling reaction was successfully accomplished 
using Pd(dba)2 catalyst and ligand P(t-Bu)3 with K3PO4 as a base in toluene solvent by 
following Hartwig protocol
12
 (Scheme 4-11). Importantly, no product was formed in the 
coupling of diethyl malonate with aryl bromide (5) with various other palladium catalysts 
e.g., Pd2(dba)3, Pd(PPh3)4 and Pd(OAc)2 in combination with PPh3 and P(t-Bu)3 ligands.  
The structure of the 1,3-dister(6) was established from NMR spectral data (Fig. 4-2). The 
resonance for the active methylene hydrogen (He) was at 4.4 ppm in the 
1
H NMR and at 
57.1 ppm in the 
13
C NMR spectrum.  The reduction of 1,3-diester was accomplished by 
LiAlH4 in dry THF to yield the prochiral 1,3-Diol (7) (Scheme 4-11).  
 
 
Scheme 4-11. Synthesis of 1,3-diol 7 via 1,3-diester 6. 
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Fig. 4-2. NMR Spectra of 1,3-diester 6. (a). 
1
H NMR. (b). 
13
C NMR 
This 1,3-diol is prochiral
9b,c,10
 and can be used to introduce enantiomeric center by 
enantioselective acylation or it can also be diacylated and the resulting 1,3-diacetate (8) 
can be disymmetrized to yield enantiomeric center. The importance of this 
disymmetrization is that the quantitative conversion (~ 100%) can be achieved as against 
resolution where the highest yield of enantiopure compound is limited to 50%. 
4.3.3 Synthesis of the monoacetate (9) via selective protection 
Absorbents such as silicagel (SiO2) 
7
 and alumina (Al2O3) 
8
 are reported to be 
efficient catalysts for the selective monoacetylation of various symmetric diols, hindered 
alcohols in unsymmetric diols and even per-O-acylation of hydroxyl groups in 
carbohydrates.
6d
 Following this approach, 1,3-Diol (7) was preferentially acylated to 
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monoacetate (9) using SiO2 (0.6 equival.) and acetyl chloride (0.94 equival.) in CH2Cl2 
solvent. The monoacetate (9) was isolated in 78% yield along with 1,3-diacetate (8) and 
1,3-Diol (7). The reaction procedure was optimized after screening with various SiO2 and 
acetyl chloride ratios to synthesize monoacetate (9) in high yield. 
 
Scheme 4-12. Synthesis of monoacetate via selective acylation of 1,3-Diol. 
The structure of the monoacetate (9) was established from its NMR spectrum and 
its comparison with 1,3-diol (7) and 1,3-diacetate (8) (Fig. 4-3).  The methylene 
hydrogen (He) in 1,3-diol (7) and in monoacetate (9) was observed at 2.9 and 3.0 ppm 
respectively, while it was at 3.3 ppm in the 1,3-diacetate (8) (Fig. 4-3). The resonance for 
CH2-OH protons (Hi) in monoacetate (9) appears at 3.6 ppm while it is at 3.8 ppm (Hf) in 
1,3-diol (7). Having the acetoxy methylene (Hf) hydrogens at 4.5 ppm and the CH2-OH 
hydrogens at 3.6 ppm (Hi) in monoacetate 9 confirms its structure (Fig. 4-3). 
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Fig. 4-3. NMR Spectra. (a). 1,3-diol 7 .(b). 1,3-diacetate 8 .(c). monoacetate 9. 
4.3.4 Synthesis of methoxyalkene (13) via homologation 
The monoacetate (9) was oxidized to the aldehyde (10) with dess-martin 
periodinane
13
 in dry dichloromethane in 96% yield (Scheme 4-13). The structure of the 
aldehyde was confirmed by its 
1
H NMR spectrum in which aldehyde hydrogen (Hj) 
resonance was present at 9.6 ppm and acetoxy methylene hydrogens (Hf) resonance was 
present at 4.2 ppm (Fig. 4-4).  
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Scheme 4-13 Synthesis of Alkene 13 from monoacetate 9 via homologation. 
 
Fig. 4-4. 1H NMR spectra of Aldehyde 10. 
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In a homologation reaction, the aldehyde 10 was treated with wittig reagent 
(methoxymethyl)triphenylphosphonium chloride,
14
 at -78
0
C with n-BuLi to yield the 
vinyl ether 12 as a E/Z mixture.
15
 Presence of both isomers was confirmed by its 
1
H 
NMR spectrum (Fig. 4-5). For example, the alkene hydrogens  showed resonance at 6.4 
(Hj) and 4.8 (Hi) in the E isomer and at 6.0 (Hj) and 4.5 (Hi) ppm in the Z- isomer (Fig. 
4-5).  Since this methoxy alkene moiety will be hydrolyzed further to aldehyde, (E/Z )-
homologated alkene (11) was used in next step without separation of the isomers.  
 
Fig. 4-5. 1H NMR spectra of (E/Z )-homologated alkene (11). 
Since acetate group is labile in acidic condition needed in subsequent steps,  (E/Z 
)-homologated alkene (11) was hydrolyzed to the (E/Z ) -homologated alcohol (12) by 
K2CO3 and methanol.  The hydroxyl group in 12 was then protected with benzyl group
16
 
by treating with benzyl bromide to yield the benzylated vinylether (13) (Scheme 4-13).  
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4.3.5 Synthesis of esteralcohol (17)  
Hydrolysis
17
 of vinyl ether in 13 with 1N HCl in dry THF at 60
0
c led to the 
aldehyde (14) in 97% yield (Scheme 4-14). Temperature higher than 60
0
c led to cleavage 
of benzyl protection in the hydrolysis reaction. The presence of resonance for aldehyde 
proton (Hi) at 9.6 ppm and benzylic protons (Hg) at 4.4 ppm in 
1
H NMR (Fig. 4-6) 
confirmed the structure of aldehyde (14).  
 
Scheme 4-14 Synthesis of Ester alcohol 17. 
 
 
Fig. 4-6. 1H NMR spectra of Aldehyde 14. 
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Aldehyde (14) was then oxidized
18
 with Oxone® (Potassium 
peroxymonosulfate)
19
 to receive carboxylic acid (15) in 96% yield. The carboxylic acid 
was further esterified with ethanol in the presence of conc. H2SO4 at 45
0
c (Scheme 4-14). 
In this reaction maintaining temperature below 50
0
c and excess solvent was crucial to 
retain benzyl group protection on the alcohol since reflux led to removal of benzyl group 
on the alcohol.  
Once the desired ester (16) was received, benzyl protection on the alcohol was 
removed by hydrogenolysis over palladium and charcoal (Pd/C 10 wt%) (Scheme 4-14).  
The debenzylation was monitored using TLC, after shaking reaction mixture for 12 hrs, 
all of the starting material was debenzylated. The structure of ester alcohol (17) was 
confirmed by its 
1
H NMR spectrum (Fig. 4-7). The CH2-OH hydrogens (Hf) showed 
resonance at 3.6 ppm and ethyl hydrogens (Hi and Hj) showed resonances at 4.0 ppm and 
1.2 ppm respectively.  
 
Fig. 4-7. 1H NMR spectra of Ester 17. 
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4.3.6 Synthesis of azide (19) for rolipram 
 
 
Scheme 4-15 Synthesis of azide for the Rolipram from Esteralcohol 17. 
Having established a synthetic route to the ester alcohol (17), the next task was to 
introduce the azide group (Scheme 4-15).  The bromide serves as facile leaving group to 
substitute with azide nucleophile,
20
 so the alcohol (17) was treated with PBr3 to 
synthesize bromide (18).  The bromide was then treated with NaN3 in 
dimethylformamide to synthesize the azide (19). The structure of the azide(19) was 
established from its 
1
H NMR spectrum (Fig. 4-8). The resonance for CH2-N3 hydrogens 
(Hf) was present at 3.4 ppm while the methylene (Hg) hydrogens showed resonance at 
2.6 ppm. Since azide (19) was already transformed into Rolipram by Honda et. al.,
5d
 the 
synthesis of azide (19) constitutes the formal synthesis to Rolipram. 
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Fig. 4-8. 
1
H NMR spectra of Azide 19. 
4.4 Synthesis of -substituted--(±)-Lactone 
Previous sections described the utilization of selective protection of hydroxyl 
group in 1,3-diol for the formal synthesis of Rolipram. In a chemoenzymatic study for the 
synthesis of -lactone, unsymmetric 1,4-diol was also regioselectively deacylated with 
lipases. The following sections demonstrate the regioselective deacylation of 1,4-diols by 
Ps-30 lipase for the synthesis of -lactone. The strategy for the synthesis of -aryl--
lactone was shown in scheme (4-16). The synthesis of arylmaleate (21) from aryl 
bromide (5) was envisioned  via Heck cross coupling protocol. The synthesis of the 
precursor aryl bromide (5) from guaiacol (1) was shown in scheme 4-10. The arylmaleate 
(21) would be converted to the monoacetate (26) via lipase catalyzed regioselective 
deacylation. The monoacetate (26) would then be converted to the methyl ester (29) via 
oxidation and esterification. The methyl ester (29) would finally be lactonized to the 
lactone (30).  
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Scheme 4-16 Retrosynthetic analysis for the synthesis of Lactone (30) from Aryl 
bromide (5) via monoacetate (26). 
4.4.1 Synthesis of 1,4-diol (24) via heck reaction 
The aryl bromide (5) was used in heck cross coupling reaction with diethyl 
maleate with Pd(OAc)2 catalyst and triethylamine base. No product was observed even at 
prolonged reaction times and elevated temperatures in the heck reaction. It is not 
surprising that the ability of aryl halides to undergo oxidative addition with palladium(0) 
catalysts in heck reaction depends on the bond strengths of Ar-X. The established trend 
for the ease of cross coupling of aryl halides with activated alkenes in heck reaction is 
Ar-Cl<Ar-Br<Ar-I.
21
  
Aryl bromide (5) also has electron donating groups which also led them to 
participate poorly in heck reaction. So,  the aryl bromide was converted to aryl iodide 
(21) since iodide is better leaving group in palladium(0) catalyzed heck reaction. 
Bromine in aryl bromide was converted to aryl iodide (21) in halogen exchange 
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reaction
22
 with KI in the presence of CuI catalyst. The aryl iodide (21) was received as 
pale yellow oil. The structure of the aryl iodide (21) was confirmed by its 
13
C NMR 
spectrum (Fig. 4-9). The presence of resonance for the carbon in aromatic ring with 
iodide at 82.5 ppm confirmed the structure of aryl iodide (21). Same carbon in aromatic 
ring attached to bromide was showed resonance at 112 ppm in 
13
C NMR spectrum (Fig. 
4-9).  
 
Scheme 4-17 Synthesis of 1,4-Diol 24 via Heck arylation of diethylmaleate. 
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Fig. 4-9. 
13
C NMR spectra. (a). Aryl bromide 5. (b). Aryl iodide 21. 
The heck reaction
23
 between aryl iodide (21) and diethyl maleate was successfully 
accomplished with Pd(OAc)2 and triethylamine base in CH3CN yielding aryl maleate 
(22) with 90% yield
24
(Scheme 4-17). In this reaction, the aryl maleate (22) was received 
as E/Z mixture which was used directly in next step without separation of the isomers 
since alkene will be hydrogenated in the following reaction. The double bond in the aryl 
maleate (22) was hydrogenated to 1,4-diester (23) in the presence of Pd/C and H2 gas at 1 
atm pressure.
25
  Further reduction of ester groups in 1,4-diester (23) was accomplished by 
using lithium aluminiumhydride (LAH)
26
 to 1,4-diol (24) ( Scheme 4-17).  
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4.4.2 Synthesis of the monoacetate (26) via regioselective deacylation 
After synthesizing 1,4-diol successfully via heck reaction, the next step was to 
introduce selective protection of one hydroxyl group. Monoacylation of the unsymmetric 
1,4-diol in a regioselective fashion was proved to be difficult with SiO2 (silicagel) and 
acetyl chloride (AcCl). The reaction was yielded the mixture of monoacetates. Next, we 
studied the effect of lipases on regioselective deacylation of 1,4-diacetate (25) since 
lipases
27
 were also proved to be suitable catalysts.   
 
Scheme 4-18 Synthesis of Monoacetate 26 via Regioselective deacylation of 1,4-
Diacetate by Lipase Ps-30 (Lipase Pseudomonas Sepacia).  
Acylation of both hydroxyl groups in 1,4-Diol (24) was done with AcCl and 
DMAP to synthesize key intermediate 1,4-Diacetate (25). The presence of both acetoxy 
methylene hydrogens (Hf and Hh) resonance at 4.2 ppm and 3.8-4.0 ppm respectively in 
the 
1
H NMR spectrum (Fig. 4-10) confirmed the structure of 1,4-diacetate (25).  The 1,4-
Diacetate (25) was then regioselectively deacylated with Pseudomonas Sepacia (PS-30) 
lipase in acetone solvent while maintaining the pH of reaction mixture at 7 with 1N 
NaOH.  
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The selective deacylation in the diacetate (25) was occurred at 4-acetyl group 
regioselectively in 24 hrs yielding monoacetate (26) in 49% yield (Scheme 4-18). The 
structure of the monoacetate (26) was confirmed by its 
1
H NMR (Fig 4-10). Previous 
reports in the literature claimed either slow reaction rates (>40 hrs) or preferential 
hydrolysis of 1-acetyl group regioselectively when aryl group is present at C2 carbon in 
1,4-Diacetate with lipases.
28
 
 
Fig. 4-10. 
1
H NMR spectra. (a). 1,4-Diacetate 25. (b). Mixtures of monoacetates 26 and 
26a. 
The monoacetate 26 was then taken immediately in the next step since storing of 
this compound longer than 48 hrs led to transesterification of hydroxyl group yielding 
both isomers. The presence of both isomers of monoacetate was confirmed by the 
1
H 
NMR spectrum [(b) in Fig. 4-10] after monoacetate 26 was stored for 50 hrs.  
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4.4.3 Synthesis of ester (29) 
 
Scheme 4-19. Synthesis of Ester acetate 29 from monoacetate 26. 
The free hydroxyl group in the monoacetate (26) was oxidized by treating with 
dess-martin periodinane
29
 to the aldehyde (27) which was then further oxidized with 
Oxone to the carboxylic acid (28) (Scheme 4-19). Direct esterification
19,30
 of the 
aldehyde (27) to the methyl ester (29) was not proceded with Oxone rather it yielded the 
acid (28). So the esterification of the acid (28) to the methyl ester (29) was accomplished 
with DCC (dicyclohexylcarbodiimide), DMAP (dimethylamino pyridine) and MeOH in 
CH2Cl2 solvent (Scheme 4-19). The presence of the resonance for methoxy group (Hk) in 
1
H NMR spectrum at 3.6 ppm was confirmed the structure of ester (29) (Fig. 4-11).  
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Fig. 4-11. 
1
H NMR spectra. (a). Carboxylic acid 28. (b). Ester 29.  
4.4.4 Synthesis of lactone (30) via lactonization 
The deacylation of 1-acetoxy group in the ester (29) was performed to fecilitate 
the final assembly of the lactone (30). No reaction was observed when the lipase PPL 
(Pigliver pancreatic lipase)
31
 was used at pH=7 to hydrolyse 1-acetoxy group.
32
 The 
deacylation of 1-acetoxy group was also unsuccessful even with the Novozyme 435 
lipase
33
 in the presence of n-butanol and dry. tetrahydrofuran at prolonged reaction times 
(>60 hrs). Mild hydrolysis of this acetate group with sodium acetate (CH3COONa)
34
 or 
LiCl
35
 was also not proceeded to the product.  
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Scheme 4-20. Synthesis of -Lactone 30 via Ester acetate 29. 
Finally the acetate group in the ester (29) was hydrolyzed to alcohol by sodium 
methoxide (NaOMe)
36
 in methanol. After quenching the reaction with dil. acetic acid, the 
reaction mixture was extracted with dichloromethane. The organic layer was then added 
by dicyclohexylcarbodiimide (DCC), N,N-dimethylamino pyridine (DMAP), MeOH and 
stirred at room temperature for 16 hrs. The lactone (30) was then isolated as a major 
product. Alternatively treating the reaction mixture isolated above with the dess-martin 
periodinane also yielded the lactone (30) as major product with 62% yield instead of 
aldehyde (Fig. 4-20).  
4.5 Conclusions 
In Summary, We were able to establish the formal synthesis of the Rolipram by 
employing the selective acylation of the 1,3-diol (7) by SiO2 catalyst. Optical purity in 
the 1,3-diol (7) can also be established via disymmetrization of the corresponding 1,3-
diacetate via enzyme catalysis. Key steps for the efficient synthesis of the azide (19) 
starting from the aryl bromide (5) includes Palladium catalyzed cross-coupling of the aryl 
bromide (5) with diethylmalonate and selective acylation of the 1,3-diol (7). -
substituted--Lactone (7), an analogue of the Rolipram, was also synthesized efficiently 
by the regioselective deacylation of the 1,4-diacetate (25). Key steps for the synthesis of 
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-substituted--Lactone (30) includes the heck arylation of diethyl maleate, regioselective 
deacylation of -substituted-1,4-diacetate (25) via lipase catalysis and lactonization. 
4.6 Experimental Section 
4.6.1 General  
Lipase PS-30 was generous gifts from Amano Enzymes. 
1
H-NMR and 
13
C-NMR spectra 
were recorded on a Bruker 250 MHz and Varian 400 MHz  spectrometer in CDCl3 and 
DMSO-d6 with TMS as the standard.  Chemical shifts are reported in ppm, multiplicities 
are indicated by s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), h (sextet), m 
(multiplet), dd (doublet of doublet), td (triplet of doublet), qd (quartet of doublet) and bs 
(broad singlet). Coupling constants  are reported in hertz (Hz). All 
13
C NMR spectra were 
proton decoupled. Thin-Layer chromatography (TLC) was performed on glass plates 
coated with 0.25 mm thickness of silica-gel. All solvents were dried and distilled prior to 
use and organic solvent extracts were dried over anhydrous Na2SO4. Toluene and 
tetrahydrofuran were distilled from sodium and benzophenone and were stored in a dry 
box. Chromatographic purifications were performed by flash chromatography using silica 
gel (63-200μ) from Dynamic Adsorbents Inc. Pd(dba)2 and P(t-Bu)3 were purchased from 
Aldrich Inc. All reagents and bases were purchased from Aldrich, Fisher Scientific, VWR 
and used without further purification.  
 
Acetic acid 2-methoxy-phenyl ester (2): To a solution of a guaiacol 1 (15 g, 0.12 mol) 
and pyridine (22.75 mL, 0.279 mol) in CH2Cl2 (300 mL) at 0
0
C was added AcCl (13 mL, 
0.181 mol) portion wise and the resulting mixture was allowed to stir for overnight at 
room temperature. The reaction mixture was poured into 1M H3PO4 solution (100 mL) 
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and the aqueous layer was extracted with CH2Cl2 (4×50 mL). The Combined organic 
phases were then washed with brine solution (80 mL), water (2×30 mL), dried over 
anhydrous Na2SO4 and filtered. The resulting light filtrate was concentrated under 
reduced pressure and chromatographed over silica gel column by eluting with 
EtOAc:Hexanes (1:9) to receive compound 2 as light brown color oil in 95% yield (18.9 
g, 0.114 mol).  
1
H NMR (250 MHz, CDCl3)  7.0 - 7.1 (m, 1H), 6.7 - 6.9 (m, 3H), 3.6 - 
3.7 (bs, 3H), 2.1 - 2.2 (bs, 3H). 
13
C NMR (62.5 MHz, CDCl3)  169.1, 151.1, 139.8, 
126.9, 122.8, 120.8, 112.4, 55.8, 20.7. 
 
Acetic acid 5-bromo-2-methoxy-phenyl ester (3): To a solution of 2 (13.639 g, 0.082 
mol) in CH3CN (180 mL) was added N-Bromosuccinimide (17.533 g, 0.098 mol) under 
N2 atmosphere and the reaction mixture was allowed to stir overnight at 60
0
C and 
filtered. The resulting filtrate was added by EtOAc in a separatory funnel and (200 mL), 
washed with brine solution (2×100 mL). The combined organic layers were dried over 
anhydrous Na2SO4 and filtered. The filtrate was then concentrated under reduced pressure 
and chromatographed over silicagel column to receive 3 as a light yellow color solid 
(16.17 g, 85% yield). 
1
H NMR (250 MHz, CDCl3)  7.3 (dd, J = 2.4, 8.7 Hz, 1H), 7.1 (d, 
J = 2.3 Hz, 1H), 6.8 (d, J = 8.6 Hz, 1H), 3.8 (s, 3H), 2.30 (s, 3H). 
13
C NMR (62.5 MHz, 
CDCl3)  168.6, 150.6, 140.3, 129.6, 126.1, 113.7, 112.0, 56.1, 20.6. 
 
5-Bromo-2-methoxy-phenol (4): To a solution of 3 (1.05 g, 4.3 mmol) in MeOH (6 mL) 
was added NaHCO3 (0.6 g, 8.0 mmol) and the reaction mixture was allowed to stir 
overnight at reflux and filtered. The filtrate was then poured into 1N HCl solution (10 
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mL) and the aqueous layer was extracted with diethyl ether (3×10 mL). The combined 
organic phases were then washed with brine solution (2×10 mL), dried over anhydrous 
Na2SO4 and filtered. The resulting filtrate was then concentrated under reduced pressure 
and chromatographed over silicagel column by eluting with EtOAc:Hexanes (1:9) to 
receive compound 4 as light yellow color solid (0.829 g, 95% yield). 
1
H NMR (250 MHz, 
CDCl3)  7.0 (m, 1H), 6.9 (m, 1H), 6.8 (m, 1H), 6.7 (d, J = 8.5 Hz, 1H), 3.8 (s, 3H). 
13
C 
NMR (62.5 MHz, CDCl3)  146.5, 145.9, 122.8, 117.8, 113.2, 111.9, 56.1. 
 
4-bromo-2-(cyclopentyloxy)-1-methoxybenzene (5): To a mixture of bromo phenol 4 
(23.5 g, 0.115 mol) and K2CO3 (31.79 g, 0.225 mol) in DMF (100 ml) was added  
cyclopentyl bromide (16.5 mL, 0.149 mol) using a syringe at 50
0
C with vigorous stirring. 
After completion of the reaction (monitored by TLC (1:4 EtOAc:Hexanes), the reaction 
mixture was allowed to cool to room temperature. The reaction mixture was then poured 
into 1M NaOH solution (100 mL) and EtOAc (200 mL) added to it. The organic layer 
was separated and the aqueous layer was extracted with EtOAc (2×50 ml). The combined 
organic extracts were washed with water (30 ml) followed by the brine solution (50mL), 
dried over anhydrous MgSO4 and filtered. The organic layer was then concentrated under 
reduced pressure to give crude product (30 g), which was further puriﬁed by column 
chromatography on silica gel using hexanes/EtOAc (9:1) as eluent to afford the aryl 
bromide 5 (26.5 g, 96% yield, yellowish liquid). 
1
H NMR (250MHz, CDCl3)  = 6.9 - 6.8 
(m, 2 H), 6.6 (d, J = 8.5 Hz, 1 H), 4.6 (bs, 1 H), 3.7 (s, 3 H), 1.9 - 1.6 (m, 6 H), 1.5 (bs., 2 
H). 
13
C NMR (62.5 MHz , CDCl3)  = 148.7, 148.0, 122.6, 117.3, 112.6, 112.1, 80.1, 
55.6, 32.2, 23.5. 
145 
 
2-(3-Cyclopentyloxy-4-methoxy-phenyl)-malonic acid diethyl ester (6): To a schlenk 
tube containing diethyl malonate (0.176 g, 1.1 mmol) and aryl bromide 5 (0.271 g, 1.0 
mmol) were added P(t-Bu)3 (0.009 g, 0.040 mmol), Pd(dba)2 (0.0115 g, 0.020 mmol), 
and K3PO4 (0.636 g, 3.0mmol) followed by toluene (3.0 mL) under N2 atmosphere. The 
tube was sealed with the stopper and the heterogeneous reaction mixture was stirred at 70 
°C for 16 hrs and monitored by TLC (1:4 EtOAc:Hexanes). The crude reaction mixture 
was filtered through a plug of celite and concentrated in vacuuo. The residue was purified 
by column chromatography on silica gel (10:90 EtOAc/hexanes) to give the desired 
product 6 (yellowish liquid, 60% yield). 
1
H NMR (250 MHz, CDCl3)  6.8 - 6.95(m, 1H), 
6.7 (d, J = 9.6 Hz, 2H), 4.6 - 4.7 (m, 1H), 4.4 - 4.4 (m, 1H), 4.1 (d, J = 7.1 Hz, 4H), 3.7 
(m, 3H), 1.6 - 1.9 (m, 6H), 1.4 - 1.5 (m, 2H), 1.1 (d, J = 2.2 Hz, 3H) 
13
C NMR (62.5 MHz 
, CDCl3)  = 168.3, 150.0, 147.5, 125.1, 121.7, 115.8, 111.6, 80.3, 61.6, 57.3, 55.9, 32.7, 
24.0, 14.0. 
 
2-(3-Cyclopentyloxy-4-methoxy-phenyl)-propane-1,3-diol (7): To a solution of 6 
(0.573 g, 1.63 mmol) in diethyl ether, cooled at 0
0
C was added lithium aluminiumhydride 
(0.745 g, 19.64 mmol). The reaction warmed to room temperature and allowed to stir for 
a further 8 hours. The reaction was quenched at 0
0
C with water (3 mL) and 2N NaOH 
solution (6 mL) until white color suspension received and filtered. The filtrate was 
extracted with ethyl acetate (3×25 ml). The organic layer was dried over sodium sulfate 
and filtered. The organic layer was concentrated under reduced pressure and purified over 
column chromatography on silica gel (3:7 EtOAc/ Hexanes) to receive 1,3-Diol as a 
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colorless viscous liquid (68% yield). 
1
H NMR (250 MHz, CDCl3)  6.5 - 6.7 (m, 3H), 4.6 
- 4.7 (m, 1H), 3.6 - 3.9 (m, 7H), 2.8 - 3.0 (m, 1H), 1.6 - 1.8 (m, 6H), 1.4 - 1.5 (m, 2H). 
 
Acetic acid 3-acetoxy-2-(3-cyclopentyloxy-4-methoxy-phenyl)propyl ester (8): To a 
solution of 1,3-Diol (7) (0.827 g, 3.109 mmol) in CH2Cl2 was added acetylchloride (0.8 
mL, 12.43 mmol) and pyridine (1.01 mL, 12.43 mmol). The reaction was stirred for 6 hrs 
at room temperature and quenched with NaHCO3 (20 mL). The reaction mixture was 
extracted with CH2Cl2 (2×25 mL). Combined organic layer was washed with 1N HCl, 
brine solution and dried over Anhydrous Na2SO4. The resulting crude reaction mixture 
from evaporation under rotavap was purified by column chromatography on silica gel by 
eluting with EtOAc/Hexanes (1:9) to receive 8 as yellowish liquid (85% yield). 
1
H NMR 
(250 MHz, CDCl3)  6.6 - 6.8 (m, 3H), 4.62 - 4.7 (m, 1H), 4.2 (d, J = 6.79 Hz, 4H), 3.7 - 
3.8 (m, 3H), 3.1 (t, J = 6.56 Hz, 1H), 1.97 (s, 6H), 1.70 - 1.89 (m, 6H), 1.46 - 1.60 (m, 
2H) 
 
Acetic acid 2-(3-cyclopentyloxy-4-methoxy-phenyl)-3-hydroxy-propyl ester (9): 
Acetyl chloride (0.183 ml, 2.57 mmol) was added to a stirred solution of diol (0.720 g, 
2.7 mmol), SiO2 (0.100 g, 1.664 mmol) in CH2Cl2 (5 ml) under a nitrogen atmosphere 
and the resulting reaction mixture was stirred at room temperature.  When judged 
complete by TLC (approx. 3 hrs 1:1 EtOAc:Hexanes), the reaction was diluted with Et2O 
and washed twice with a saturated NaHCO3 solution and once with brine. The organic 
layer was dried over anhydrous. MgSO4 and filtered. The organic layer was concentrated 
under reduced pressure and puriﬁed via ﬂash column chromatography (1:4 EtOAc–
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hexane mixtures) to receive monoacetate 9 (64% yield, 78% yield based on recovered 
1,3-Diol 7). 
1
H NMR (250MHz , CDCl3)  = 6.8 - 6.6 (m, 3 H), 4.7 - 4.6 (m, 1 H), 4.2 (d, 
J = 6.8 Hz, 2 H), 3.8 - 3.6 (m, 5 H), 2.9 (t, J = 6.5 Hz, 1 H), 2.0 - 1.9 (m, 3 H), 1.9 - 1.6 
(m, 6 H), 1.6 - 1.4 (m, 2 H). 
 
Acetic acid 2-(3-cyclopentyloxy-4-methoxy-phenyl)-3-oxo-propyl ester (10): To a 
solution of 9 (0.156 g, 1.75 mmol) in dry dichloromethane (5 ml) at 0
0
C was added Dess-
Martin periodinane (5ml, 15%w/v). The reaction was allowed to stir at 0
0
C for a further 
90 minutes then allowed to warm to room temperature and stirred for an additional 2 
hours. A solution of sodium thiosulfate (15ml) was added followed by a solution of sat. 
NaHCO3 and  the solution stirred for an additional 15 minutes, then vacuum-filtered over 
celite. An additional 30 ml of dichloromethane was added and extracted with aqueous 
sodium chloride (20 ml). The organic layer was dried over sodium sulfate, concentrated, 
and  the product (amber liquid, 0.508 g, 1.73 mmol, 96% yield) used immediately in the 
next reaction without further purification. 
1
H NMR (250 MHz, CDCl3)  9.5 - 9.6 (m, 
1H), 6.7 - 6.8 (m, 1H), 6.5 - 6.6 (m, 2H), 4.6 - 4.7 (m, 1H), 4.4 - 4.6 (m, 1H), 4.2 (dd, J = 
4.4, 5.8 Hz, 1H), 3.6 - 3.8 (m, 5H), 1.8 - 1.9 (m, 3H), 1.6 - 1.8 (m, 6H), 1.4 - 1.5 (m, 2H). 
13
C NMR (62.5 MHz , CDCl3)  = 190.8, 170.6, 154.9, 147.8, 128.0, 121.9, 113.1, 110.5, 
80.6, 65.8, 56.1, 56.0, 32.7, 24.1, 20.6. 
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(E/Z)-Acetic acid 2-(3-cyclopentyloxy-4-methoxy-phenyl)-4-methoxy-but-3-enyl 
ester (11): To a solution of the Wittig reagent [(Methoxymethyl) 
triphenylphosphoniumchloride] (2.97 g, 8.68 mmol) in dry THF under a nitrogen 
atmosphere at -78
0
C was added  n-butyl lithium (5.64 mL,  9.03 mmol). The reaction was 
allowed to stir for an additional 30 minutes and a solution of the aldehyde 10 (0.508 g, 
1.736 mmol) in dry THF (10 ml) was added to the sanguineous solution at -78
0
C. The 
reaction was allowed to warm to room temperature  and stirred for an additional 19 hours. 
The solution was then concentrated and added by ethyl acetate (50 ml),brine solution (20 
ml). The organic layer was concentrated under reduced pressure and purified over wet 
silica chromatography using ethyl acetate: hexane (2:8) to receive compound  11 as a 
viscous, amber liquid (88% yield) as E/Z mixture.
 1
H NMR (250 MHz, CDCl3)  6.7 - 6.8 
(m, 3H), 6.3 (d, J = 12.6 Hz, 1H), 6.0 (d, J = 8.3 Hz, 1H), 4.8 (d, J = 8.3 Hz), 4.7 - 4.8 
(bs, 1H), 4.2 (d, J = 7.4 Hz, 1H), 3.7 - 3.8 (m, 3H), 3.6 (s, 2H), 3.5 - 3.6 (m, 3H), 1.9 - 2.0 
(m, 3H), 1.7 - 1.9 (m, 6H), 1.5 - 1.7 (m, 2H) 
 
(E/Z)-2-(3-Cyclopentyloxy-4-methoxy-phenyl)-4-methoxy-but-3-en-1-ol (12): To a 
solution of the alkene 11 (0.35 g, 1.04 mmol) in dry methanol (20 ml) was added 
anhydrous potassium carbonate (0.3 g). The reaction was allowed to stir at room 
temperature for 3 hours upon which it was quenched with sat. NaHCO3 solution (10 mL) 
and extracted with dichloromethane. The organic layer was dried over anhydrous. 
Na2SO4, concentrated and purified by flash column chromatography using ethyl acetate:  
hexane (4:6) to receive viscous colorless liquid 12 (0.22 g, 0.75 mmol, 72% yield)
 1
H 
NMR (250 MHz, CDCl3)  6.6 - 6.8 (m, 3H), 6.3 (d, J = 12.00 Hz, 1H), 5.9 (d, J = 7.27 
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Hz,), 4.7 (dd, J = 8.37, 10.43 Hz, 1H), 4.6 - 4.7 (bs, 1H), 3.7 - 3.7 (m, 3H), 3.5 - 3.7 (m, 
2H), 3.4 - 3.5 (bs, 3H), 3.2 (d, J = 8.53 Hz, 1H), 1.6 - 1.9 (m, 6H), 1.4 - 1.6 (bs, 2H) 
 
4-(1-Benzyloxymethyl-3-methoxy-allyl)-2-cyclopentyloxy-1-methoxy-benzene (13): 
To a solution of alcohol(0.22 g, 0.75 mmol) in dry THF (150 ml) at 0
0
C was added 
sodium hydride (0.04 g, 1.575 mmol) portion wise under a nitrogen atmosphere. The 
reaction was allowed to stir for 20 minutes and a solution of TBAI and Benzyl bromide 
(0.154 g, 0.9 mmol) in dry THF (100 ml) was added dropwise over a 10 minute period. 
The solution was warmed to room temperature and allowed to stir at room temperature 
for a further 16 hrs. The solution was concentrated under reduced pressure and the 
viscous liquid taken up in Et2O (20 ml) and extracted with aqueous ammonium chloride 
(30 ml). The organic layer was dried over sodium sulfate and concentrated. The product 
was purified by silica gel chromatography using a gradient eluent of ethyl acetate: hexane 
(10:90) followed by ethyl acetate: hexane (20:80) to afford 13 (0.2 g, 0.54 mmol, 72% 
yield) as light yellow viscous oil. 
1
H NMR (250 MHz, CDCl3)  7.1 - 7.3 (m, 5H), 6.6 - 
6.8 (m, 3H), 6.3 (d, J = 12.8 Hz, 1H), 5.9 (d, J = 6.2 Hz), 4.8 (dd, J = 7.9, 12.64 Hz, 1H), 
4.6 (quin, J = 4.58 Hz, 1H), 4.4 (s, 2H), 3.7 - 3.8 (bs, 3H), 3.5 - 3.6 (m, 2H), 3.3 - 3.4 (bs, 
3H), 1.7 - 1.8 (m, 6H), 1.4 - 1.6 (m, 2H). 
 
4-Benzyloxy-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyraldehyde (14):
 
To the 
solution of 13 (0.3 g, 0.78 mmol) in 10 mL dry. THF was added 1 mL 2N HCl. The 
reaction mixture was then stirred at 60
0
C for 16 hrs. After the reaction was completed, 
and then concentrated, 25 mL of EtOAc and 15 mL of water was added. The phases were 
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separated and the aqueous phase was extracted with ethyl acetate (3×10 mL). The 
combined organic phases were washed with 10 mL brine, dried over Na2SO4 and filtered. 
The organic layer was concentrated under reduced pressure and purification by silica gel 
column chromatography (hexanes/ethyl acetate 1:9) provided 0.28 g (0.759 mmol) (97% 
yield) of 14 as a colorless oil. 
1
H NMR (250 MHz, CHLOROFORM-d)  9.5 - 9.6 (m, 
1H), 7.1 - 7.3 (m, 5H), 6.6 - 6.7 (m, 3H), 4.6 (quin, J = 4.50 Hz, 1H), 4.3 - 4.4 (m, 2H), 
3.6 - 3.7 (m, 3H), 3.5 - 3.6 (m, 1H), 3.3 - 3.4 (m, 2H), 3.3 - 3.3 (m, 0H), 2.8 (dd, J = 
10.27, 11.06 Hz, 0H), 2.6 (dd, J = 7.42, 8.85 Hz, 1H), 1.6 - 1.8 (m, 6H), 1.4 - 1.5 (m, 
2H). 
 
4-Benzyloxy-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyric acid (15): The aldehyde 
(0.2 g, 0.542 mmol) was dissolved in DMF (6 mL).  Oxone (0.217 g, 0.705 mmol) was 
added in one portion and stirred at room temperature for 3 days.  The reaction was 
monitored by TLC (1:4 EtOAc:Hexanes) and 1N HCl (3 mL) was added to dissolve the 
salts and EtOAc was added to extract the products.  The organic layer was washed with 
1N HCl (3x10 mL), brine, dried over Na2SO4 and filtered. The organic layer was 
concentrated under reduced pressure and purified by silica gel column chromatography to 
receive 15 as a colorless liquid (0.2 g, 0.52 mmol, 96% yield). 
1
H NMR (250 MHz, 
CDCl3)  7.1 - 7.3 (m, 5H), 6.5 - 6.7 (m, 3H), 4.5 - 4.7 (m, 1H), 4.4 (s, 2H), 3.6 - 3.7 (m, 
3H), 3.3 - 3.61 (m, 2H), 3.2 - 3.3 (m, 1H), 2.7 - 2.9 (m, 2H), 2.4 - 2.6 (dd, J = 11.8, 7.9 
Hz, 1H), 1.6 - 1.8 (m, 6H), 1.3 - 1.6 (m, 2H).  
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4-Benzyloxy-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyric acid ethyl ester (16): 
The acid 15 (0.115 g, 0.3 mmol) was dissolved in ethanol and stirred at 50
0
C for 10 min. 
5 drops of Conc. H2SO4  was added to above solution at 45
0
C and allowed to stir for 16 
hrs. The reaction was monitored by TLC (1:4 EtOAc:Hexanes). After starting material 
was consumed completely, reaction was concentrated and partitioned between diethyl 
ether and sat. NaHCO3. The organic layer was dried over anhydrous. Na2SO4 and 
concentrated. Product was purified over column chromatography on silicagel by eluting 
with EtOAc/hexanes (15:85) to receive 16 as colorless liquid (0.108 g, 0.261 mmol, 87% 
yield). 
1
H NMR (250 MHz, CDCl3)  7.1 - 7.3 (m, 5H), 6.5 - 6.8 (m, 3H), 4.5 - 4.7 (m, 
1H), 4.3 - 4.5 (m, 2H), 3.8 - 4.0 (m, 2H), 3.6 - 3.8 (m, 3H), 3.2 - 3.6 (m, 3H), 2.7 - 2.8 
(dd, J = 8.1, 8.1 Hz,, 1H), 2.4 - 2.6 (dd, J = 8.1, 8.1 Hz,,,1H), 1.6 - 1.9 (m, 6H), 1.4 - 1.6 
(m, 2H), 0.9 - 1.1 (m, 3H).  
 
3-(3-Cyclopentyloxy-4-methoxy-phenyl)-4-hydroxy-butyric acid ethyl ester (17): To 
a  solution of 16 (0.108 g, 0.262 mmol) in absolute ethanol (20 mL) was added 
palladium/charcoal(0.05 g, 10wt%), and the  suspension  was   shaken  for  12  hrs  under  
H2 atmosphere (45  psi)  in a  Parr apparatus. The suspension was filtered over  a short  
pad  of  silica gel and the filtrate was evaporated to an oily residue. Product was purified 
over column chromatography on silica gel to receive alcohol 17 (0.6 g, 0.186 mmol, 72% 
yield) as yellowish color liquid. 
1
H NMR (250 MHz, CDCl3)  6.5 - 6.8 (m, 3H), 4.6 - 4.7 
(m, 1H), 3.9 - 4.0 (q, J = 6.8 Hz, 2H), 3.5 - 3.7 (m, 5H), 3.1 (t, J = 7.11 Hz, 1H), 2.4 - 2.7 
(dd, J = 10.4, 8.2 Hz,2H), 1.6 - 1.9 (m, 6H), 1.4 - 1.6 (m, 2H), 1.0 - 1.1 (m, 3H). 
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4-Bromo-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyric acid ethyl ester (18): To a 
solution of 17 (0.045 g, 0.1395 mmol) in anhydrous Et2O (30 mL) was added slowly PBr3 
(0.04 mL, 0.3 mmol) at 0
0
C. After stirring for 6 hrs at room temperature, MeOH (5 mL) 
was added and the resulting mixture was allowed to stir for 1 hr. The organic layer was 
concentrated under reduced pressure and puriﬁed by ﬂash column chromatography on 
silica gel by eluting with hexanes/EtOAc (9:1) to afford 18 (0.04 g, 96%) as a pale yellow 
oil. 
1
H NMR (250 MHz, CDCl3)  6.5 - 6.8 (m, 3H), 4.6 - 4.7 (m, 1H), 3.9 - 4.1 (m, 2H), 
3.6 - 3.7 (m, 3H), 3.2 - 3.6 (m, 3H), 2.8 - 2.9 (m, 1H), 2.4 - 2.6 (dd, J = 8.2, 6.0 Hz 1H), 
1.6 - 1.9 (m, 6H), 1.5 - 1.6 (m, 2H), 1.0 (t, J = 7.19 Hz, 3H). 
13
C (DEPT) NMR (62.5 
MHz, CDCl3)  118.3, 113.6, 111.1, 79.6, 59.5, 55.0, 42.2, 37.9, 37.0, 31.9, 23.0, 13.0. 
 
4-Azido-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyric acid ethyl ester (19): To a 
solution of Bromide 18 (0.04 g, 0.103 mmol) in DMF (3 mL) was added sodium azide 
(0.010 g, 0.1557 mmol) and the reaction mixture was heated to 40
0
C over night. The 
mixture was diluted with water (5 mL) and extracted with ethyl acetate (3×5 mL). The 
combined organic phases were washed with brine, dried over anhydrous Na2SO4 and 
ﬁltered. The organic layer was concentrated under reduced pressure and purified over 
column chromatography on silica gel to receive azide 19 (0.02 g, 0.057 mmol, 55% 
yield). 
1
H NMR (250 MHz, CDCl3)  6.6 (d, J = 1.11 Hz, 3H), 4.6 - 4.7 (m, 1H), 3.9 - 4.0 
(m, 2H), 3.7 (s, 3H), 3.1 - 3.5 (m, 3H), 2.4 - 2.7 (dd, J = 8.8, 7.3 Hz 2H), 1.7 - 1.9 (m, 
6H), 1.4 - 1.6 (m, 2H), 1.1 (t, J = 7.11 Hz, 3H). 
13
C NMR (DEPT) (62.5 MHz, CDCl3)  
118.5, 113.7, 111.1, 79.5, 59.5, 55.4, 55.0, 40.4, 37.0, 31.8, 23.0. 
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2-Cyclopentyloxy-4-iodo-1-methoxy-benzene (21): To a solution of aryl bromide 5 (1 
g, 3.7 mmol) in DMF (10 mL) was added potassium iodide (9.213 g, 55.5 mmol) and 
copper(I) iodide (3.52 g, 18.5 mmol). The heterogeneous reaction mixture was stirred at 
160
0
C for 24 hrs. After the reaction was quenched with 1N HCl, EtOAc (25 mL) was 
added and insoluble copper(I) was filtered over celite. The filtrate was extracted with 
EtOAc (50 mL). The combined organic phase was washed with 1N HCl, brine, dried over 
anhydrous. Na2SO4 and filtered. The organic layer was concentrated under reduced 
pressure and purified over column chromatography on silica gel to receive aryl iodide 21 
as a pale yellow oil (0.9 g, 2.83 mmol, 76% yield). 
1
H NMR (250 MHz, CDCl3)  6.9 - 
7.2 (m, 2H), 6.5 (d, J = 8.37 Hz, 1H), 4.6 (dt, J = 3.00, 5.92 Hz, 1H), 3.6 - 3.7 (m, 3H), 
1.6 - 1.9 (m, 6H), 1.4 - 1.6 (m, 2H). 
13
C NMR (62.5 MHz, CDCl3)  150.1, 148.7, 129.6, 
123.6, 113.7, 82.4, 80.7, 56.1, 32.7, 24.1. 
 
2-(3-Cyclopentyloxy-4-methoxy-phenyl)-but-2-enedioic acid diethyl ester (22): To a 
solution of aryl iodide 21 (0.9 g, 2.83 mmol) in CH3CN (5 mL) was added diethyl 
maleate (1.3 mL, 7.86 mmol), Triethylamine (1.11 ml, 7.86 mmol), Pd(OAc)2 (0.007 g, 
0.03 mmol) and stirred at 70
0
C for 16 hrs. The reaction mixture was cooled and filtered 
over celite plug. The filtrate was concentrated in vacuuo and purified over column 
chromatography on silica gel by eluting with EtOAc/hexanes (1:4) to receive aryl maleate 
22 as yellowish liquid (0.92 g, 2.547 mol, 90% yield). 
1
H NMR (250 MHz, CDCl3)  6.8 
- 7.0 (m, 1H), 6.8 (s, 1H), 6.6 - 6.8 (m, 2H), 6.1 (s, 1H), 4.5 - 4.7 (m, 1H), 4.3 (q, J = 7.11 
Hz, 1H), 4.1 (qd, J = 7.16, 10.58 Hz, 2H), 3.9 - 4.0(q, J = 9.2 Hz, 1H) , 3.6 - 3.7 (m, 3H), 
1.6 - 1.9 (m, 6H), 1.4 - 1.6 (m, 2H), 0.9 - 1.3 (t, J = 8.5 Hz, 6H). 
154 
 
 
13
C NMR (101 MHz, CDCl3)  168.1, 166.5, 165.9, 165.1, 152.3, 150.4, 148.7, 147.8, 
146.8, 143.3, 128.1, 126.2, 125.8, 121.1, 116.1, 114.8, 112.7, 111.6, 111.0, 80.5, 61.4, 
56.0, 32.7, 24.0, 14.0. 
 
2-(3-Cyclopentyloxy-4-methoxy-phenyl)-succinic acid diethyl ester  (23): To a  
solution of 22 (6.8 g, 18.75 mmol) in absolute ethanol (50 mL) was added 
palladium/charcoal (0.8 g, 10wt%),  and the  suspension  was   shaken  for  12  hrs  under  
H2 atmosphere (45  psi)  in a  Parr apparatus. The suspension was filtered over  a short  
pad  of  silica gel and the filtrate was evaporated to an oily residue. The product was 
purified over column chromatography on silica gel to receive 1,4-diester 23 (6.45 g, 17.7 
mmol, 95% yield) as yellowish color liquid. 
1
H NMR (400 MHz, CDCl3)  6.7 - 6.8 (m, 
3H), 4.7 (td, J = 3.1, 6.2 Hz, 1H), 4.0 - 4.1 (m, 4H), 3.9 (dd, J = 5.0, 10.1 Hz, 1H), 3.7 - 
3.8 (m, 3H), 3.1 (dd, J = 10.1, 16.7 Hz, 1H), 2.6 (dd, J = 5.4, 16.78 Hz, 1H), 1.7 - 1.9 (m, 
6H), 1.5 - 1.6 (m, 2H), 1.1 - 1.2 (q, J = 11.3 Hz, 6H). 
 
2-(3-Cyclopentyloxy-4-methoxy-phenyl)-butane-1,4-diol (24): To a solution of 23 
(6.45 g, 18.75 mmol) in dry. THF (40 mL), cooled at 0
0
C was added lithium 
aluminiumhydride (2.82 g, 74.32 mmol). The reaction was warmed  to room temperature 
and allowed to stir for a further 8 hours. The reaction was quenched  at 0
0
C with water 
and 2N NaOH solution dropwise until white color suspension received and filtered. The 
filtrate was extracted with ethyl acetate (3×25 ml). The organic layer was dried over 
anhydrous Na2SO4, concentrated under reduced pressure and purified over column 
chromatography on silica gel (3:7 EtOAc/ Hexanes) to receive 1,4-Diol as a colorless 
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viscous liquid (4 g, 14.466 mmol, 77% yield). 
1
H NMR (400 MHz, CDCl3)  6.6 - 6.8 
(m, 3H), 4.6 - 4.7 (m, 1H), 3.7 - 3.8 (d, J = 5.9 Hz, 3H), 3.4 - 3.7 (m, 4H), 2.8 (quin, J = 
6.9 Hz, 1H), 2.5 - 2.7 (m, 1H), 1.7 - 1.9 (m, 8H), 1.4 - 1.6 (m, 2H). 
13
C NMR (101 MHz, 
CDCl3)  148.9, 147.7, 134.7, 119.8, 114.9, 112.1, 80.5, 67.5, 61.0, 56.1, 45.4, 35.9, 32.7, 
24.0. 
 
Acetic acid 4-acetoxy-2-(3-cyclopentyloxy-4-methoxy-phenyl)-butyl ester (25): To a 
solution of 1,4-Diol (24) (4 g, 14.466 mmol) in CH2Cl2 was added acetylchloride (2.05 
mL, 28.93 mmol) and pyridine (2.35 mL, 28.93 mmol). The reaction was stirred for 6 hrs 
at room temperature and quenched with NaHCO3 (20 mL). The reaction mixture was 
extracted with CH2Cl2 (2×25 mL). Combined organic layer was washed with 1N HCl, 
brine solution and dried over Anhydrous. Na2SO4. Resulting crude reaction mixture from 
evaporation under rotavap was purified by column chromatography on silica gel by 
eluting with EtOAc/Hexanes (10:90) to receive 25 as yellowish liquid (4.4 g, 12.06 
mmol, 84% yield).
1
H NMR (400 MHz, CDCl3)  6.7 - 6.8 (m, 1H), 6.6 - 6.7 (m, 2H), 4.6 
- 4.7 (m, 1H), 4.1 - 4.2 (m, J = 7.0 Hz, 2H), 3.9 - 4.0 (m, 1H), 3.8 - 3.9 (m, 1H), 3.7 - 3.8 
(m, 3H), 2.8 - 3.0 (m, 1H), 1.95 - 2.11 (m, 7H), 1.7 - 1.9 (m, 7H), 1.5 - 1.6 (m, 2H). 
13
C 
NMR (101 MHz, CDCl3)  170.9, 149.1, 147.6, 132.8, 119.8, 114.8, 112.1, 80.5, 68.3, 
62.4, 56.0, 41.3, 32.7, 31.4, 24.0, 20.9. 
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Acetic acid 2-(3-cyclopentyloxy-4-methoxy-phenyl)-4-hydroxy-butyl ester (26): 
10.23g (0.0284 mol) of 1,4-diacetate 25,  was stirred in a mixture of phosphate buffer 
(pH 7.0; 60ml) and acetone (3ml) in a round bottom flask at room temperature.  Lipase 
PS-30 (1.0 g) was added while maintaining the pH of the reaction mixture at 7.0 using 1N 
NaOH solution.  The reaction was stopped when no change in the pH of the reaction 
medium occurred (approx. 24 hrs).  The reaction was monitored by TLC (1:4 
EtOAc:Hexanes). The reaction mixture was extracted with ethyl acetate (3 x 200 mL). 
The organic layer was dried over Na2SO4. The organic layer was concentrated under 
reduced pressure and purified by column chromatography over silica gel using 
ethylacetate: hexane (1:3) to isolate the monoacetate 26 (49% yield). 
1
H NMR (400 MHz, 
CDCl3)  6.6 - 6.8 (m, 3H), 4.6 - 4.7 (m, 1H), 4.1 - 4.2 (m, 2H), 3.7 - 3.8 (m, 3H), 3.4 - 
3.6 (m, 2H), 2.9 - 3.0 (m, 1H), 1.9 - 2.0 (m, 3H), 1.7 - 1.9 (m, 6H), 1.5 - 1.6 (m, 2H). 
13
C 
NMR (101 MHz, CDCl3)  171.1, 149.0, 147.7, 133.5, 119.9, 115.0, 112.2, 80.4, 68.4, 
60.5, 56.0, 41.0, 35.3, 32.8, 24.0, 20.9. 
 
Acetic acid 2-(3-cyclopentyloxy-4-methoxy-phenyl)-4-oxo-butyl ester (27):  To a 
solution of monoacetate 25 (4.3 g, 13.33 mmol) in dry dichloromethane (20 ml) at 0
0
C 
was added Dess-Martin periodinane (40ml, 15%w/v). The reaction was allowed to stir at 
0
0
C for a further 90 minutes then allowed to warm to room temperature and stirred for an 
additional 3 hours. A solution of sodium thiosulfate (30ml) was added followed by a 
solution of sat. NaHCO3 (30 mL) and  the solution stirred for an additional 60 minutes, 
then vacuum-filtered over celite. An additional 30 ml of dichloromethane was added and 
extracted with aqueous sodium chloride (20 ml). The organic layer was dried over 
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sodium sulfate, concentrated, and  the product (yellow liquid, 4.2 g, 13.02 mmol, 98% 
yield) is pure enough by 
1
H NMR and used immediately in the next reaction without 
further purification.
1
H NMR (400 MHz, CDCl3)  9.6 - 9.7 (m, 1H), 6.6 - 6.8 (m, 3H), 
4.6 - 4.8 (m, 1H), 4.0 - 4.3 (m, 2H), 3.7 - 3.8 (m, 3H), 3.4 - 3.5 (m, 1H), 2.7 - 2.8 (m, 2H), 
1.7 - 2.0 (m, 9H), 1.5 - 1.6 (m, 2H). 
13
C NMR (101 MHz, CDCl3)  200.7, 170.8, 149.3, 
147.7, 132.2, 119.6, 114.8, 112.1, 80.4, 67.8,  56.0, 46.8, 38.5, 32.8, 24.02, 20.9. 
 
4-Acetoxy-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyric acid (28): The aldehyde 27 
(5.62 g, 17.541 mmol) was dissolved in DMF (20 mL).  The Oxone (5.059 g, 26.312 
mmol) was added to above solution in one portion and stirred at room temperature for 24 
hrs.  The reaction was monitored by TLC (1:4 EtOAc:Hexanes) and 1N HCl (3 mL) was 
added to dissolve the salts and EtOAc was added to extract the products.  The organic 
layer was washed with 1N HCl (3x10 mL), brine and dried over anhydrous Na2SO4. The 
organic layer was concentrated under reduced pressure and purified by silica gel column 
chromatography to receive 28 as a colorless liquid (5.510 g, 16.38 mmol, 94% yield). 
1
H 
NMR (400 MHz, CDCl3)  6.6 - 6.8 (m, 3H), 4.7 (tt, J = 3.17, 6.00 Hz, 1H), 4.1 - 4.2 (dd, 
J = 7.8, 10.9 Hz, 1H), 4.0 (dd, J = 7.8, 10.9 Hz, 1H), 3.7 - 3.8 (m, 3H), 3.3 - 3.4 (m, 1H), 
2.7 - 2.8 (m, 1H), 2.5 - 2.6 (m, 1H), 1.7 - 2.0 (m, 9H), 1.5 - 1.6 (m, 2H). 
13
C NMR (101 
MHz, CDCl3)  177.3, 170.8, 149.2, 147.6, 132.3, 119.5, 114.8, 112.1, 80.5, 67.7, 56.1, 
40.5, 37.5, 32.7, 24.0, 20.7. 
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4-Acetoxy-3-(3-cyclopentyloxy-4-methoxy-phenyl)-butyric acid methyl ester (29): To 
a solution of the acid 28 (5.51 g, 16.38 mmol) in dichloromethane (30 mL) was added 
dicyclohexyldicarbodiimide (DCC) (4.4 g, 21.3 mmol), dimethylaminopyrimidine 
(DMAP) (0.2 g, 1.638 mmol) MeOH (13.2 mL) and stirred at room temperature for 24 
hrs. The resulting reaction mixture was quenched by adding 1N HCl (20 mL) and 
extracted with CH2Cl2 (2×50 mL). Combined organic phase was washed with brine, dried 
over anhydrous Na2SO4. The organic layer was concentrated under reduced pressure and 
purified  by silica gel column chromatography to receive 29 as a colorless liquid (4.87 g, 
13.923 mmol, 94% yield). 
1
H NMR (400 MHz, CDCl3)  6.6 - 6.8 (m, 3H), 4.6 - 4.7 (m, 
1H), 4.1 - 4.3 (m, 1H), 4.0 (dd, J = 7.61, 11.13 Hz, 1H), 3.7 - 3.8 (m, 3H), 3.5 - 3.6 (m, 
3H), 3.3 - 3.4 (m, 1H), 2.6 - 2.7 (dd, J = 7.8, 7.8 Hz, 1H), 2.5 - 2.6 (m, 1H), 1.9 - 2.0 (m, 
3H), 1.6 - 1.9 (m, 6H), 1.4 - 1.6 (m, 2H). 
13
C NMR (101 MHz, CDCl3)  172.2, 170.7, 
149.2, 147.5, 132.6, 119.5, 115.0, 112.1, 80.6, 67.5, 56.0, 51.5, 40.6, 37.6, 32.6, 24.0, 
20.8. 
 
4-(3-Cyclopentyloxy-4-methoxy-phenyl)-dihydro-furan-2-one (30): To a solution of 
ester acetate 29 (0.160 g, 0.456 mmol) in dry. MeOH (4 mL) was added a solution 
prepared from sodium (0.1 g) and dry. MeOH (4 mL) and the resulting mixture was 
stirred for 3 hrs at room temperature. The reaction was quenched with glacial acetic acid 
until pH=7 and water (5 mL) was added. The resulting reaction mixture was extracted 
with CH2Cl2. To this reaction mixture was added DCC (0.147 g), DMAP (0.025 g) and 
stirred at 40
0
C for 6 hrs. The reaction mixture was then concentrated without heat under 
reduced pressure and the crude product was purified by column chromatography on silica 
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gel by eluting with EtOAc/Hexanes (10:90) to receive 30 as yellowish liquid (0.103 g, 
3.74 mmol, 82% yield). 
1
H NMR (400 MHz, CDCl3)  6.6 - 6.8 (m, 3H), 4.6 - 4.7 (m, 
1H), 4.6- 4.5 (m, 1H), 4.0-4.2 (m,1H), 3.7 - 3.8 (m, 3H), 3.5 - 3.6 (m, 1H), 2.7 - 2.9 (m, 
1H), 2.5 - 2.6 (m, 1H), 1.6 - 1.9 (m, 6H), 1.4 - 1.6 (m, 2H). 
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Appendix-A 
Spectroscopic data for compounds of chapter 2 
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Fig. A-1 
1
H and 
13
C NMR spectra of E-4,4'-[1,2-diethyl-1,2-ethenediyl]bis Phenol (6). 
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Fig. A-2 
1
H and 
13
C NMR spectra of E/Z-4,4'-[1,2-dimethyl-1,2-ethenediyl]bis Phenol 
(7). 
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Fig. A-3 
1
H and 
13
C NMR spectra of E- 4,4'-(1,2-ethenediyl)bis Phenol  (8). 
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Fig. A-4 
1
H and 
13
C NMR spectra of E/Z-3,3'-[1,2-dimethyl-1,2-ethenediyl]bis Phenol 
(9). 
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Fig. A-5 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-
[(diethylamino)methyl]-Phenol (11). 
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Fig. A-6 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-
[(dimethylamino)methyl]-Phenol (12). 
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Fig. A-7 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-
[(pyrrolidine)methyl]-Phenol  (13). 
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Fig. A-8 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-
[(piperidine)methyl]-Phenol (14). 
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Fig. A-9 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-diethyl-1,2-ethenediyl)bis[2-
[(morpholine)methyl]-Phenol  (15). 
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Fig. A-10 
1
H and 
13
C NMR spectra of 4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(diethylamino)methyl]-Phenol (16). 
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Fig. A-11 
1
H and 
13
C NMR spectra of 4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(dimethylamino)methyl]-Phenol (17). 
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Fig. A-12 
1
H and 
13
C NMR spectra of 4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(pyrrolidine)methyl]-Phenol (18). 
178 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
14.437.984.004.001.99
OH
N
OH
N
19
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
OH
N
OH
N
19
  
Fig. A-13 
1
H and 
13
C NMR spectra of 4,4'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(Piperidine)methyl]-Phenol (19). 
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Fig. A-14 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-ethenediyl)bis[2-[(morpholine)methyl]-
Phenol (20). 
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Fig. A-15 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-ethenediyl)bis[2-
[(diethylamino)methyl]-Phenol (21). 
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Fig. A-16 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-ethenediyl)bis[2-
[(dimethylamino)methyl]-Phenol (22). 
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Fig. A-17 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-
Phenol (23). 
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Fig. A-18 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-ethenediyl)bis[2-[(piperidine)methyl]-
Phenol (24). 
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Fig. A-19 
1
H and 
13
C NMR spectra of E-4,4'-(1,2-ethenediyl)bis[2-[(morpholine)methyl]-
Phenol (25). 
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Fig. A-20 
1
H and 
13
C NMR spectra of 3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(diethylamino)methyl]-Phenol (26). 
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Fig. A-21 
1
H and 
13
C NMR spectra of 3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(dimethylamino)methyl]-Phenol (27). 
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Fig. A-22 
1
H and 
13
C NMR spectra of 3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(pyrrolidine)methyl]-Phenol (28). 
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Fig. A-23 
1
H and 
13
C NMR spectra of 3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(piperidine)methyl]-Phenol (29). 
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Fig. A-24 
1
H and 
13
C NMR spectra of 3,3'-(1,2-dimethyl-1,2-ethenediyl)bis[2-
[(morpholine)methyl]-Phenol (30). 
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Fig. A-25 
1
H and 
13
C NMR spectra of E-3,3'-(1,2-ethenediyl)bis[2-
[(diethylamino)methyl]-Phenol (31). 
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Fig. A-26 
1
H and 
13
C NMR spectra of E-3,3'-(1,2-ethenediyl)bis[2-
[(dimethylamino)methyl]-Phenol (32). 
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Fig. A-27 
1
H and 
13
C NMR spectra of E-3,3'-(1,2-ethenediyl)bis[2-[(pyrrolidine)methyl]-
Phenol (33). 
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Fig. A-28 
1
H and 
13
C NMR spectra of E-3,3'-(1,2-ethenediyl)bis[2-[(piperidine)methyl]-
Phenol (34). 
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Fig. A-29 
1
H and 
13
C NMR spectra of E-3,3'-(1,2-ethenediyl)bis[2-[(morpholine)methyl]-
Phenol (35). 
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Fig. A-30 
1
H and 
13
C NMR spectra of E-6,6'-(vinylene)bis[3-cyclohexyl-3,4-dihydro- 
2H-1,3-Benzoxazine] (36). 
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Fig. A-31 
1
H and 
13
C NMR spectra of E-6,6'-(vinylene)bis[3-cyclopentyl-3,4-dihydro- 
2H-1,3-Benzoxazine] (37). 
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Fig. A-32 
1
H and 
13
C NMR spectra of E-6,6'-(vinylene)bis[3-benzyl-3,4-dihydro- 2H-
1,3-Benzoxazine] (38). 
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Fig. A-33 
1
H and 
13
C NMR spectra of E-6,6'-(vinylene)bis[3-(4-methoxy benzyl)-3,4-
dihydro- 2H-1,3-Benzoxazine] (39). 
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Fig. A-34 
1
H and 
13
C NMR spectra of E-7,7'-(vinylene)bis[3-cyclohexyl-3,4-dihydro- 
2H-1,3-Benzoxazine] (40). 
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Fig. A-35 
1
H and 
13
C NMR spectra of E-7,7'-(vinylene)bis[3-cyclopentyl-3,4-dihydro- 
2H-1,3-Benzoxazine] (41). 
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Fig. A-36 
1
H and 
13
C NMR spectra of E-7,7'-(vinylene)bis[3-benzyl-3,4-dihydro- 2H-
1,3-Benzoxazine] (42). 
202 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
15.314.244.0016.186.08
43
N
O
N
O
O
O
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
43
N
O
N
O
O
O
  
Fig. A-37 
1
H and 
13
C NMR spectra of E-7,7'-(vinylene)bis[3-(4-methoxy benzyl)-3,4-
dihydro- 2H-1,3-Benzoxazine] (43). 
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Fig. A-38 
1
H and 
13
C NMR spectra of E-7,7'-(vinylene)bis[3-furfuryl-3,4-dihydro- 2H-
1,3-Benzoxazine] (44). 
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APPENDIX  B 
Spectroscopic Data for Compounds of Chapter 3 
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Fig. B-1 
1
H and 
13
C-NMR spectra of 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone 
oxime (2). 
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Fig. B-2 
1
H and 
13
C-NMR spectra of 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone 
O-methyl-oxime (3). 
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Fig. B-3 
1
H and 
13
C-NMR spectra of 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone 
O-benzyl-oxime (4). 
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Fig. B-4 
1
H and 
13
C-NMR spectra of 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone 
O-semicarbazone (5) 
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Fig. B-5 
1
H and 
13
C-NMR spectra of 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanol 
(6). 
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APPENDIX  C 
Spectroscopic Data for Compounds of Chapter 4  
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Fig. C-1 
1
H and 
13
C-NMR spectra of Acetic acid 2-methoxy-phenyl ester (2). 
210 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
O
O
O
Br
3
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
O
O
O
Br
3
 
Fig. C-2 
1
H and 
13
C-NMR spectra of Acetic acid 5-bromo-2-methoxy-phenyl ester (3). 
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Fig. C-3 
1
H and 
13
C-NMR spectra of 5-Bromo-2-methoxy-phenol (4). 
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Fig. C-4 
1
H and 
13
C-NMR spectra of 4-bromo-2-(cyclopentyloxy)-1-methoxybenzene 
(5). 
213 
 
O
O
OO
O O
a b
c
d
e
f
g
h
6
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
6.002.135.972.873.960.960.951.950.95
e
a
d
h
g
Aromatic
b     &     c
 
O
O
OO
O O
a b
c
d
e
f
g
h
6
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
Hd
He
Hc
Hh
Hg
Hb
Ha
f Aromatic
 
Fig. C-5 
1
H and 
13
C-NMR spectra of 2-(3-Cyclopentyloxy-4-methoxy-phenyl)-malonic 
acid diethyl ester (6). 
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Fig. C-6 
1
H and DEPT-NMR spectra of 2-(3-Cyclopentyloxy-4-methoxy-phenyl)-
propane-1,3-diol (7). 
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Fig. C-7 
1
H NMR spectra of Acetic acid 3-acetoxy-2-(3-cyclopentyloxy-4-methoxy-
phenyl)propyl ester (8) and 
1
H -NMR spectra of Acetic acid 2-(3-cyclopentyloxy-4-
methoxy-phenyl)-3-hydroxy-propyl ester (9). 
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Fig. C-8: 1H and 13C-NMR spectra of Acetic acid 2-(3-cyclopentyloxy-4-methoxy-
phenyl)-3-oxo-propyl ester (10). 
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Fig. C-9 
1
H NMR spectra of (E/Z)-Acetic acid 2-(3-cyclopentyloxy-4-methoxy-phenyl)-
4-methoxy-but-3-enyl ester (11) and 
1
H -NMR spectra of (E/Z)-2-(3-Cyclopentyloxy-4-
methoxy-phenyl)-4-methoxy-but-3-en-1-ol (12). 
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Fig. C-10 
1
H NMR spectra of 4-(1-Benzyloxymethyl-3-methoxy-allyl)-2-
cyclopentyloxy-1-methoxy-benzene (13) and 
1
H -NMR spectra of 4-Benzyloxy-3-(3-
cyclopentyloxy-4-methoxy-phenyl)-butyraldehyde (14). 
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Fig. C-11 
1
H NMR spectra of 4-Benzyloxy-3-(3-cyclopentyloxy-4-methoxy-phenyl)-
butyric acid (15) and 
1
H -NMR spectra of 4-Benzyloxy-3-(3-cyclopentyloxy-4-methoxy-
phenyl)-butyric acid ethyl ester (16). 
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Fig. C-12 
1
H NMR spectra of 3-(3-Cyclopentyloxy-4-methoxy-phenyl)-4-hydroxy-
butyric acid ethyl ester (17) and 
1
H -NMR spectra of 4-Bromo-3-(3-cyclopentyloxy-4-
methoxy-phenyl)-butyric acid ethyl ester (18). 
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Fig. C-13 DEPT- NMR spectra of 4-Bromo-3-(3-cyclopentyloxy-4-methoxy-phenyl)-
butyric acid ethyl ester (18) and 
1
H -NMR spectra of 4-Azido-3-(3-cyclopentyloxy-4-
methoxy-phenyl)-butyric acid ethyl ester (19). 
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Fig. C-14 DEPT- NMR spectra of 4-Azido-3-(3-cyclopentyloxy-4-methoxy-phenyl)-
butyric acid ethyl ester (19). 
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Fig. C-15 
1
H and 
13
C-NMR spectra of 2-Cyclopentyloxy-4-iodo-1-methoxy-benzene 
(21). 
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Fig. C-16 
1
H and 
13
C-NMR spectra of 2-(3-Cyclopentyloxy-4-methoxy-phenyl)-but-2-
enedioic acid diethyl ester (22). 
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Fig. C-17 
1
H NMR spectra of 2-(3-Cyclopentyloxy-4-methoxy-phenyl)-succinic acid 
diethyl ester  (23) and 
1
H -NMR spectra of 2-(3-Cyclopentyloxy-4-methoxy-phenyl)-
butane-1,4-diol (24). 
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Fig. C-18 
13
C -NMR spectra of 2-(3-Cyclopentyloxy-4-methoxy-phenyl)-butane-1,4-diol 
(24) and 
1
H -NMR spectra of Acetic acid 4-acetoxy-2-(3-cyclopentyloxy-4-methoxy-
phenyl)-butyl ester (25). 
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Fig. C-19 
13
C -NMR spectra of Acetic acid 4-acetoxy-2-(3-cyclopentyloxy-4-methoxy-
phenyl)-butyl ester (25). 
 
228 
 
 
 
Fig. C-20 
1
H and 
13
C-NMR spectra of Acetic acid 2-(3-cyclopentyloxy-4-methoxy-
phenyl)-4-hydroxy-butyl ester (26). 
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Fig. C-21 
1
H and 
13
C-NMR spectra of Acetic acid 2-(3-cyclopentyloxy-4-methoxy-
phenyl)-4-oxo-butyl ester (27). 
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Fig. C-22 
1
H and 
13
C-NMR spectra of 4-Acetoxy-3-(3-cyclopentyloxy-4-methoxy-
phenyl)-butyric acid (28). 
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Fig. C-23 
1
H and 
13
C-NMR spectra of 4-Acetoxy-3-(3-cyclopentyloxy-4-methoxy-
phenyl)-butyric acid methyl ester (29). 
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Fig. C-24 
1
H NMR spectra of 4-(3-Cyclopentyloxy-4-methoxy-phenyl)-dihydro-furan-2-
one (30). 
 
 
 
 
 
 
